LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma

The LOGIC 2 Trial A Phase II, Multi-center, Open-label Study of Sequential LGX818/MEK162 Combination Followed by a Rational Combination With Targeted Agents After Progression, to Overcome Resistance in Adult Patients With Locally Advanced or Metastatic BRAF V600 Melanoma.

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02159066

Acronym

LOGIC-2

Enrollment

158

Registered

2014-06-09

Start date

2014-07-23

Completion date

2023-01-10

Last updated

2024-03-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Melanoma

Keywords

Melanoma

Brief summary

The primary purpose of this study is to assess the anti-tumor activity of LGX818/MEK162 in combination with targeted agents after progression on LGX818/MEK162 combination therapy, as well as the safety and tolerability of the novel triple combinations.

Detailed description

This study consists of two parts: in Part I/Run-In, patients naïve to selective BRAF and MEK inhibitors will be treated with the LGX818/MEK162 combination until disease progression (as defined per RECIST v1.1). Based on the genetic analysis of a tumor biopsy obtained at that time, patients will enter Part II of the study for tailored combination treatment in one of four arms of LGX818/MEK162 + either BKM120, BGJ398, INC280 or LEE011 Patients with BRAF mutant melanoma treated by LGX818/MEK162 combination in other studies can be enrolled directly in Part II of CLGX818X2109 after relapse. Dose-escalations in the combination arms for which no MTD has been established will be based on the recommendations of a Bayesian logistic regression model guided by an escalation with overdose control criterion

Interventions

DRUGLGX818

Combination of LGX818 and MEK162 (Part I)

DRUGMEK162

Combination of LGX818 and MEK162 (Part I)

DRUGLEE011

Combination of LGX818 + MEK162 + LEE011 (Part II)

DRUGBGJ398

Combination of LGX818 + MEK162 + BGJ398 (Part II)

DRUGBKM120

Combination of LGX818 + MEK162 + BKM120 (Part II)

DRUGINC280

Combination of LGX818 + MEK162 + INC280 (Part II)

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Age ≥ 18 years * Histologically confirmed diagnosis of unresectable stage III or metastatic melanoma (stage IIIC to IV per American Joint Committee on Cancer \[AJCC\]) * Documented evidence of BRAF V600 mutation. * Newly obtained tumor biopsy at baseline, and patient agrees to a mandatory biopsy at the time of progression, if not medically contraindicated. * Evidence of measurable disease, as determined by RECIST v1.1. INCLUSION CRITERIA for triple combinations: Progressive disease following prior treatment with LGX818/MEK162 combination. PRINCIPAL

Exclusion criteria

Symptomatic or untreated leptomeningeal disease. * Symptomatic brain metastases. Patients previously treated or untreated for brain metastases that are asymptomatic in the absence of corticosteroid therapy or on a stable dose of steroids for four weeks are allowed to enroll. Brain metastases must be stable at least 4 weeks with verification by imaging (e.g. brain MRI completed at screening demonstrating no current evidence of progressive brain metastases). Patients are not permitted to receive enzyme inducing anti-epileptic drugs. * Patients who have developed brain metastases during Part I of the study may continue to Part II upon discussion with Novartis Medical Monitor. The brain metastasis must be either asymptomatic or treated and stable for at least 4 weeks and on a stable or tapering dose of steroids for at least 2 weeks. Patients with brain metastasis are not eligible for the combination with LEE011. * Known acute or chronic pancreatitis. * History or current evidence of retinal vein occlusion (RVO) or current risk factors for RVO (e.g. uncontrolled glaucoma or ocular hypertension, history of hyperviscosity or hypercoagulability syndromes); * Clinically significant cardiac disease including any of the following: * CHF requiring treatment (NYH grade ≥ 2), * LVEF \< 50% as determined by MUGA scan or ECHO * History or presence of clinically significant ventricular arrhythmias or atrial fibrillation * Clinically significant resting bradycardia * Unstable angina pectoris ≤ 3 months prior to starting study drug * Acute Myocardial Infarction (AMI) ≤ 3 months prior to starting study drug, * QTcF \> 480 msec. Patients with any of the following laboratory values at Screening/baseline: * Absolute neutrophil count (ANC) \<1,500/mm3 \[1.5 x 109/L\] * Platelets \< 100,000/mm3 \[100 x 109/L\] * Hemoglobin \< 9.0 g/dL * Serum creatinine \>1.5 x ULN or calculated or directly measured CrCl \< 50% LLN (lower limit of normal) * Serum total bilirubin \>1.5 x ULN * AST/SGOT or ALT/SGPT \> 2.5 x ULN, or \> 5 x ULN if liver metastases are present Additional

Design outcomes

Primary

Measure	Time frame	Description
Overall Response Rate (ORR): Part II	From the start of the treatment until disease/clinical progression or death or early study discontinuation, whichever happened earlier (maximum treatment exposure for Part II was 97.0 weeks)	ORR: percentage of participants with confirmed complete response (CR) and partial response (PR). Response evaluation criteria in solid tumors (RECIST) v1.1: a) CR = disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions that had a reduction in short axis to less than (\<) 10 millimeter (mm). Disappearance of all non-target lesions. In addition, all lymph nodes assigned a non-target lesion must be non-pathological in size (\<10 mm short axis) and b) PR = at least a 30 percent (%) decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters. Any radiological assessments taken more than 30 days after the last dose of study therapy or after antineoplastic agents other than study treatments taken by the participants was excluded from the best overall response derivation. Confirmation of CR or PR was to be at least 4 weeks apart from the previous radiological assessment.

Secondary

Measure	Time frame	Description
Number of Participants With Dose Limiting Toxicities (DLTs) in Cycle 1: Part II	Cycle 1 (21 days following the first dose of the combination treatment with buparlisib and capmatinib; 28 days for the combination with ribociclib and infigratinib)	DLT was defined as an adverse event or abnormal laboratory value assessed as unrelated to disease, disease progression, inter-current illness, or concomitant medications that occurred within the first cycle (first 21 days for infigratinib and capmatinib; 28 days for ribociclib and buparlisib) of treatment initiation and met the defined criteria for study.
Number of Participants With Adverse Events (AEs) and Serious AEs (SAEs): Part I	Day 1 up to 30 days after last dose (maximum treatment exposure for Part I was 403.7 weeks)	An AE was defined as the appearance of (or worsening of any pre-existing) undesirable sign(s), symptom(s), or medical condition(s) that occurred after participants' signed informed consent has been obtained. An SAE was an AE resulting in any of the following outcomes: was fatal or life-threatening; resulted in persistent or significant disability/incapacity; constituted a congenital anomaly/birth defect; was medically significant; required inpatient hospitalization or prolongation of existing hospitalization. AEs included both SAEs and all Non-SAEs.
Number of Participants With AEs and SAEs: Part II	Day 1 up to 30 days after last dose (maximum treatment exposure for Part II was 97.0 weeks)	An AE was defined as the appearance of (or worsening of any pre-existing) undesirable sign(s), symptom(s), or medical condition(s) that occurred after participants' signed informed consent has been obtained. An SAE was an AE resulting in any of the following outcomes: was fatal or life-threatening; resulted in persistent or significant disability/incapacity; constituted a congenital anomaly/birth defect; was medically significant; required inpatient hospitalization or prolongation of existing hospitalization. AEs included both SAEs and all Non-SAEs.
Actual Dose Intensity: Part II	During study treatment (maximum treatment exposure for Part II was 97.0 weeks)	Dose intensity = cumulative dose/ duration of exposure. Treatment cycle = 21days for the combination treatment with buparlisib and capmatinib and 28 days for the combination treatment with ribociclib and infigratinib.
Number of Participants With Worst Post-baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03 Grade: Part I	Baseline up to last dose (maximum treatment exposure for Part I was 403.7 weeks)	Parameters evaluated were: Activated partial thromboplastin time (APTT) (seconds \[sec\]) - CTCAE graded high, fibrinogen (gram per liter \[g/L\]) - CTCAE graded low, hemoglobin (g/L) - CTCAE graded low, hemoglobin (g/L) - CTCAE graded high, prothrombin international normalized ratio (PINR) - CTCAE graded high, lymphocytes (10\^9 cells/L) - CTCAE graded low, lymphocytes (10\^9 cells/L) - CTCAE graded high, neutrophils (10\^9 cells/L) - CTCAE graded low, platelets (10\^9 cells/L) - CTCAE graded low, leukocytes (10\^9 cells/L) - CTCAE graded low, leukocytes (10\^9 cells/L) - CTCAE graded high. CTCAE version 4.03 was used: grade 1 = mild, grade 2 = moderate, grade 3 = severe, grade 4 = life-threatening consequences; grade 0 = values not meeting any of the criteria for grade 1 or higher. Baseline = last non-missing value prior to the first dose of study treatment.
Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Baseline up to last dose (maximum treatment exposure for Part II was 97.0 weeks)	Parameters evaluated were: APTT (sec) - CTCAE graded high, fibrinogen (g/L) - CTCAE graded low, hemoglobin (g/L) - CTCAE graded low, hemoglobin (g/L) - CTCAE graded high, PINR - CTCAE graded high, lymphocytes (10\^9 cells/L) - CTCAE graded low, lymphocytes (10\^9 cells/L) - CTCAE graded high, neutrophils (10\^9 cells/L) - CTCAE graded low, platelets (10\^9 cells/L) - CTCAE graded low, leukocytes (10\^9 cells/L) - CTCAE graded low, leukocytes (10\^9 cells/L) - CTCAE graded high. CTCAE version 4.03 was used: grade 1 = mild, grade 2 = moderate, grade 3 = severe, grade 4 = life-threatening consequences; grade 0 = values not meeting any of the criteria for grade 1 or higher. Baseline = last non-missing value prior to the first dose of study treatment in Part II.
Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Baseline up to last dose (maximum treatment exposure for Part I was 403.7 weeks)	Parameters evaluated were: albumin (g/L)- CTCAE graded low, alkaline phosphatase (units per liter \[U/L\])- CTCAE graded high, alanine aminotransferase (U/L)- CTCAE graded high, amylase (U/L - CTCAE graded high, aspartate aminotransferase(U/L)- CTCAE graded high, bilirubin (micromole per liter \[umol/L\])- CTCAE graded high, creatinine (umol/L) - CTCAE graded high, creatine kinase (U/L)- CTCAE graded high, gamma glutamyl transferase (U/L)- CTCAE graded high, glucose (millimole per liter \[mmol/L\])- CTCAE graded low, high, potassium (mmol/L)- CTCAE graded low, potassium (mmol/L)- CTCAE graded high, magnesium (mmol/L)- CTCAE graded low, high, phosphate (mmol/L)- CTCAE graded low, sodium (mmol/L)- CTCAE graded low, sodium (mmol/L)- CTCAE graded high, urate (umol/L)- CTCAE graded high. CTCAE version 4.03 was used: grade 1 = mild, grade 2 = moderate, grade 3 = severe, grade 4 = life-threatening consequences; grade 0 = values not meeting any of the criteria for grade 1 or higher.
Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Baseline up to last dose (maximum treatment exposure for Part II was 97.0 weeks)	Parameters evaluated were: albumin (g/L)- CTCAE graded low, alkaline phosphatase (U/L)- CTCAE graded high, alanine aminotransferase (U/L)- CTCAE graded high, amylase (U/L) - CTCAE graded high, aspartate aminotransferase(U/L)- CTCAE graded high, bilirubin (umol/L)- CTCAE graded high, creatinine (umol/L) - CTCAE graded high, creatine kinase (U/L)- CTCAE graded high, gamma glutamyl transferase (U/L)- CTCAE graded high, glucose (mmol/L)- CTCAE graded low, high, potassium (mmol/L)- CTCAE graded low, potassium (mmol/L)- CTCAE graded high, magnesium (mmol/L)- CTCAE graded low, high, phosphate (mmol/L)- CTCAE graded low, sodium (mmol/L)- CTCAE graded low, sodium (mmol/L)- CTCAE graded high, urate (umol/L)- CTCAE graded high. CTCAE version 4.03 was used: grade 1 = mild, grade 2 = moderate, grade 3 = severe, grade 4 = life-threatening consequences; grade 0 = values not meeting any of the criteria for grade 1 or higher.
Number of Participants With Newly Occurring Notably Abnormal Vital Signs: Part I	During study treatment (maximum treatment exposure for Part I was 403.7 weeks)	Vital signs evaluated were: Low/high systolic blood pressure (BP) (millimeter of Mercury \[mmHg\]): less than or equal to (\<=) 90 mmHg with decrease from baseline of \>=20 mmHg / \>=160 mmHg with increase from baseline of \>=20 mmHg; low/high diastolic BP \[mmHg\]: \<=50 mmHg with decrease from baseline of \>=15 mmHg / \>=100 mmHg with increase from baseline of \>=15 mmHg; low/high pulse rate (beats per minute \[bpm\]): \<=50 bpm with decrease from baseline of \>=15 bpm / \>=120 bpm with increase from baseline of \>=15 bpm; low/high weight (kilogram \[kg\]): \>=20% decrease/increase from baseline; and low/high body temperature (degree Celsius \[C\]): \<=36 C / \>= 37.5 C.
Number of Participants With Newly Occurring Notably Abnormal Vital Signs: Part II	During study treatment (maximum treatment exposure for Part II was 97.0 weeks)	Vital signs evaluated were: Low/high systolic BP (mmHg): \<=90 mmHg with decrease from baseline of \>=20 mmHg / \>=160 mmHg with increase from baseline of \>=20 mmHg; low/high diastolic BP \[mmHg\]: \<=50 mmHg with decrease from baseline of \>=15 mmHg / \>=100 mmHg with increase from baseline of \>=15 mmHg; low/high pulse rate (bpm): \<=50 bpm with decrease from baseline of \>=15 bpm / \>=120 bpm with increase from baseline of \>=15 bpm; low/high weight (kg): \>=20% decrease/increase from baseline; and low/high body temperature (C): \<=36 C / \>= 37.5 C.
Number of Participants With Notable Electrocardiograms (ECG) Values: Part I	During study treatment (maximum treatment exposure for Part I was 403.7 weeks)	Number of participants with notable ECG values were reported in this outcome measure. Abnormality categories were: Heart rate (HR): increase from baseline \>25% and to a value \>100 bpm, decrease from baseline \>25% and to a value \<60 bpm; PR: increase from baseline \>25% and to a value \>200 millisecond (ms); QRS: increase from baseline \>25% and to a value \>110 ms; QT: increase from baseline \>30 ms, increase from baseline \>60 ms, new interval \>450 ms, new interval \>480 ms, new interval \>500 ms; and Corrected QT interval by Fridericia (QTcF): increase from baseline \>30 ms, increase from baseline \>60 ms, new interval \>450 ms, new interval \>480 ms, new interval \>500 ms. New = newly occurred post-baseline value.
Number of Participants With Notable ECG Values: Part II	During study treatment (maximum treatment exposure for Part II was 97.0 weeks)	Number of participants with notable ECG values were reported in this outcome measure. Abnormality categories were: HR: increase from baseline \>25% and to a value \>100 bpm, decrease from baseline \>25% and to a value \<60 bpm; PR: increase from baseline \>25% and to a value \>200 ms; QRS: increase from baseline \>25% and to a value \>110 ms; QT: increase from baseline \>30 ms, increase from baseline \>60 ms, new interval \>450 ms, new interval \>480 ms, new interval \>500 ms; and QTcF: increase from baseline \>30 ms, increase from baseline \>60 ms, new interval \>450 ms, new interval \>480 ms, new interval \>500 ms. New = newly occurred post-baseline value.
Number of Participants With At Least One Dose Interruption: Part I	During study treatment (maximum treatment exposure for Part I was 403.7 weeks)	In this outcome measure number of participants with at least 1 dose interruption for encorafenib and binimetinib were reported.
Number of Participants With At Least One Dose Interruption: Part II	During study treatment (maximum treatment exposure for Part II was 97.0 weeks)	In this outcome measure number of participants with at least 1 dose interruption for encorafenib, binimetinib, and each third combination agent were reported.
Number of Participants With At Least One Dose Reduction: Part I	During study treatment (maximum treatment exposure for Part I was 403.7 weeks)	In this outcome measure number of participants with at least 1 dose reduction for encorafenib and binimetinib were reported.
Number of Participants With At Least One Dose Reduction: Part II	During study treatment (maximum treatment exposure for Part II was 97.0 weeks)	In this outcome measure number of participants with at least 1 dose reduction for encorafenib, binimetinib, and each third combination agent were reported.
Progression-Free Survival (PFS): Part I	From start of study drug until documented PD or death due to any cause or censoring date (maximum treatment exposure for Part I was 403.7 weeks)	PFS was defined as the time from the start date of study drug in Part I until documented PD or death due to any cause. All participants who had not progressed or died at the time of the data cut-off were censored at the date of last tumor assessment (other than those who were unknown or missing) prior to cut-off date or start date of new anti-neoplastic therapy, whichever is earlier. Per RECIST 1.1, PD= At least a 20% increase in the sum of diameter of all measured target lesions, taking as reference the smallest sum of diameter of all target lesions recorded at or after baseline. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. Kaplan Meier method used for estimation.
PFS: Part II	From start of study drug until documented PD or death due to any cause or censoring date (maximum treatment exposure for Part II was 97.0 weeks)	PFS was defined as the time from the start date of study drug in Part II until documented PD or death due to any cause. All participants who had not progressed or died at the time of the data cut-off were censored at the date of last tumor assessment (other than those who were unknown or missing) prior to cut-off date or start date of new anti-neoplastic therapy, whichever is earlier. Per RECIST 1.1, PD= At least a 20% increase in the sum of diameter of all measured target lesions, taking as reference the smallest sum of diameter of all target lesions recorded at or after baseline. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. Kaplan Meier method used for estimation.
Duration of Response (DOR): Part I	From date of first documented response (CR or PR) till the date of first documented progression or death due to underlying cancer or censoring date (maximum treatment exposure for Part I was 403.7 weeks)	DOR: time between date of first documented response (CR or PR) and date of first documented progression or death due to underlying cancer. If there was no progression or death due to underlying cancer, then the participant was censored at the date of last tumor assessment other than unknown. RECIST v1.1: CR = disappearance of all non-nodal target lesions. Any pathological lymph nodes assigned as target lesions must had a reduction in short axis to \<10 mm. Disappearance of all non-target lesions. All lymph nodes assigned a non-target lesion must be non-pathological in size (\<10 mm short axis); b) PR = at least a 30% decrease in sum of diameter of all target lesions, taking as reference baseline sum of diameters; c) PD= At least a 20% increase in sum of diameter of all measured target lesions, taking as reference the smallest sum of diameter of all target lesions recorded at or after baseline. In addition, sum must also demonstrate an absolute increase of at least 5 mm.
DOR: Part II	From date of first documented response (CR or PR) till the date of first documented progression or death due to underlying cancer or censoring date (maximum treatment exposure for Part II was 97.0 weeks)	DOR: time between date of first documented response (CR or PR) and date of first documented progression or death due to underlying cancer. If there was no progression or death due to underlying cancer, then the participant was censored at the date of last tumor assessment other than unknown. RECIST v1.1: CR = disappearance of all non-nodal target lesions. Any pathological lymph nodes assigned as target lesions must had a reduction in short axis to \<10 mm. Disappearance of all non-target lesions. All lymph nodes assigned a non-target lesion must be non-pathological in size (\<10 mm short axis); b) PR = at least a 30% decrease in sum of diameter of all target lesions, taking as reference baseline sum of diameters; c) PD= At least a 20% increase in sum of diameter of all measured target lesions, taking as reference the smallest sum of diameter of all target lesions recorded at or after baseline. In addition, sum must also demonstrate an absolute increase of at least 5 mm.
Time to Response (TTR): Part I	From start date of study drug till first documented response (CR or PR) (maximum treatment exposure for Part I was 403.7 weeks)	TTR was defined as the time between the start date of study drug in Part I and first documented response (CR or PR). RECIST v1.1: a) CR = disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must had a reduction in short axis to \<10 mm. Disappearance of all non-target lesions. In addition, all lymph nodes assigned a non-target lesion must be non-pathological in size (\<10 mm short axis) and b) PR = at least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters. Kaplan Meier method used for estimation.
TTR: Part II	From start date of study drug till first documented response (CR or PR) (maximum treatment exposure for Part II was 97.0 weeks)	TTR was defined as the time between the start date of study drug in Part II and first documented response (CR or PR). RECIST v1.1: a) CR = disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must had a reduction in short axis to \<10 mm. Disappearance of all non-target lesions. In addition, all lymph nodes assigned a non-target lesion must be non-pathological in size (\<10 mm short axis) and b) PR = at least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters. Kaplan Meier method used for estimation.
Disease Control Rate (DCR): Part I	From start date of study drug till first documented response (CR or PR or SD) (maximum treatment exposure for Part I was 403.7 weeks)	DCR was defined as percentage of participants with a best overall response of CR or PR or SD. RECIST v1.1: a) CR = disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must had a reduction in short axis to \<10 mm. Disappearance of all non-target lesions. In addition, all lymph nodes assigned a non-target lesion must be non-pathological in size (\<10 mm short axis); b) PR = at least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters and c) SD = neither sufficient shrinkage to qualify for PR or CR nor an increase in lesions which would qualify for PD. PD= At least a 20% increase in the sum of diameter of all measured target lesions, taking as reference the smallest sum of diameter of all target lesions recorded at or after baseline. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.
DCR: Part II	From start date of study drug till first documented response (CR or PR or SD) (maximum treatment exposure for Part II was 97.0 weeks)	DCR was defined as percentage of participants with a best overall response of CR or PR or SD. RECIST v1.1: a) CR = disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must had a reduction in short axis to \<10 mm. Disappearance of all non-target lesions. In addition, all lymph nodes assigned a non-target lesion must be non-pathological in size (\<10 mm short axis); b) PR = at least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters and c) SD = neither sufficient shrinkage to qualify for PR or CR nor an increase in lesions which would qualify for PD. PD= At least a 20% increase in the sum of diameter of all measured target lesions, taking as reference the smallest sum of diameter of all target lesions recorded at or after baseline. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.
Overall Survival (OS): Part II	From date of start of treatment to date of death due to any cause or censoring date (maximum treatment exposure for Part II was 97.0 weeks)	OS was defined as the time from the start date of study treatment (3rd agent combined with encorafenib and binimetinib) to date of death due to any cause. If a participant was not known to have died, survival was censored at the date of last known date participant alive. Kaplan Meier method used for estimation.
Summary of Genomic Biomarkers From Tumor Samples: Part I	Baseline up to end of treatment (EOT) (maximum treatment exposure for Part I was 403.7 weeks)	Number of participants with multiple alterations in genomic biomarkers like biomarker BRAF, CCND1, CDK4, EGFR, FGFR1, FGFR4, KRAS, MET, NRAS, PIK3CA, and PTEN were reported and alterations included copy number variant/copy number ratio (CNV/CNR), rearrangement, short variant. It was not necessary that all biomarkers had all alterations. Baseline = last non-missing value prior to the first dose of study treatment.
Plasma Concentration for Encorafenib (LGX): Part I	C1 (1.5 hrs post-dose on D1; pre-dose, 1.5 hrs post-dose on D15); C2 (pre-dose on D8 and D21); C3 pre-dose on D15; C4 pre-dose on D15; C5 pre-dose on D15; EOT	In results reported below, following abbreviation have been used: Cycle 1 (C1), Day 1 (D1), Day 8 (D8), Day 15 (D15), Day 21 (D21), Cycle 2 (C2), Cycle 3 (C3), Cycle 4 (C4), Cycle 5 (C5) and end of treatment (EOT). Maximum treatment exposure for Part I was of 403.7 weeks.
Plasma Concentration for Encorafenib (LGX): Part II	C1 (1.5, 4 hrs post-dose on D1; pre-dose on D8; pre-dose, 0.5, 1.5, 2.5, 4, 6, 8 hrs post-dose on D15; 24 hrs post-dose on D16; pre-dose on D21); C2 (pre-dose on D1 and D15); C3 pre-dose on D1; C4 pre-dose on D1; C5 pre-dose on D1; EOT	In results reported below, following abbreviation have been used: Cycle 1 (C1), Day 1 (D1), Day 8 (D8), Day 15 (D15), Day 16 (D16), Day 21 (D21), Cycle 2 (C2), Cycle 3 (C3), Cycle 4 (C4), Cycle 5 (C5). Maximum treatment exposure for Part II was of 97.0 weeks.
Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part I	C1 (1.5 hrs post-dose on D1; pre-dose, 1.5 hrs post-dose on D15); C2 (pre-dose on D8 and D21); C3 pre-dose on D15; C4 pre-dose on D15; C5 pre-dose on D15; EOT	AR00426032 is metabolite of binimetinib. Maximum treatment exposure for Part I was of 403.7 weeks.
Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	C1 (1.5, 4 hrs post-dose on D1; pre-dose on D8; pre-dose, 0.5, 1.5, 2.5, 4, 6, 8 hrs post-dose on D15; 24 hrs post-dose on D16; pre-dose on D21); C2 (pre-dose on D1 and D15); C3 pre-dose on D1; C4 pre-dose on D1; C5 pre-dose on D1; EOT	AR00426032 is metabolite of binimetinib. Maximum treatment exposure for Part II was of 97.0 weeks.
Plasma Concentration for Ribociclib (LEE) and Its Metabolite: Part II	C1 (1.5, 4 hrs post-dose on D1; pre-dose on D8; pre-dose, 0.5, 1.5, 2.5, 4, 6, 8 hrs post-dose on D15; 24 hrs post-dose on D16; pre-dose on D21); C2 (pre-dose on D1 and D15); C3 pre-dose on D1; C4 pre-dose on D1; C5 pre-dose on D1; EOT	LEQ803 is metabolite of ribociclib. Maximum treatment exposure for Part II was of 97.0 weeks.
Plasma Concentration for Infigratinib (BGJ) and Its Metabolites: Part II	C1 (1.5 hrs post-dose on D1; pre-dose on D8; pre-dose, 0.5, 1.5, 2.5, 4, 6 hrs post-dose on D15; 24 hrs post-dose on D16; pre-dose on D21); C2 (pre-dose on D1 and D15); C3 pre-dose on D1; EOT	BHS697 and CQM157 are metabolites of infigratinib. Maximum treatment exposure for Part II was of 97.0 weeks.
Plasma Concentration for Capmatinib (INC): Part II	C1 (1.5 hrs post-dose on D1; pre-dose on D8; pre-dose, 0.5, 1.5, 2.5, 4, 6, 8 hrs post-dose on D15; 24 hrs post-dose on D16); C2 (pre-dose on D1 and D15); C3 pre-dose on D1; C4 pre-dose on D1; C5 pre-dose on D1; EOT	Maximum treatment exposure for Part II was of 97.0 weeks.
Plasma Concentration for Buparlisib (BKM): Part II	C1 (1.5 hrs post-dose on D1; pre-dose on D8; pre-dose, 0.5, 1.5, 2.5, 4, 6, 8 hrs post-dose on D15; 24 hrs post-dose on D16); C2 (pre-dose on D1 and D15); C3 pre-dose on D1; C4 pre-dose on D1; C5 pre-dose on D1; EOT	Maximum treatment exposure for Part II was of 97.0 weeks.
Maximum Observed Plasma Concentration at Steady State (Cmax,ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	C1 D15: 0.5 hour ± 10 (minutes) min; 1 hour ± 10 min; 1.5 hour ± 15 min; 2 hour ± 15 min; 2.5 hour ± 15 min; 4 hour ± 30 min; 6 hour ± 30 min; 8 hour ± 60 min; 24 hour ± 2 hour	—
Time to Reach Cmax at Steady State (Tmax, ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	C1 D15: 0.5 hour ± 10 min; 1 hour ± 10 min; 1.5 hour ± 15 min; 2 hour ± 15 min; 2.5 hour ± 15 min; 4 hour ± 30 min; 6 hour ± 30 min; 8 hour ± 60 min; 24 hour ± 2 hour	—
Area Under the Concentration-time Curve From Time Zero to Time Tau at Steady-State (AUCtau,ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Capmatinib, and Buparlisib: Part II	C1 D15: 0.5 hour ± 10 min; 1 hour ± 10 min; 1.5 hour ± 15 min; 2 hour ± 15 min; 2.5 hour ± 15 min; 4 hour ± 30 min; 6 hour ± 30 min; 8 hour ± 60 min; 24 hour ± 2 hour	—
Actual Dose Intensity: Part I	During study treatment (maximum treatment exposure for Part I was 403.7 weeks)	Dose intensity across all cycles = cumulative dose/duration of exposure. Treatment cycle for encorafenib and binimetinib =21 days.
Apparent Total Plasma Clearance at Steady State (Cl, ss/F) of Encorafenib, Binimetinib, Ribociclib, Capmatinib, and Buparlisib: Part II	C1 D15: 0.5 hour ± 10 min; 1 hour ± 10 min; 1.5 hour ± 15 min; 2 hour ± 15 min; 2.5 hour ± 15 min; 4 hour ± 30 min; 6 hour ± 30 min; 8 hour ± 60 min; 24 hour ± 2 hour	Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes.
Apparent Volume of Distribution at Steady State (Vz, ss/F) of Encorafenib, Binimetinib, Ribociclib, Capmatinib, and Buparlisib: Part II	C1 D15: 0.5 hour ± 10 min; 1 hour ± 10 min; 1.5 hour ± 15 min; 2 hour ± 15 min; 2.5 hour ± 15 min; 4 hour ± 30 min; 6 hour ± 30 min; 8 hour ± 60 min; 24 hour ± 2 hour	Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug. Steady state volume of distribution is the apparent volume of distribution at steady-state.
Last Measurable Plasma Concentration at Steady State (Clast, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	C1 D15: 0.5 hour ± 10 min; 1 hour ± 10 min; 1.5 hour ± 15 min; 2 hour ± 15 min; 2.5 hour ± 15 min; 4 hour ± 30 min; 6 hour ± 30 min; 8 hour ± 60 min; 24 hour ± 2 hour	—
Measured Concentration at the End of a Dosing Interval at Steady State (Ctrough, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	C1 D15: at the end of a dosing interval at steady-state (24 hour ± 2 hour), taken directly before next administration	—
Elimination Half-life at Steady State (t1/2, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Capmatinib, and Buparlisib: Part II	C1 D15: 0.5 hour ± 10 min; 1 hour ± 10 min; 1.5 hour ± 15 min; 2 hour ± 15 min; 2.5 hour ± 15 min; 4 hour ± 30 min; 6 hour ± 30 min; 8 hour ± 60 min; 24 hour ± 2 hour	Elimination half-life means the time required for the plasma concentration to decline by 50% during the elimination phase.

Countries

Australia, Canada, Germany, Italy, Netherlands, Spain, Switzerland, United Kingdom, United States

Participant flow

Recruitment details

This study had 2 parts. In Part I, 158 participants were enrolled and treated with encorafenib/ binimetinib (LGX818/MEK162) combination until disease progression (PD) \[as per RECISTv1.1\]. Based on the genetic assessment of a tumor biopsy obtained at PD, participants from Part I entered Part II. In Part II, 58 participants received tailored combination treatment in one of the 4 arms: encorafenib/ binimetinib + buparlisib (BKM120), infigratinib (BGJ398), capmatinib (INC280) or ribociclib (LEE011).

Participants by arm

Arm	Count
Part I: Encorafenib + Binimetinib (Naive) Participants naive to selective V-raf murine sarcoma viral oncogene homolog B1 (BRAF) and mitogen-activated protein kinase (MEK) inhibitors, received encorafenib 450 milligram (mg) once a day and binimetinib 45 mg twice a day until disease progression or no clinical benefit. No dose reduction below 150 mg for encorafenib and 15 mg for binimetinib was permitted for this study. Treatment cycle for encorafenib and binimetinib was defined as 21 days of daily continuous treatment.	75
Part I: Encorafenib + Binimetinib (Non-naive) Participants non-naive to selective BRAF and MEK inhibitors, received encorafenib 450 mg once a day and binimetinib 45 mg twice a day until disease progression or no clinical benefit and initiation of triple combination treatment. No dose reduction below 150 mg for encorafenib and 15 mg for binimetinib was permitted for this study. Treatment cycle for both drugs was defined as 21 days of daily continuous treatment.	83
Part II: Encorafenib + Binimetinib + Ribociclib Participants, received encorafenib 200 mg (starting dose) once a day, binimetinib 45 mg (starting dose) twice a day and ribociclib 100 mg (starting dose) once a day until disease progression or no clinical benefit. No dose reduction below 50 mg for encorafenib and 15 mg for binimetinib was permitted for this study. For ribociclib dose escalation was allowed till 600 mg and dose reduction was permitted till 50 mg. Ribociclib was taken for 21 consecutive days followed by a 7-day planned break. Treatment cycle =28 days.	38
Part II: Encorafenib + Binimetinib + Infigratinib Participants, received encorafenib 450 mg (starting dose) once a day, binimetinib 45 mg (starting dose) twice a day and infigratinib 75 mg (starting dose) once a day until disease progression or no clinical benefit. No dose reduction below 150 mg for encorafenib and 15 mg for binimetinib was permitted for this study. For infigratinib dose escalation was allowed till 125 mg and dose reduction was permitted till 25 mg. Infigratinib was taken for 21 consecutive days followed by a 7-day planned break. Treatment cycle =28 days.	1
Part II: Encorafenib + Binimetinib + Capmatinib Participants, received encorafenib 200 mg (starting dose) once a day, binimetinib 45 mg (starting dose) twice a day and capmatinib 200 mg (starting dose) capsule or 400 mg (starting dose) tablet twice a day until disease progression or no clinical benefit. No dose reduction below 50 mg for encorafenib and 15 mg for binimetinib was permitted for this study. For capmatinib dose escalation was allowed till 600 mg and dose reduction was permitted till 50 mg. Treatment cycle for encorafenib, binimetinib and capmatinib was defined as 21 days of daily continuous treatment.	13
Part II: Encorafenib + Binimetinib + Buparlisib Participants, received encorafenib 450 mg (starting dose) once a day, binimetinib 45 mg (starting dose) twice a day and buparlisib 60 mg (starting dose) once a day until disease progression or no clinical benefit. No dose reduction below 150 mg for encorafenib and 15 mg for binimetinib was permitted for this study. For buparlisib dose escalation was allowed till 100 mg and dose reduction was permitted till 30 mg. Treatment cycle for encorafenib, binimetinib and buparlisib was defined as 21 days of daily continuous treatment.	6
Total	216

Withdrawals & dropouts

Period	Reason	FG000	FG001	FG002	FG003	FG004	FG005
Part I	Adverse Event	7	5	0	0	0	0
Part I	Death	11	9	0	0	0	0
Part I	Missing Data	1	0	0	0	0	0
Part I	New Therapy for Study Indication	5	4	0	0	0	0
Part I	Participant/Guardian Decision	9	3	0	0	0	0
Part I	Physician Decision	2	9	0	0	0	0
Part I	Progressive Disease	37	46	0	0	0	0
Part I	Termination of participants from the study	3	3	0	0	0	0
Part II	Adverse Event	0	0	1	0	1	1
Part II	Death	0	0	1	0	2	1
Part II	New Therapy for Study Indication	0	0	0	0	1	0
Part II	Participant/Guardian Decision	0	0	0	0	2	0
Part II	Physician Decision	0	0	1	0	0	0
Part II	Progressive Disease	0	0	35	1	7	4

Baseline characteristics

Characteristic	Part I: Encorafenib + Binimetinib (Naive)	Part I: Encorafenib + Binimetinib (Non-naive)	Part II: Encorafenib + Binimetinib + Ribociclib	Part II: Encorafenib + Binimetinib + Infigratinib	Part II: Encorafenib + Binimetinib + Capmatinib	Part II: Encorafenib + Binimetinib + Buparlisib	Total
Age, Customized Part I 18-44 years	14 Participants	24 Participants	0 Participants	0 Participants	0 Participants	0 Participants	38 Participants
Age, Customized Part I 45-64 years	43 Participants	37 Participants	0 Participants	0 Participants	0 Participants	0 Participants	80 Participants
Age, Customized Part I 65 years and over	18 Participants	22 Participants	0 Participants	0 Participants	0 Participants	0 Participants	40 Participants
Age, Customized Part I Not disclosed	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Age, Customized Part II 18-44 years	0 Participants	0 Participants	9 Participants	0 Participants	0 Participants	1 Participants	10 Participants
Age, Customized Part II 45-64 years	0 Participants	0 Participants	19 Participants	0 Participants	7 Participants	4 Participants	30 Participants
Age, Customized Part II 65 years and over	0 Participants	0 Participants	10 Participants	0 Participants	6 Participants	1 Participants	17 Participants
Age, Customized Part II Not disclosed	0 Participants	0 Participants	0 Participants	1 Participants	0 Participants	0 Participants	1 Participants
Race/Ethnicity, Customized Ethnicity: Part I Hispanic or Latino	3 Participants	7 Participants	0 Participants	0 Participants	0 Participants	0 Participants	10 Participants
Race/Ethnicity, Customized Ethnicity: Part I Not Disclosed	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Race/Ethnicity, Customized Ethnicity: Part I Not Hispanic or Latino	72 Participants	76 Participants	0 Participants	0 Participants	0 Participants	0 Participants	148 Participants
Race/Ethnicity, Customized Ethnicity: Part II Hispanic or Latino	0 Participants	0 Participants	1 Participants	0 Participants	0 Participants	0 Participants	1 Participants
Race/Ethnicity, Customized Ethnicity: Part II Not Disclosed	0 Participants	0 Participants	0 Participants	1 Participants	0 Participants	0 Participants	1 Participants
Race/Ethnicity, Customized Ethnicity: Part II Not Hispanic or Latino	0 Participants	0 Participants	37 Participants	0 Participants	13 Participants	6 Participants	56 Participants
Race/Ethnicity, Customized Race: Part I Asian	1 Participants	1 Participants	0 Participants	0 Participants	0 Participants	0 Participants	2 Participants
Race/Ethnicity, Customized Race: Part I Caucasian	74 Participants	82 Participants	0 Participants	0 Participants	0 Participants	0 Participants	156 Participants
Race/Ethnicity, Customized Race: Part I Not Disclosed	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Race/Ethnicity, Customized Race: Part II Asian	0 Participants	0 Participants	1 Participants	0 Participants	0 Participants	0 Participants	1 Participants
Race/Ethnicity, Customized Race: Part II Caucasian	0 Participants	0 Participants	37 Participants	0 Participants	13 Participants	6 Participants	56 Participants
Race/Ethnicity, Customized Race: Part II Not Disclosed	0 Participants	0 Participants	0 Participants	1 Participants	0 Participants	0 Participants	1 Participants
Sex/Gender, Customized Part I Female	28 Participants	39 Participants	0 Participants	0 Participants	0 Participants	0 Participants	67 Participants
Sex/Gender, Customized Part I Male	47 Participants	44 Participants	0 Participants	0 Participants	0 Participants	0 Participants	91 Participants
Sex/Gender, Customized Part I Not Disclosed	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Sex/Gender, Customized Part II Female	0 Participants	0 Participants	22 Participants	0 Participants	5 Participants	1 Participants	28 Participants
Sex/Gender, Customized Part II Male	0 Participants	0 Participants	16 Participants	0 Participants	8 Participants	5 Participants	29 Participants
Sex/Gender, Customized Part II Not Disclosed	0 Participants	0 Participants	0 Participants	1 Participants	0 Participants	0 Participants	1 Participants

Adverse events

Event type	EG000 affected / at risk	EG001 affected / at risk	EG002 affected / at risk	EG003 affected / at risk	EG004 affected / at risk	EG005 affected / at risk
deaths Total, all-cause mortality	20 / 75	29 / 83	28 / 38	1 / 1	8 / 13	4 / 6
other Total, other adverse events	75 / 75	73 / 83	33 / 38	0 / 1	11 / 13	5 / 6
serious Total, serious adverse events	47 / 75	37 / 83	19 / 38	0 / 1	6 / 13	4 / 6

Outcome results

Primary

Overall Response Rate (ORR): Part II

ORR: percentage of participants with confirmed complete response (CR) and partial response (PR). Response evaluation criteria in solid tumors (RECIST) v1.1: a) CR = disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions that had a reduction in short axis to less than (\<) 10 millimeter (mm). Disappearance of all non-target lesions. In addition, all lymph nodes assigned a non-target lesion must be non-pathological in size (\<10 mm short axis) and b) PR = at least a 30 percent (%) decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters. Any radiological assessments taken more than 30 days after the last dose of study therapy or after antineoplastic agents other than study treatments taken by the participants was excluded from the best overall response derivation. Confirmation of CR or PR was to be at least 4 weeks apart from the previous radiological assessment.

Time frame: From the start of the treatment until disease/clinical progression or death or early study discontinuation, whichever happened earlier (maximum treatment exposure for Part II was 97.0 weeks)

Population: For Part II, full analysis set (FAS) consisted of all participants who received at least 1 dose of encorafenib or binimetinib or the assigned third agent following the assignment of the triple combination treatment.

Arm	Measure	Value (NUMBER)
Part II: Encorafenib + Binimetinib + Ribociclib	Overall Response Rate (ORR): Part II	2.6 Percentage of participants
Part II: Encorafenib + Binimetinib + Infigratinib	Overall Response Rate (ORR): Part II	0 Percentage of participants
Part II: Encorafenib + Binimetinib + Capmatinib	Overall Response Rate (ORR): Part II	0 Percentage of participants
Part II: Encorafenib + Binimetinib + Buparlisib	Overall Response Rate (ORR): Part II	0 Percentage of participants

Secondary

Actual Dose Intensity: Part I

Dose intensity across all cycles = cumulative dose/duration of exposure. Treatment cycle for encorafenib and binimetinib =21 days.

Time frame: During study treatment (maximum treatment exposure for Part I was 403.7 weeks)

Population: Safety set included all participants who received at least 1 dose of encorafenib or binimetinib for Part I and had at least 1 valid post-baseline safety assessment.

Arm	Measure	Group	Value (MEAN)	Dispersion
Part II: Encorafenib + Binimetinib + Ribociclib	Actual Dose Intensity: Part I	Encorafenib	425.311 Milligram per day	Standard Deviation 53.5392
Part II: Encorafenib + Binimetinib + Ribociclib	Actual Dose Intensity: Part I	Binimetinib	81.920 Milligram per day	Standard Deviation 13.0994
Part II: Encorafenib + Binimetinib + Infigratinib	Actual Dose Intensity: Part I	Encorafenib	408.711 Milligram per day	Standard Deviation 65.5297
Part II: Encorafenib + Binimetinib + Infigratinib	Actual Dose Intensity: Part I	Binimetinib	82.083 Milligram per day	Standard Deviation 10.9117

Secondary

Actual Dose Intensity: Part II

Dose intensity = cumulative dose/ duration of exposure. Treatment cycle = 21days for the combination treatment with buparlisib and capmatinib and 28 days for the combination treatment with ribociclib and infigratinib.

Time frame: During study treatment (maximum treatment exposure for Part II was 97.0 weeks)

Population: Safety set included all participants who received at least 1 dose of 3rd combination agent for Part II and had at least 1 valid post-baseline safety assessment. Here, Number Analyzed signifies number of participants evaluable for specified drug.

Arm	Measure	Group	Value (MEAN)	Dispersion
Part II: Encorafenib + Binimetinib + Ribociclib	Actual Dose Intensity: Part II	Encorafenib	197.856 Milligram per day	Standard Deviation 42.6637
Part II: Encorafenib + Binimetinib + Ribociclib	Actual Dose Intensity: Part II	Ribociclib	486.628 Milligram per day	Standard Deviation 79.4485
Part II: Encorafenib + Binimetinib + Ribociclib	Actual Dose Intensity: Part II	Binimetinib	79.749 Milligram per day	Standard Deviation 14.7267
Part II: Encorafenib + Binimetinib + Infigratinib	Actual Dose Intensity: Part II	Encorafenib	450.000 Milligram per day	—
Part II: Encorafenib + Binimetinib + Infigratinib	Actual Dose Intensity: Part II	Infigratinib	60.227 Milligram per day	—
Part II: Encorafenib + Binimetinib + Infigratinib	Actual Dose Intensity: Part II	Binimetinib	90.000 Milligram per day	—
Part II: Encorafenib + Binimetinib + Capmatinib	Actual Dose Intensity: Part II	Binimetinib	87.373 Milligram per day	Standard Deviation 3.6593
Part II: Encorafenib + Binimetinib + Capmatinib	Actual Dose Intensity: Part II	Encorafenib	195.945 Milligram per day	Standard Deviation 8.4015
Part II: Encorafenib + Binimetinib + Capmatinib	Actual Dose Intensity: Part II	Capmatinib	579.519 Milligram per day	Standard Deviation 259.1157
Part II: Encorafenib + Binimetinib + Buparlisib	Actual Dose Intensity: Part II	Encorafenib	405.014 Milligram per day	Standard Deviation 102.5218
Part II: Encorafenib + Binimetinib + Buparlisib	Actual Dose Intensity: Part II	Buparlisib	72.206 Milligram per day	Standard Deviation 15.7019
Part II: Encorafenib + Binimetinib + Buparlisib	Actual Dose Intensity: Part II	Binimetinib	78.791 Milligram per day	Standard Deviation 20.1538

Secondary

Apparent Total Plasma Clearance at Steady State (Cl, ss/F) of Encorafenib, Binimetinib, Ribociclib, Capmatinib, and Buparlisib: Part II

Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes.

Time frame: C1 D15: 0.5 hour ± 10 min; 1 hour ± 10 min; 1.5 hour ± 15 min; 2 hour ± 15 min; 2.5 hour ± 15 min; 4 hour ± 30 min; 6 hour ± 30 min; 8 hour ± 60 min; 24 hour ± 2 hour

Population: PAS consisted of all participants who had at least one blood sample providing evaluable PK data. All participants reported under Number of Participants Analyzed contributed data to the table; however, may not have evaluable data for every row. Here, Number Analyzed signifies number of participants evaluable for specified study treatment for respective arms.

Arm	Measure	Group	Value (GEOMETRIC_MEAN)	Dispersion
Part II: Encorafenib + Binimetinib + Ribociclib	Apparent Total Plasma Clearance at Steady State (Cl, ss/F) of Encorafenib, Binimetinib, Ribociclib, Capmatinib, and Buparlisib: Part II	Buparlisib	28.2 Liter per hour	Geometric Coefficient of Variation 53.6
Part II: Encorafenib + Binimetinib + Ribociclib	Apparent Total Plasma Clearance at Steady State (Cl, ss/F) of Encorafenib, Binimetinib, Ribociclib, Capmatinib, and Buparlisib: Part II	Binimetinib	28.5 Liter per hour	Geometric Coefficient of Variation 14.8
Part II: Encorafenib + Binimetinib + Ribociclib	Apparent Total Plasma Clearance at Steady State (Cl, ss/F) of Encorafenib, Binimetinib, Ribociclib, Capmatinib, and Buparlisib: Part II	Encorafenib	49.6 Liter per hour	Geometric Coefficient of Variation 42.1
Part II: Encorafenib + Binimetinib + Infigratinib	Apparent Total Plasma Clearance at Steady State (Cl, ss/F) of Encorafenib, Binimetinib, Ribociclib, Capmatinib, and Buparlisib: Part II	Buparlisib	23.2 Liter per hour	—
Part II: Encorafenib + Binimetinib + Infigratinib	Apparent Total Plasma Clearance at Steady State (Cl, ss/F) of Encorafenib, Binimetinib, Ribociclib, Capmatinib, and Buparlisib: Part II	Encorafenib	44.7 Liter per hour	Geometric Coefficient of Variation 18.4
Part II: Encorafenib + Binimetinib + Infigratinib	Apparent Total Plasma Clearance at Steady State (Cl, ss/F) of Encorafenib, Binimetinib, Ribociclib, Capmatinib, and Buparlisib: Part II	Binimetinib	36.9 Liter per hour	Geometric Coefficient of Variation 105.7
Part II: Encorafenib + Binimetinib + Capmatinib	Apparent Total Plasma Clearance at Steady State (Cl, ss/F) of Encorafenib, Binimetinib, Ribociclib, Capmatinib, and Buparlisib: Part II	Binimetinib	35.6 Liter per hour	—
Part II: Encorafenib + Binimetinib + Capmatinib	Apparent Total Plasma Clearance at Steady State (Cl, ss/F) of Encorafenib, Binimetinib, Ribociclib, Capmatinib, and Buparlisib: Part II	Encorafenib	60.7 Liter per hour	—
Part II: Encorafenib + Binimetinib + Buparlisib	Apparent Total Plasma Clearance at Steady State (Cl, ss/F) of Encorafenib, Binimetinib, Ribociclib, Capmatinib, and Buparlisib: Part II	Capmatinib	65.9 Liter per hour	Geometric Coefficient of Variation 52.2
Part II: Encorafenib + Binimetinib + Buparlisib	Apparent Total Plasma Clearance at Steady State (Cl, ss/F) of Encorafenib, Binimetinib, Ribociclib, Capmatinib, and Buparlisib: Part II	Binimetinib	20.8 Liter per hour	Geometric Coefficient of Variation 28.1
Part II: Encorafenib + Binimetinib + Buparlisib	Apparent Total Plasma Clearance at Steady State (Cl, ss/F) of Encorafenib, Binimetinib, Ribociclib, Capmatinib, and Buparlisib: Part II	Encorafenib	40.1 Liter per hour	Geometric Coefficient of Variation 42.6
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 300 mg	Apparent Total Plasma Clearance at Steady State (Cl, ss/F) of Encorafenib, Binimetinib, Ribociclib, Capmatinib, and Buparlisib: Part II	Encorafenib	18.6 Liter per hour	—
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 300 mg	Apparent Total Plasma Clearance at Steady State (Cl, ss/F) of Encorafenib, Binimetinib, Ribociclib, Capmatinib, and Buparlisib: Part II	Capmatinib	24.8 Liter per hour	—
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 300 mg	Apparent Total Plasma Clearance at Steady State (Cl, ss/F) of Encorafenib, Binimetinib, Ribociclib, Capmatinib, and Buparlisib: Part II	Binimetinib	15.1 Liter per hour	—
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 400 mg	Apparent Total Plasma Clearance at Steady State (Cl, ss/F) of Encorafenib, Binimetinib, Ribociclib, Capmatinib, and Buparlisib: Part II	Binimetinib	16.3 Liter per hour	Geometric Coefficient of Variation 5
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 400 mg	Apparent Total Plasma Clearance at Steady State (Cl, ss/F) of Encorafenib, Binimetinib, Ribociclib, Capmatinib, and Buparlisib: Part II	Capmatinib	45.7 Liter per hour	Geometric Coefficient of Variation 24.4
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 400 mg	Apparent Total Plasma Clearance at Steady State (Cl, ss/F) of Encorafenib, Binimetinib, Ribociclib, Capmatinib, and Buparlisib: Part II	Encorafenib	23.4 Liter per hour	Geometric Coefficient of Variation 10.7
Part II: Encorafenib 100 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Apparent Total Plasma Clearance at Steady State (Cl, ss/F) of Encorafenib, Binimetinib, Ribociclib, Capmatinib, and Buparlisib: Part II	Encorafenib	28.7 Liter per hour	—
Part II: Encorafenib 100 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Apparent Total Plasma Clearance at Steady State (Cl, ss/F) of Encorafenib, Binimetinib, Ribociclib, Capmatinib, and Buparlisib: Part II	Binimetinib	17.4 Liter per hour	—
Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 400 mg	Apparent Total Plasma Clearance at Steady State (Cl, ss/F) of Encorafenib, Binimetinib, Ribociclib, Capmatinib, and Buparlisib: Part II	Ribociclib	243 Liter per hour	—
Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 400 mg	Apparent Total Plasma Clearance at Steady State (Cl, ss/F) of Encorafenib, Binimetinib, Ribociclib, Capmatinib, and Buparlisib: Part II	Encorafenib	33.3 Liter per hour	—
Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 400 mg	Apparent Total Plasma Clearance at Steady State (Cl, ss/F) of Encorafenib, Binimetinib, Ribociclib, Capmatinib, and Buparlisib: Part II	Binimetinib	15.8 Liter per hour	—
Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Apparent Total Plasma Clearance at Steady State (Cl, ss/F) of Encorafenib, Binimetinib, Ribociclib, Capmatinib, and Buparlisib: Part II	Binimetinib	26.5 Liter per hour	Geometric Coefficient of Variation 22.6
Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Apparent Total Plasma Clearance at Steady State (Cl, ss/F) of Encorafenib, Binimetinib, Ribociclib, Capmatinib, and Buparlisib: Part II	Ribociclib	161 Liter per hour	Geometric Coefficient of Variation 61.1
Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Apparent Total Plasma Clearance at Steady State (Cl, ss/F) of Encorafenib, Binimetinib, Ribociclib, Capmatinib, and Buparlisib: Part II	Encorafenib	34.9 Liter per hour	Geometric Coefficient of Variation 6.9
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 400 mg	Apparent Total Plasma Clearance at Steady State (Cl, ss/F) of Encorafenib, Binimetinib, Ribociclib, Capmatinib, and Buparlisib: Part II	Ribociclib	173 Liter per hour	—
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 400 mg	Apparent Total Plasma Clearance at Steady State (Cl, ss/F) of Encorafenib, Binimetinib, Ribociclib, Capmatinib, and Buparlisib: Part II	Encorafenib	32.2 Liter per hour	—
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 400 mg	Apparent Total Plasma Clearance at Steady State (Cl, ss/F) of Encorafenib, Binimetinib, Ribociclib, Capmatinib, and Buparlisib: Part II	Binimetinib	25.9 Liter per hour	—
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 600 mg	Apparent Total Plasma Clearance at Steady State (Cl, ss/F) of Encorafenib, Binimetinib, Ribociclib, Capmatinib, and Buparlisib: Part II	Encorafenib	19.5 Liter per hour	Geometric Coefficient of Variation 44.3
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 600 mg	Apparent Total Plasma Clearance at Steady State (Cl, ss/F) of Encorafenib, Binimetinib, Ribociclib, Capmatinib, and Buparlisib: Part II	Binimetinib	19.9 Liter per hour	Geometric Coefficient of Variation 29.2
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 600 mg	Apparent Total Plasma Clearance at Steady State (Cl, ss/F) of Encorafenib, Binimetinib, Ribociclib, Capmatinib, and Buparlisib: Part II	Ribociclib	62.4 Liter per hour	Geometric Coefficient of Variation 58.5
Part II: Encorafenib 300 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Apparent Total Plasma Clearance at Steady State (Cl, ss/F) of Encorafenib, Binimetinib, Ribociclib, Capmatinib, and Buparlisib: Part II	Ribociclib	99.3 Liter per hour	—

Secondary

Apparent Volume of Distribution at Steady State (Vz, ss/F) of Encorafenib, Binimetinib, Ribociclib, Capmatinib, and Buparlisib: Part II

Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug. Steady state volume of distribution is the apparent volume of distribution at steady-state.

Time frame: C1 D15: 0.5 hour ± 10 min; 1 hour ± 10 min; 1.5 hour ± 15 min; 2 hour ± 15 min; 2.5 hour ± 15 min; 4 hour ± 30 min; 6 hour ± 30 min; 8 hour ± 60 min; 24 hour ± 2 hour

Arm	Measure	Group	Value (GEOMETRIC_MEAN)	Dispersion
Part II: Encorafenib + Binimetinib + Ribociclib	Apparent Volume of Distribution at Steady State (Vz, ss/F) of Encorafenib, Binimetinib, Ribociclib, Capmatinib, and Buparlisib: Part II	Encorafenib	268 Liter	Geometric Coefficient of Variation 45.4
Part II: Encorafenib + Binimetinib + Ribociclib	Apparent Volume of Distribution at Steady State (Vz, ss/F) of Encorafenib, Binimetinib, Ribociclib, Capmatinib, and Buparlisib: Part II	Binimetinib	324 Liter	Geometric Coefficient of Variation 58.3
Part II: Encorafenib + Binimetinib + Ribociclib	Apparent Volume of Distribution at Steady State (Vz, ss/F) of Encorafenib, Binimetinib, Ribociclib, Capmatinib, and Buparlisib: Part II	Buparlisib	604 Liter	Geometric Coefficient of Variation 17.4
Part II: Encorafenib + Binimetinib + Infigratinib	Apparent Volume of Distribution at Steady State (Vz, ss/F) of Encorafenib, Binimetinib, Ribociclib, Capmatinib, and Buparlisib: Part II	Binimetinib	185 Liter	Geometric Coefficient of Variation 83.4
Part II: Encorafenib + Binimetinib + Infigratinib	Apparent Volume of Distribution at Steady State (Vz, ss/F) of Encorafenib, Binimetinib, Ribociclib, Capmatinib, and Buparlisib: Part II	Encorafenib	324 Liter	Geometric Coefficient of Variation 69.8
Part II: Encorafenib + Binimetinib + Capmatinib	Apparent Volume of Distribution at Steady State (Vz, ss/F) of Encorafenib, Binimetinib, Ribociclib, Capmatinib, and Buparlisib: Part II	Encorafenib	313 Liter	—
Part II: Encorafenib + Binimetinib + Capmatinib	Apparent Volume of Distribution at Steady State (Vz, ss/F) of Encorafenib, Binimetinib, Ribociclib, Capmatinib, and Buparlisib: Part II	Binimetinib	82.5 Liter	—
Part II: Encorafenib + Binimetinib + Buparlisib	Apparent Volume of Distribution at Steady State (Vz, ss/F) of Encorafenib, Binimetinib, Ribociclib, Capmatinib, and Buparlisib: Part II	Encorafenib	226 Liter	Geometric Coefficient of Variation 92.9
Part II: Encorafenib + Binimetinib + Buparlisib	Apparent Volume of Distribution at Steady State (Vz, ss/F) of Encorafenib, Binimetinib, Ribociclib, Capmatinib, and Buparlisib: Part II	Binimetinib	244 Liter	Geometric Coefficient of Variation 75.9
Part II: Encorafenib + Binimetinib + Buparlisib	Apparent Volume of Distribution at Steady State (Vz, ss/F) of Encorafenib, Binimetinib, Ribociclib, Capmatinib, and Buparlisib: Part II	Capmatinib	190 Liter	Geometric Coefficient of Variation 30.3
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 300 mg	Apparent Volume of Distribution at Steady State (Vz, ss/F) of Encorafenib, Binimetinib, Ribociclib, Capmatinib, and Buparlisib: Part II	Capmatinib	89.5 Liter	—
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 300 mg	Apparent Volume of Distribution at Steady State (Vz, ss/F) of Encorafenib, Binimetinib, Ribociclib, Capmatinib, and Buparlisib: Part II	Encorafenib	91.7 Liter	—
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 400 mg	Apparent Volume of Distribution at Steady State (Vz, ss/F) of Encorafenib, Binimetinib, Ribociclib, Capmatinib, and Buparlisib: Part II	Capmatinib	233 Liter	—
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 400 mg	Apparent Volume of Distribution at Steady State (Vz, ss/F) of Encorafenib, Binimetinib, Ribociclib, Capmatinib, and Buparlisib: Part II	Encorafenib	133 Liter	Geometric Coefficient of Variation 13.5
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 400 mg	Apparent Volume of Distribution at Steady State (Vz, ss/F) of Encorafenib, Binimetinib, Ribociclib, Capmatinib, and Buparlisib: Part II	Binimetinib	125 Liter	Geometric Coefficient of Variation 56.1
Part II: Encorafenib 100 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Apparent Volume of Distribution at Steady State (Vz, ss/F) of Encorafenib, Binimetinib, Ribociclib, Capmatinib, and Buparlisib: Part II	Binimetinib	147 Liter	—
Part II: Encorafenib 100 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Apparent Volume of Distribution at Steady State (Vz, ss/F) of Encorafenib, Binimetinib, Ribociclib, Capmatinib, and Buparlisib: Part II	Encorafenib	177 Liter	—
Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 400 mg	Apparent Volume of Distribution at Steady State (Vz, ss/F) of Encorafenib, Binimetinib, Ribociclib, Capmatinib, and Buparlisib: Part II	Encorafenib	180 Liter	—
Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 400 mg	Apparent Volume of Distribution at Steady State (Vz, ss/F) of Encorafenib, Binimetinib, Ribociclib, Capmatinib, and Buparlisib: Part II	Binimetinib	86.8 Liter	—
Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 400 mg	Apparent Volume of Distribution at Steady State (Vz, ss/F) of Encorafenib, Binimetinib, Ribociclib, Capmatinib, and Buparlisib: Part II	Ribociclib	3160 Liter	—
Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Apparent Volume of Distribution at Steady State (Vz, ss/F) of Encorafenib, Binimetinib, Ribociclib, Capmatinib, and Buparlisib: Part II	Binimetinib	184 Liter	Geometric Coefficient of Variation 111.8
Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Apparent Volume of Distribution at Steady State (Vz, ss/F) of Encorafenib, Binimetinib, Ribociclib, Capmatinib, and Buparlisib: Part II	Encorafenib	210 Liter	Geometric Coefficient of Variation 32.3
Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Apparent Volume of Distribution at Steady State (Vz, ss/F) of Encorafenib, Binimetinib, Ribociclib, Capmatinib, and Buparlisib: Part II	Ribociclib	1930 Liter	Geometric Coefficient of Variation 30.5
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 400 mg	Apparent Volume of Distribution at Steady State (Vz, ss/F) of Encorafenib, Binimetinib, Ribociclib, Capmatinib, and Buparlisib: Part II	Ribociclib	2660 Liter	—
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 400 mg	Apparent Volume of Distribution at Steady State (Vz, ss/F) of Encorafenib, Binimetinib, Ribociclib, Capmatinib, and Buparlisib: Part II	Binimetinib	406 Liter	—
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 400 mg	Apparent Volume of Distribution at Steady State (Vz, ss/F) of Encorafenib, Binimetinib, Ribociclib, Capmatinib, and Buparlisib: Part II	Encorafenib	178 Liter	—
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 600 mg	Apparent Volume of Distribution at Steady State (Vz, ss/F) of Encorafenib, Binimetinib, Ribociclib, Capmatinib, and Buparlisib: Part II	Binimetinib	113 Liter	Geometric Coefficient of Variation 48.5
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 600 mg	Apparent Volume of Distribution at Steady State (Vz, ss/F) of Encorafenib, Binimetinib, Ribociclib, Capmatinib, and Buparlisib: Part II	Encorafenib	99.3 Liter	Geometric Coefficient of Variation 46
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 600 mg	Apparent Volume of Distribution at Steady State (Vz, ss/F) of Encorafenib, Binimetinib, Ribociclib, Capmatinib, and Buparlisib: Part II	Ribociclib	677 Liter	Geometric Coefficient of Variation 65
Part II: Encorafenib 300 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Apparent Volume of Distribution at Steady State (Vz, ss/F) of Encorafenib, Binimetinib, Ribociclib, Capmatinib, and Buparlisib: Part II	Ribociclib	1440 Liter	—

Secondary

Area Under the Concentration-time Curve From Time Zero to Time Tau at Steady-State (AUCtau,ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Capmatinib, and Buparlisib: Part II

Time frame: C1 D15: 0.5 hour ± 10 min; 1 hour ± 10 min; 1.5 hour ± 15 min; 2 hour ± 15 min; 2.5 hour ± 15 min; 4 hour ± 30 min; 6 hour ± 30 min; 8 hour ± 60 min; 24 hour ± 2 hour

Arm	Measure	Group	Value (GEOMETRIC_MEAN)	Dispersion
Part II: Encorafenib + Binimetinib + Ribociclib	Area Under the Concentration-time Curve From Time Zero to Time Tau at Steady-State (AUCtau,ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Capmatinib, and Buparlisib: Part II	Encorafenib	9080 Hour*nanogram per milliliter	Geometric Coefficient of Variation 42.2
Part II: Encorafenib + Binimetinib + Ribociclib	Area Under the Concentration-time Curve From Time Zero to Time Tau at Steady-State (AUCtau,ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Capmatinib, and Buparlisib: Part II	Buparlisib	2130 Hour*nanogram per milliliter	Geometric Coefficient of Variation 54.6
Part II: Encorafenib + Binimetinib + Ribociclib	Area Under the Concentration-time Curve From Time Zero to Time Tau at Steady-State (AUCtau,ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Capmatinib, and Buparlisib: Part II	Binimetinib	1580 Hour*nanogram per milliliter	Geometric Coefficient of Variation 17
Part II: Encorafenib + Binimetinib + Ribociclib	Area Under the Concentration-time Curve From Time Zero to Time Tau at Steady-State (AUCtau,ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Capmatinib, and Buparlisib: Part II	Binimetinib metabolite, AR00426032	116 Hour*nanogram per milliliter	Geometric Coefficient of Variation 66.8
Part II: Encorafenib + Binimetinib + Infigratinib	Area Under the Concentration-time Curve From Time Zero to Time Tau at Steady-State (AUCtau,ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Capmatinib, and Buparlisib: Part II	Buparlisib	3400 Hour*nanogram per milliliter	Geometric Coefficient of Variation 18.5
Part II: Encorafenib + Binimetinib + Infigratinib	Area Under the Concentration-time Curve From Time Zero to Time Tau at Steady-State (AUCtau,ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Capmatinib, and Buparlisib: Part II	Binimetinib	1220 Hour*nanogram per milliliter	Geometric Coefficient of Variation 105.7
Part II: Encorafenib + Binimetinib + Infigratinib	Area Under the Concentration-time Curve From Time Zero to Time Tau at Steady-State (AUCtau,ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Capmatinib, and Buparlisib: Part II	Encorafenib	10100 Hour*nanogram per milliliter	Geometric Coefficient of Variation 18.4
Part II: Encorafenib + Binimetinib + Infigratinib	Area Under the Concentration-time Curve From Time Zero to Time Tau at Steady-State (AUCtau,ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Capmatinib, and Buparlisib: Part II	Binimetinib metabolite, AR00426032	94.4 Hour*nanogram per milliliter	Geometric Coefficient of Variation 222.2
Part II: Encorafenib + Binimetinib + Capmatinib	Area Under the Concentration-time Curve From Time Zero to Time Tau at Steady-State (AUCtau,ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Capmatinib, and Buparlisib: Part II	Binimetinib metabolite, AR00426032	42.0 Hour*nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Capmatinib	Area Under the Concentration-time Curve From Time Zero to Time Tau at Steady-State (AUCtau,ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Capmatinib, and Buparlisib: Part II	Encorafenib	7420 Hour*nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Capmatinib	Area Under the Concentration-time Curve From Time Zero to Time Tau at Steady-State (AUCtau,ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Capmatinib, and Buparlisib: Part II	Binimetinib	1260 Hour*nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Buparlisib	Area Under the Concentration-time Curve From Time Zero to Time Tau at Steady-State (AUCtau,ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Capmatinib, and Buparlisib: Part II	Binimetinib	2180 Hour*nanogram per milliliter	Geometric Coefficient of Variation 29.4
Part II: Encorafenib + Binimetinib + Buparlisib	Area Under the Concentration-time Curve From Time Zero to Time Tau at Steady-State (AUCtau,ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Capmatinib, and Buparlisib: Part II	Encorafenib	4990 Hour*nanogram per milliliter	Geometric Coefficient of Variation 42.6
Part II: Encorafenib + Binimetinib + Buparlisib	Area Under the Concentration-time Curve From Time Zero to Time Tau at Steady-State (AUCtau,ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Capmatinib, and Buparlisib: Part II	Binimetinib metabolite, AR00426032	124 Hour*nanogram per milliliter	Geometric Coefficient of Variation 113.9
Part II: Encorafenib + Binimetinib + Buparlisib	Area Under the Concentration-time Curve From Time Zero to Time Tau at Steady-State (AUCtau,ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Capmatinib, and Buparlisib: Part II	Capmatinib	3070 Hour*nanogram per milliliter	Geometric Coefficient of Variation 52.6
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 300 mg	Area Under the Concentration-time Curve From Time Zero to Time Tau at Steady-State (AUCtau,ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Capmatinib, and Buparlisib: Part II	Capmatinib	12200 Hour*nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 300 mg	Area Under the Concentration-time Curve From Time Zero to Time Tau at Steady-State (AUCtau,ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Capmatinib, and Buparlisib: Part II	Binimetinib	3040 Hour*nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 300 mg	Area Under the Concentration-time Curve From Time Zero to Time Tau at Steady-State (AUCtau,ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Capmatinib, and Buparlisib: Part II	Binimetinib metabolite, AR00426032	135 Hour*nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 300 mg	Area Under the Concentration-time Curve From Time Zero to Time Tau at Steady-State (AUCtau,ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Capmatinib, and Buparlisib: Part II	Encorafenib	10800 Hour*nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 400 mg	Area Under the Concentration-time Curve From Time Zero to Time Tau at Steady-State (AUCtau,ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Capmatinib, and Buparlisib: Part II	Binimetinib	2760 Hour*nanogram per milliliter	Geometric Coefficient of Variation 4.8
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 400 mg	Area Under the Concentration-time Curve From Time Zero to Time Tau at Steady-State (AUCtau,ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Capmatinib, and Buparlisib: Part II	Encorafenib	8570 Hour*nanogram per milliliter	Geometric Coefficient of Variation 10.6
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 400 mg	Area Under the Concentration-time Curve From Time Zero to Time Tau at Steady-State (AUCtau,ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Capmatinib, and Buparlisib: Part II	Capmatinib	8420 Hour*nanogram per milliliter	Geometric Coefficient of Variation 22
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 400 mg	Area Under the Concentration-time Curve From Time Zero to Time Tau at Steady-State (AUCtau,ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Capmatinib, and Buparlisib: Part II	Binimetinib metabolite, AR00426032	182 Hour*nanogram per milliliter	Geometric Coefficient of Variation 43.1
Part II: Encorafenib 100 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Area Under the Concentration-time Curve From Time Zero to Time Tau at Steady-State (AUCtau,ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Capmatinib, and Buparlisib: Part II	Encorafenib	3490 Hour*nanogram per milliliter	—
Part II: Encorafenib 100 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Area Under the Concentration-time Curve From Time Zero to Time Tau at Steady-State (AUCtau,ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Capmatinib, and Buparlisib: Part II	Ribociclib	5630 Hour*nanogram per milliliter	—
Part II: Encorafenib 100 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Area Under the Concentration-time Curve From Time Zero to Time Tau at Steady-State (AUCtau,ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Capmatinib, and Buparlisib: Part II	Binimetinib metabolite, AR00426032	81.5 Hour*nanogram per milliliter	—
Part II: Encorafenib 100 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Area Under the Concentration-time Curve From Time Zero to Time Tau at Steady-State (AUCtau,ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Capmatinib, and Buparlisib: Part II	Binimetinib	1700 Hour*nanogram per milliliter	—
Part II: Encorafenib 100 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Area Under the Concentration-time Curve From Time Zero to Time Tau at Steady-State (AUCtau,ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Capmatinib, and Buparlisib: Part II	Ribociclib metabolite, LEQ803	2770 Hour*nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 400 mg	Area Under the Concentration-time Curve From Time Zero to Time Tau at Steady-State (AUCtau,ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Capmatinib, and Buparlisib: Part II	Binimetinib	1900 Hour*nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 400 mg	Area Under the Concentration-time Curve From Time Zero to Time Tau at Steady-State (AUCtau,ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Capmatinib, and Buparlisib: Part II	Ribociclib metabolite, LEQ803	1640 Hour*nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 400 mg	Area Under the Concentration-time Curve From Time Zero to Time Tau at Steady-State (AUCtau,ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Capmatinib, and Buparlisib: Part II	Encorafenib	6000 Hour*nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 400 mg	Area Under the Concentration-time Curve From Time Zero to Time Tau at Steady-State (AUCtau,ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Capmatinib, and Buparlisib: Part II	Ribociclib	1650 Hour*nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 400 mg	Area Under the Concentration-time Curve From Time Zero to Time Tau at Steady-State (AUCtau,ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Capmatinib, and Buparlisib: Part II	Binimetinib metabolite, AR00426032	47.0 Hour*nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Area Under the Concentration-time Curve From Time Zero to Time Tau at Steady-State (AUCtau,ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Capmatinib, and Buparlisib: Part II	Ribociclib	3730 Hour*nanogram per milliliter	Geometric Coefficient of Variation 62.5
Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Area Under the Concentration-time Curve From Time Zero to Time Tau at Steady-State (AUCtau,ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Capmatinib, and Buparlisib: Part II	Ribociclib metabolite, LEQ803	1900 Hour*nanogram per milliliter	Geometric Coefficient of Variation 24.9
Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Area Under the Concentration-time Curve From Time Zero to Time Tau at Steady-State (AUCtau,ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Capmatinib, and Buparlisib: Part II	Encorafenib	5740 Hour*nanogram per milliliter	Geometric Coefficient of Variation 7.1
Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Area Under the Concentration-time Curve From Time Zero to Time Tau at Steady-State (AUCtau,ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Capmatinib, and Buparlisib: Part II	Binimetinib	1140 Hour*nanogram per milliliter	Geometric Coefficient of Variation 21.1
Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Area Under the Concentration-time Curve From Time Zero to Time Tau at Steady-State (AUCtau,ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Capmatinib, and Buparlisib: Part II	Binimetinib metabolite, AR00426032	57.9 Hour*nanogram per milliliter	Geometric Coefficient of Variation 128.5
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 400 mg	Area Under the Concentration-time Curve From Time Zero to Time Tau at Steady-State (AUCtau,ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Capmatinib, and Buparlisib: Part II	Binimetinib metabolite, AR00426032	66.9 Hour*nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 400 mg	Area Under the Concentration-time Curve From Time Zero to Time Tau at Steady-State (AUCtau,ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Capmatinib, and Buparlisib: Part II	Encorafenib	6200 Hour*nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 400 mg	Area Under the Concentration-time Curve From Time Zero to Time Tau at Steady-State (AUCtau,ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Capmatinib, and Buparlisib: Part II	Binimetinib	1740 Hour*nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 400 mg	Area Under the Concentration-time Curve From Time Zero to Time Tau at Steady-State (AUCtau,ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Capmatinib, and Buparlisib: Part II	Ribociclib	2320 Hour*nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 400 mg	Area Under the Concentration-time Curve From Time Zero to Time Tau at Steady-State (AUCtau,ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Capmatinib, and Buparlisib: Part II	Ribociclib metabolite, LEQ803	930 Hour*nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 600 mg	Area Under the Concentration-time Curve From Time Zero to Time Tau at Steady-State (AUCtau,ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Capmatinib, and Buparlisib: Part II	Binimetinib metabolite, AR00426032	115 Hour*nanogram per milliliter	Geometric Coefficient of Variation 92.6
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 600 mg	Area Under the Concentration-time Curve From Time Zero to Time Tau at Steady-State (AUCtau,ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Capmatinib, and Buparlisib: Part II	Encorafenib	11300 Hour*nanogram per milliliter	Geometric Coefficient of Variation 41.1
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 600 mg	Area Under the Concentration-time Curve From Time Zero to Time Tau at Steady-State (AUCtau,ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Capmatinib, and Buparlisib: Part II	Binimetinib	2270 Hour*nanogram per milliliter	Geometric Coefficient of Variation 29.5
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 600 mg	Area Under the Concentration-time Curve From Time Zero to Time Tau at Steady-State (AUCtau,ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Capmatinib, and Buparlisib: Part II	Ribociclib	9230 Hour*nanogram per milliliter	Geometric Coefficient of Variation 60.9
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 600 mg	Area Under the Concentration-time Curve From Time Zero to Time Tau at Steady-State (AUCtau,ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Capmatinib, and Buparlisib: Part II	Ribociclib metabolite, LEQ803	2540 Hour*nanogram per milliliter	Geometric Coefficient of Variation 31.3
Part II: Encorafenib 300 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Area Under the Concentration-time Curve From Time Zero to Time Tau at Steady-State (AUCtau,ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Capmatinib, and Buparlisib: Part II	Ribociclib	5960 Hour*nanogram per milliliter	—
Part II: Encorafenib 300 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Area Under the Concentration-time Curve From Time Zero to Time Tau at Steady-State (AUCtau,ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Capmatinib, and Buparlisib: Part II	Ribociclib metabolite, LEQ803	2300 Hour*nanogram per milliliter	—
Part II: Encorafenib 300 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Area Under the Concentration-time Curve From Time Zero to Time Tau at Steady-State (AUCtau,ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Capmatinib, and Buparlisib: Part II	Binimetinib metabolite, AR00426032	41.1 Hour*nanogram per milliliter	—
Part II: Encorafenib 300 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Area Under the Concentration-time Curve From Time Zero to Time Tau at Steady-State (AUCtau,ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Capmatinib, and Buparlisib: Part II	Binimetinib	1470 Hour*nanogram per milliliter	—

Secondary

DCR: Part II

DCR was defined as percentage of participants with a best overall response of CR or PR or SD. RECIST v1.1: a) CR = disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must had a reduction in short axis to \<10 mm. Disappearance of all non-target lesions. In addition, all lymph nodes assigned a non-target lesion must be non-pathological in size (\<10 mm short axis); b) PR = at least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters and c) SD = neither sufficient shrinkage to qualify for PR or CR nor an increase in lesions which would qualify for PD. PD= At least a 20% increase in the sum of diameter of all measured target lesions, taking as reference the smallest sum of diameter of all target lesions recorded at or after baseline. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.

Time frame: From start date of study drug till first documented response (CR or PR or SD) (maximum treatment exposure for Part II was 97.0 weeks)

Arm	Measure	Value (NUMBER)
Part II: Encorafenib + Binimetinib + Ribociclib	DCR: Part II	26.3 Percentage of participants
Part II: Encorafenib + Binimetinib + Infigratinib	DCR: Part II	0 Percentage of participants
Part II: Encorafenib + Binimetinib + Capmatinib	DCR: Part II	15.4 Percentage of participants
Part II: Encorafenib + Binimetinib + Buparlisib	DCR: Part II	16.7 Percentage of participants

Secondary

Disease Control Rate (DCR): Part I

Time frame: From start date of study drug till first documented response (CR or PR or SD) (maximum treatment exposure for Part I was 403.7 weeks)

Population: For Part I, FAS consisted of all participants who received at least 1 dose (partial or full) of encorafenib or binimetinib.

Arm	Measure	Value (NUMBER)
Part II: Encorafenib + Binimetinib + Ribociclib	Disease Control Rate (DCR): Part I	92.0 Percentage of participants
Part II: Encorafenib + Binimetinib + Infigratinib	Disease Control Rate (DCR): Part I	42.2 Percentage of participants

Secondary

DOR: Part II

DOR: time between date of first documented response (CR or PR) and date of first documented progression or death due to underlying cancer. If there was no progression or death due to underlying cancer, then the participant was censored at the date of last tumor assessment other than unknown. RECIST v1.1: CR = disappearance of all non-nodal target lesions. Any pathological lymph nodes assigned as target lesions must had a reduction in short axis to \<10 mm. Disappearance of all non-target lesions. All lymph nodes assigned a non-target lesion must be non-pathological in size (\<10 mm short axis); b) PR = at least a 30% decrease in sum of diameter of all target lesions, taking as reference baseline sum of diameters; c) PD= At least a 20% increase in sum of diameter of all measured target lesions, taking as reference the smallest sum of diameter of all target lesions recorded at or after baseline. In addition, sum must also demonstrate an absolute increase of at least 5 mm.

Time frame: From date of first documented response (CR or PR) till the date of first documented progression or death due to underlying cancer or censoring date (maximum treatment exposure for Part II was 97.0 weeks)

Population: For Part II, FAS consisted of all participants who received at least 1 dose of encorafenib or binimetinib or the assigned third agent following the assignment of the triple combination treatment. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure who were confirmed responders. Kaplan Meier method used for estimation.

Arm	Measure	Value (MEDIAN)
Part II: Encorafenib + Binimetinib + Ribociclib	DOR: Part II	2.1 Months

Secondary

Duration of Response (DOR): Part I

Population: For Part I, FAS consisted of all participants who received at least 1 dose (partial or full) of encorafenib or binimetinib. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure who were confirmed responders. Kaplan Meier method used for estimation.

Arm	Measure	Value (MEDIAN)
Part II: Encorafenib + Binimetinib + Ribociclib	Duration of Response (DOR): Part I	10.9 Months
Part II: Encorafenib + Binimetinib + Infigratinib	Duration of Response (DOR): Part I	5.6 Months

Secondary

Elimination Half-life at Steady State (t1/2, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Capmatinib, and Buparlisib: Part II

Elimination half-life means the time required for the plasma concentration to decline by 50% during the elimination phase.

Time frame: C1 D15: 0.5 hour ± 10 min; 1 hour ± 10 min; 1.5 hour ± 15 min; 2 hour ± 15 min; 2.5 hour ± 15 min; 4 hour ± 30 min; 6 hour ± 30 min; 8 hour ± 60 min; 24 hour ± 2 hour

Arm	Measure	Group	Value (MEAN)	Dispersion
Part II: Encorafenib + Binimetinib + Ribociclib	Elimination Half-life at Steady State (t1/2, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Capmatinib, and Buparlisib: Part II	Binimetinib metabolite, AR00426032	6.35 Hour	Standard Deviation 1.21
Part II: Encorafenib + Binimetinib + Ribociclib	Elimination Half-life at Steady State (t1/2, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Capmatinib, and Buparlisib: Part II	Encorafenib	3.75 Hour	Standard Deviation 0.302
Part II: Encorafenib + Binimetinib + Ribociclib	Elimination Half-life at Steady State (t1/2, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Capmatinib, and Buparlisib: Part II	Buparlisib	15.4 Hour	Standard Deviation 4.62
Part II: Encorafenib + Binimetinib + Ribociclib	Elimination Half-life at Steady State (t1/2, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Capmatinib, and Buparlisib: Part II	Binimetinib	8.35 Hour	Standard Deviation 3.52
Part II: Encorafenib + Binimetinib + Infigratinib	Elimination Half-life at Steady State (t1/2, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Capmatinib, and Buparlisib: Part II	Binimetinib metabolite, AR00426032	4.14 Hour	Standard Deviation 0.683
Part II: Encorafenib + Binimetinib + Infigratinib	Elimination Half-life at Steady State (t1/2, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Capmatinib, and Buparlisib: Part II	Binimetinib	3.48 Hour	Standard Deviation 0.484
Part II: Encorafenib + Binimetinib + Infigratinib	Elimination Half-life at Steady State (t1/2, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Capmatinib, and Buparlisib: Part II	Encorafenib	5.89 Hour	Standard Deviation 4.32
Part II: Encorafenib + Binimetinib + Capmatinib	Elimination Half-life at Steady State (t1/2, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Capmatinib, and Buparlisib: Part II	Binimetinib metabolite, AR00426032	1.59 Hour	—
Part II: Encorafenib + Binimetinib + Capmatinib	Elimination Half-life at Steady State (t1/2, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Capmatinib, and Buparlisib: Part II	Encorafenib	3.57 Hour	—
Part II: Encorafenib + Binimetinib + Capmatinib	Elimination Half-life at Steady State (t1/2, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Capmatinib, and Buparlisib: Part II	Binimetinib	1.60 Hour	—
Part II: Encorafenib + Binimetinib + Buparlisib	Elimination Half-life at Steady State (t1/2, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Capmatinib, and Buparlisib: Part II	Encorafenib	4.18 Hour	Standard Deviation 1.85
Part II: Encorafenib + Binimetinib + Buparlisib	Elimination Half-life at Steady State (t1/2, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Capmatinib, and Buparlisib: Part II	Capmatinib	2.18 Hour	Standard Deviation 0.0599
Part II: Encorafenib + Binimetinib + Buparlisib	Elimination Half-life at Steady State (t1/2, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Capmatinib, and Buparlisib: Part II	Binimetinib metabolite, AR00426032	7.95 Hour	Standard Deviation 4.03
Part II: Encorafenib + Binimetinib + Buparlisib	Elimination Half-life at Steady State (t1/2, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Capmatinib, and Buparlisib: Part II	Binimetinib	10.3 Hour	Standard Deviation 6.29
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 300 mg	Elimination Half-life at Steady State (t1/2, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Capmatinib, and Buparlisib: Part II	Binimetinib metabolite, AR00426032	2.86 Hour	—
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 300 mg	Elimination Half-life at Steady State (t1/2, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Capmatinib, and Buparlisib: Part II	Capmatinib	2.50 Hour	—
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 300 mg	Elimination Half-life at Steady State (t1/2, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Capmatinib, and Buparlisib: Part II	Encorafenib	3.41 Hour	—
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 400 mg	Elimination Half-life at Steady State (t1/2, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Capmatinib, and Buparlisib: Part II	Encorafenib	3.96 Hour	Standard Deviation 0.233
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 400 mg	Elimination Half-life at Steady State (t1/2, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Capmatinib, and Buparlisib: Part II	Binimetinib	5.88 Hour	Standard Deviation 2.77
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 400 mg	Elimination Half-life at Steady State (t1/2, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Capmatinib, and Buparlisib: Part II	Binimetinib metabolite, AR00426032	5.64 Hour	Standard Deviation 2.49
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 400 mg	Elimination Half-life at Steady State (t1/2, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Capmatinib, and Buparlisib: Part II	Capmatinib	2.82 Hour	—
Part II: Encorafenib 100 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Elimination Half-life at Steady State (t1/2, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Capmatinib, and Buparlisib: Part II	Encorafenib	4.27 Hour	—
Part II: Encorafenib 100 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Elimination Half-life at Steady State (t1/2, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Capmatinib, and Buparlisib: Part II	Binimetinib	5.84 Hour	—
Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 400 mg	Elimination Half-life at Steady State (t1/2, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Capmatinib, and Buparlisib: Part II	Ribociclib metabolite, LEQ803	19.9 Hour	—
Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 400 mg	Elimination Half-life at Steady State (t1/2, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Capmatinib, and Buparlisib: Part II	Binimetinib	3.82 Hour	—
Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 400 mg	Elimination Half-life at Steady State (t1/2, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Capmatinib, and Buparlisib: Part II	Binimetinib metabolite, AR00426032	4.34 Hour	—
Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 400 mg	Elimination Half-life at Steady State (t1/2, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Capmatinib, and Buparlisib: Part II	Encorafenib	3.75 Hour	—
Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 400 mg	Elimination Half-life at Steady State (t1/2, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Capmatinib, and Buparlisib: Part II	Ribociclib	9.01 Hour	—
Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Elimination Half-life at Steady State (t1/2, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Capmatinib, and Buparlisib: Part II	Binimetinib	5.38 Hour	Standard Deviation 3.39
Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Elimination Half-life at Steady State (t1/2, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Capmatinib, and Buparlisib: Part II	Binimetinib metabolite, AR00426032	6.24 Hour	Standard Deviation 4.43
Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Elimination Half-life at Steady State (t1/2, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Capmatinib, and Buparlisib: Part II	Encorafenib	4.32 Hour	Standard Deviation 1.62
Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Elimination Half-life at Steady State (t1/2, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Capmatinib, and Buparlisib: Part II	Ribociclib	8.44 Hour	Standard Deviation 2.21
Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Elimination Half-life at Steady State (t1/2, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Capmatinib, and Buparlisib: Part II	Ribociclib metabolite, LEQ803	14.1 Hour	Standard Deviation 4.04
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 400 mg	Elimination Half-life at Steady State (t1/2, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Capmatinib, and Buparlisib: Part II	Ribociclib	10.7 Hour	—
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 400 mg	Elimination Half-life at Steady State (t1/2, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Capmatinib, and Buparlisib: Part II	Encorafenib	3.83 Hour	—
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 400 mg	Elimination Half-life at Steady State (t1/2, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Capmatinib, and Buparlisib: Part II	Ribociclib metabolite, LEQ803	19.2 Hour	—
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 400 mg	Elimination Half-life at Steady State (t1/2, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Capmatinib, and Buparlisib: Part II	Binimetinib	10.9 Hour	—
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 600 mg	Elimination Half-life at Steady State (t1/2, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Capmatinib, and Buparlisib: Part II	Binimetinib	4.13 Hour	Standard Deviation 1.42
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 600 mg	Elimination Half-life at Steady State (t1/2, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Capmatinib, and Buparlisib: Part II	Ribociclib metabolite, LEQ803	16.0 Hour	Standard Deviation 4.5
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 600 mg	Elimination Half-life at Steady State (t1/2, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Capmatinib, and Buparlisib: Part II	Binimetinib metabolite, AR00426032	5.91 Hour	Standard Deviation 3
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 600 mg	Elimination Half-life at Steady State (t1/2, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Capmatinib, and Buparlisib: Part II	Encorafenib	3.60 Hour	Standard Deviation 0.711
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 600 mg	Elimination Half-life at Steady State (t1/2, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Capmatinib, and Buparlisib: Part II	Ribociclib	7.77 Hour	Standard Deviation 1.95
Part II: Encorafenib 300 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Elimination Half-life at Steady State (t1/2, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Capmatinib, and Buparlisib: Part II	Ribociclib	10.1 Hour	—

Secondary

Last Measurable Plasma Concentration at Steady State (Clast, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II

Time frame: C1 D15: 0.5 hour ± 10 min; 1 hour ± 10 min; 1.5 hour ± 15 min; 2 hour ± 15 min; 2.5 hour ± 15 min; 4 hour ± 30 min; 6 hour ± 30 min; 8 hour ± 60 min; 24 hour ± 2 hour

Arm	Measure	Group	Value (GEOMETRIC_MEAN)	Dispersion
Part II: Encorafenib + Binimetinib + Ribociclib	Last Measurable Plasma Concentration at Steady State (Clast, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Binimetinib metabolite, AR00426032	3.99 Nanogram per milliliter	Geometric Coefficient of Variation 61.8
Part II: Encorafenib + Binimetinib + Ribociclib	Last Measurable Plasma Concentration at Steady State (Clast, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Binimetinib	44.1 Nanogram per milliliter	Geometric Coefficient of Variation 19.1
Part II: Encorafenib + Binimetinib + Ribociclib	Last Measurable Plasma Concentration at Steady State (Clast, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Buparlisib	41.8 Nanogram per milliliter	Geometric Coefficient of Variation 82.9
Part II: Encorafenib + Binimetinib + Ribociclib	Last Measurable Plasma Concentration at Steady State (Clast, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Encorafenib	11.3 Nanogram per milliliter	Geometric Coefficient of Variation 45.3
Part II: Encorafenib + Binimetinib + Infigratinib	Last Measurable Plasma Concentration at Steady State (Clast, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Binimetinib metabolite, AR00426032	2.92 Nanogram per milliliter	Geometric Coefficient of Variation 159.3
Part II: Encorafenib + Binimetinib + Infigratinib	Last Measurable Plasma Concentration at Steady State (Clast, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Binimetinib	30.2 Nanogram per milliliter	Geometric Coefficient of Variation 59.2
Part II: Encorafenib + Binimetinib + Infigratinib	Last Measurable Plasma Concentration at Steady State (Clast, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Encorafenib	25.1 Nanogram per milliliter	Geometric Coefficient of Variation 2066.8
Part II: Encorafenib + Binimetinib + Infigratinib	Last Measurable Plasma Concentration at Steady State (Clast, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Buparlisib	101 Nanogram per milliliter	Geometric Coefficient of Variation 1.4
Part II: Encorafenib + Binimetinib + Capmatinib	Last Measurable Plasma Concentration at Steady State (Clast, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Infigratinib metabolite, BHS697	5.57 Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Capmatinib	Last Measurable Plasma Concentration at Steady State (Clast, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Encorafenib	6.76 Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Capmatinib	Last Measurable Plasma Concentration at Steady State (Clast, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Binimetinib	55.8 Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Capmatinib	Last Measurable Plasma Concentration at Steady State (Clast, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Binimetinib metabolite, AR00426032	1.82 Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Capmatinib	Last Measurable Plasma Concentration at Steady State (Clast, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Infigratinib	20.5 Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Capmatinib	Last Measurable Plasma Concentration at Steady State (Clast, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Infigratinib metabolite, CQM157	32.2 Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Buparlisib	Last Measurable Plasma Concentration at Steady State (Clast, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Binimetinib metabolite, AR00426032	5.57 Nanogram per milliliter	Geometric Coefficient of Variation 130.2
Part II: Encorafenib + Binimetinib + Buparlisib	Last Measurable Plasma Concentration at Steady State (Clast, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Capmatinib	79.6 Nanogram per milliliter	Geometric Coefficient of Variation 103.1
Part II: Encorafenib + Binimetinib + Buparlisib	Last Measurable Plasma Concentration at Steady State (Clast, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Encorafenib	15.9 Nanogram per milliliter	Geometric Coefficient of Variation 315.9
Part II: Encorafenib + Binimetinib + Buparlisib	Last Measurable Plasma Concentration at Steady State (Clast, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Binimetinib	63.2 Nanogram per milliliter	Geometric Coefficient of Variation 64
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 300 mg	Last Measurable Plasma Concentration at Steady State (Clast, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Binimetinib	17.6 Nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 300 mg	Last Measurable Plasma Concentration at Steady State (Clast, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Encorafenib	5.20 Nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 300 mg	Last Measurable Plasma Concentration at Steady State (Clast, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Binimetinib metabolite, AR00426032	1.44 Nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 300 mg	Last Measurable Plasma Concentration at Steady State (Clast, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Capmatinib	58.1 Nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 400 mg	Last Measurable Plasma Concentration at Steady State (Clast, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Binimetinib	55.9 Nanogram per milliliter	Geometric Coefficient of Variation 54
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 400 mg	Last Measurable Plasma Concentration at Steady State (Clast, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Binimetinib metabolite, AR00426032	4.75 Nanogram per milliliter	Geometric Coefficient of Variation 25.4
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 400 mg	Last Measurable Plasma Concentration at Steady State (Clast, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Capmatinib	269 Nanogram per milliliter	Geometric Coefficient of Variation 68.7
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 400 mg	Last Measurable Plasma Concentration at Steady State (Clast, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Encorafenib	15.0 Nanogram per milliliter	Geometric Coefficient of Variation 20.9
Part II: Encorafenib 100 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Last Measurable Plasma Concentration at Steady State (Clast, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Encorafenib	10.7 Nanogram per milliliter	—
Part II: Encorafenib 100 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Last Measurable Plasma Concentration at Steady State (Clast, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Binimetinib	78.3 Nanogram per milliliter	—
Part II: Encorafenib 100 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Last Measurable Plasma Concentration at Steady State (Clast, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Binimetinib metabolite, AR00426032	6.53 Nanogram per milliliter	—
Part II: Encorafenib 100 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Last Measurable Plasma Concentration at Steady State (Clast, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Ribociclib	94.0 Nanogram per milliliter	—
Part II: Encorafenib 100 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Last Measurable Plasma Concentration at Steady State (Clast, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Ribociclib metabolite, LEQ803	84.5 Nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 400 mg	Last Measurable Plasma Concentration at Steady State (Clast, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Ribociclib	25.6 Nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 400 mg	Last Measurable Plasma Concentration at Steady State (Clast, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Encorafenib	7.85 Nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 400 mg	Last Measurable Plasma Concentration at Steady State (Clast, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Binimetinib	29.8 Nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 400 mg	Last Measurable Plasma Concentration at Steady State (Clast, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Ribociclib metabolite, LEQ803	46.8 Nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 400 mg	Last Measurable Plasma Concentration at Steady State (Clast, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Binimetinib metabolite, AR00426032	1.08 Nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Last Measurable Plasma Concentration at Steady State (Clast, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Ribociclib metabolite, LEQ803	42.5 Nanogram per milliliter	Geometric Coefficient of Variation 13.8
Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Last Measurable Plasma Concentration at Steady State (Clast, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Encorafenib	10.8 Nanogram per milliliter	Geometric Coefficient of Variation 106.1
Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Last Measurable Plasma Concentration at Steady State (Clast, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Ribociclib	52.7 Nanogram per milliliter	Geometric Coefficient of Variation 90.4
Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Last Measurable Plasma Concentration at Steady State (Clast, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Binimetinib metabolite, AR00426032	2.31 Nanogram per milliliter	Geometric Coefficient of Variation 47.8
Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Last Measurable Plasma Concentration at Steady State (Clast, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Binimetinib	23.1 Nanogram per milliliter	Geometric Coefficient of Variation 5.2
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 400 mg	Last Measurable Plasma Concentration at Steady State (Clast, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Binimetinib	47.9 Nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 400 mg	Last Measurable Plasma Concentration at Steady State (Clast, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Ribociclib	34.9 Nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 400 mg	Last Measurable Plasma Concentration at Steady State (Clast, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Encorafenib	10.5 Nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 400 mg	Last Measurable Plasma Concentration at Steady State (Clast, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Ribociclib metabolite, LEQ803	22.8 Nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 400 mg	Last Measurable Plasma Concentration at Steady State (Clast, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Binimetinib metabolite, AR00426032	3.54 Nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 600 mg	Last Measurable Plasma Concentration at Steady State (Clast, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Binimetinib	58.7 Nanogram per milliliter	Geometric Coefficient of Variation 60.2
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 600 mg	Last Measurable Plasma Concentration at Steady State (Clast, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Ribociclib metabolite, LEQ803	73.2 Nanogram per milliliter	Geometric Coefficient of Variation 49.6
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 600 mg	Last Measurable Plasma Concentration at Steady State (Clast, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Encorafenib	33.7 Nanogram per milliliter	Geometric Coefficient of Variation 254.3
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 600 mg	Last Measurable Plasma Concentration at Steady State (Clast, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Binimetinib metabolite, AR00426032	4.68 Nanogram per milliliter	Geometric Coefficient of Variation 92.3
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 600 mg	Last Measurable Plasma Concentration at Steady State (Clast, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Ribociclib	147 Nanogram per milliliter	Geometric Coefficient of Variation 71.8
Part II: Encorafenib 300 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Last Measurable Plasma Concentration at Steady State (Clast, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Ribociclib	91.8 Nanogram per milliliter	—
Part II: Encorafenib 300 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Last Measurable Plasma Concentration at Steady State (Clast, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Binimetinib	40.5 Nanogram per milliliter	—
Part II: Encorafenib 300 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Last Measurable Plasma Concentration at Steady State (Clast, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Ribociclib metabolite, LEQ803	59.6 Nanogram per milliliter	—
Part II: Encorafenib 300 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Last Measurable Plasma Concentration at Steady State (Clast, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Binimetinib metabolite, AR00426032	1.56 Nanogram per milliliter	—

Secondary

Maximum Observed Plasma Concentration at Steady State (Cmax,ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II

Time frame: C1 D15: 0.5 hour ± 10 (minutes) min; 1 hour ± 10 min; 1.5 hour ± 15 min; 2 hour ± 15 min; 2.5 hour ± 15 min; 4 hour ± 30 min; 6 hour ± 30 min; 8 hour ± 60 min; 24 hour ± 2 hour

Arm	Measure	Group	Value (GEOMETRIC_MEAN)	Dispersion
Part II: Encorafenib + Binimetinib + Ribociclib	Maximum Observed Plasma Concentration at Steady State (Cmax,ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Buparlisib	266 Nanogram per milliliter	Geometric Coefficient of Variation 51.5
Part II: Encorafenib + Binimetinib + Ribociclib	Maximum Observed Plasma Concentration at Steady State (Cmax,ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Binimetinib	386 Nanogram per milliliter	Geometric Coefficient of Variation 41.1
Part II: Encorafenib + Binimetinib + Ribociclib	Maximum Observed Plasma Concentration at Steady State (Cmax,ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Encorafenib	3060 Nanogram per milliliter	Geometric Coefficient of Variation 58.8
Part II: Encorafenib + Binimetinib + Ribociclib	Maximum Observed Plasma Concentration at Steady State (Cmax,ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Binimetinib metabolite, AR00426032	24.9 Nanogram per milliliter	Geometric Coefficient of Variation 92.2
Part II: Encorafenib + Binimetinib + Infigratinib	Maximum Observed Plasma Concentration at Steady State (Cmax,ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Encorafenib	2150 Nanogram per milliliter	Geometric Coefficient of Variation 54.6
Part II: Encorafenib + Binimetinib + Infigratinib	Maximum Observed Plasma Concentration at Steady State (Cmax,ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Binimetinib	221 Nanogram per milliliter	Geometric Coefficient of Variation 237.6
Part II: Encorafenib + Binimetinib + Infigratinib	Maximum Observed Plasma Concentration at Steady State (Cmax,ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Buparlisib	312 Nanogram per milliliter	Geometric Coefficient of Variation 10.9
Part II: Encorafenib + Binimetinib + Infigratinib	Maximum Observed Plasma Concentration at Steady State (Cmax,ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Binimetinib metabolite, AR00426032	18.1 Nanogram per milliliter	Geometric Coefficient of Variation 591.2
Part II: Encorafenib + Binimetinib + Capmatinib	Maximum Observed Plasma Concentration at Steady State (Cmax,ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Binimetinib metabolite, AR00426032	15.8 Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Capmatinib	Maximum Observed Plasma Concentration at Steady State (Cmax,ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Binimetinib	413 Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Capmatinib	Maximum Observed Plasma Concentration at Steady State (Cmax,ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Encorafenib	2100 Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Capmatinib	Maximum Observed Plasma Concentration at Steady State (Cmax,ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Infigratinib metabolite, BHS697	8.53 Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Capmatinib	Maximum Observed Plasma Concentration at Steady State (Cmax,ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Infigratinib metabolite, CQM157	32.2 Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Capmatinib	Maximum Observed Plasma Concentration at Steady State (Cmax,ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Infigratinib	27.5 Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Buparlisib	Maximum Observed Plasma Concentration at Steady State (Cmax,ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Capmatinib	722 Nanogram per milliliter	Geometric Coefficient of Variation 85.3
Part II: Encorafenib + Binimetinib + Buparlisib	Maximum Observed Plasma Concentration at Steady State (Cmax,ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Encorafenib	1600 Nanogram per milliliter	Geometric Coefficient of Variation 62
Part II: Encorafenib + Binimetinib + Buparlisib	Maximum Observed Plasma Concentration at Steady State (Cmax,ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Binimetinib	515 Nanogram per milliliter	Geometric Coefficient of Variation 17
Part II: Encorafenib + Binimetinib + Buparlisib	Maximum Observed Plasma Concentration at Steady State (Cmax,ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Binimetinib metabolite, AR00426032	27.9 Nanogram per milliliter	Geometric Coefficient of Variation 85.6
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 300 mg	Maximum Observed Plasma Concentration at Steady State (Cmax,ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Encorafenib	2890 Nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 300 mg	Maximum Observed Plasma Concentration at Steady State (Cmax,ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Capmatinib	3670 Nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 300 mg	Maximum Observed Plasma Concentration at Steady State (Cmax,ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Binimetinib metabolite, AR00426032	22.6 Nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 300 mg	Maximum Observed Plasma Concentration at Steady State (Cmax,ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Binimetinib	797 Nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 400 mg	Maximum Observed Plasma Concentration at Steady State (Cmax,ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Binimetinib metabolite, AR00426032	47.1 Nanogram per milliliter	Geometric Coefficient of Variation 29.2
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 400 mg	Maximum Observed Plasma Concentration at Steady State (Cmax,ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Encorafenib	2570 Nanogram per milliliter	Geometric Coefficient of Variation 23
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 400 mg	Maximum Observed Plasma Concentration at Steady State (Cmax,ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Capmatinib	1920 Nanogram per milliliter	Geometric Coefficient of Variation 31.8
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 400 mg	Maximum Observed Plasma Concentration at Steady State (Cmax,ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Binimetinib	858 Nanogram per milliliter	Geometric Coefficient of Variation 13
Part II: Encorafenib 100 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Maximum Observed Plasma Concentration at Steady State (Cmax,ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Binimetinib	261 Nanogram per milliliter	—
Part II: Encorafenib 100 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Maximum Observed Plasma Concentration at Steady State (Cmax,ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Encorafenib	622 Nanogram per milliliter	—
Part II: Encorafenib 100 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Maximum Observed Plasma Concentration at Steady State (Cmax,ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Ribociclib	434 Nanogram per milliliter	—
Part II: Encorafenib 100 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Maximum Observed Plasma Concentration at Steady State (Cmax,ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Ribociclib metabolite, LEQ803	175 Nanogram per milliliter	—
Part II: Encorafenib 100 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Maximum Observed Plasma Concentration at Steady State (Cmax,ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Binimetinib metabolite, AR00426032	12.9 Nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 400 mg	Maximum Observed Plasma Concentration at Steady State (Cmax,ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Ribociclib metabolite, LEQ803	93.2 Nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 400 mg	Maximum Observed Plasma Concentration at Steady State (Cmax,ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Encorafenib	1960 Nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 400 mg	Maximum Observed Plasma Concentration at Steady State (Cmax,ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Binimetinib	520 Nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 400 mg	Maximum Observed Plasma Concentration at Steady State (Cmax,ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Binimetinib metabolite, AR00426032	12.6 Nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 400 mg	Maximum Observed Plasma Concentration at Steady State (Cmax,ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Ribociclib	126 Nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Maximum Observed Plasma Concentration at Steady State (Cmax,ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Binimetinib	313 Nanogram per milliliter	Geometric Coefficient of Variation 15.9
Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Maximum Observed Plasma Concentration at Steady State (Cmax,ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Encorafenib	1860 Nanogram per milliliter	Geometric Coefficient of Variation 32.1
Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Maximum Observed Plasma Concentration at Steady State (Cmax,ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Binimetinib metabolite, AR00426032	16.1 Nanogram per milliliter	Geometric Coefficient of Variation 151.9
Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Maximum Observed Plasma Concentration at Steady State (Cmax,ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Ribociclib	428 Nanogram per milliliter	Geometric Coefficient of Variation 84.2
Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Maximum Observed Plasma Concentration at Steady State (Cmax,ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Ribociclib metabolite, LEQ803	144 Nanogram per milliliter	Geometric Coefficient of Variation 19.2
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 400 mg	Maximum Observed Plasma Concentration at Steady State (Cmax,ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Binimetinib metabolite, AR00426032	19.4 Nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 400 mg	Maximum Observed Plasma Concentration at Steady State (Cmax,ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Binimetinib	584 Nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 400 mg	Maximum Observed Plasma Concentration at Steady State (Cmax,ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Ribociclib	282 Nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 400 mg	Maximum Observed Plasma Concentration at Steady State (Cmax,ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Encorafenib	2010 Nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 400 mg	Maximum Observed Plasma Concentration at Steady State (Cmax,ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Ribociclib metabolite, LEQ803	67.5 Nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 600 mg	Maximum Observed Plasma Concentration at Steady State (Cmax,ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Binimetinib metabolite, AR00426032	23.7 Nanogram per milliliter	Geometric Coefficient of Variation 94.1
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 600 mg	Maximum Observed Plasma Concentration at Steady State (Cmax,ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Ribociclib	753 Nanogram per milliliter	Geometric Coefficient of Variation 70.6
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 600 mg	Maximum Observed Plasma Concentration at Steady State (Cmax,ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Ribociclib metabolite, LEQ803	156 Nanogram per milliliter	Geometric Coefficient of Variation 36.2
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 600 mg	Maximum Observed Plasma Concentration at Steady State (Cmax,ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Binimetinib	489 Nanogram per milliliter	Geometric Coefficient of Variation 31.3
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 600 mg	Maximum Observed Plasma Concentration at Steady State (Cmax,ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Encorafenib	2030 Nanogram per milliliter	Geometric Coefficient of Variation 40.6
Part II: Encorafenib 300 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Maximum Observed Plasma Concentration at Steady State (Cmax,ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Binimetinib metabolite, AR00426032	9.04 Nanogram per milliliter	—
Part II: Encorafenib 300 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Maximum Observed Plasma Concentration at Steady State (Cmax,ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Ribociclib metabolite, LEQ803	138 Nanogram per milliliter	—
Part II: Encorafenib 300 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Maximum Observed Plasma Concentration at Steady State (Cmax,ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Ribociclib	597 Nanogram per milliliter	—
Part II: Encorafenib 300 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Maximum Observed Plasma Concentration at Steady State (Cmax,ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Binimetinib	291 Nanogram per milliliter	—

Secondary

Measured Concentration at the End of a Dosing Interval at Steady State (Ctrough, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II

Time frame: C1 D15: at the end of a dosing interval at steady-state (24 hour ± 2 hour), taken directly before next administration

Arm	Measure	Group	Value (GEOMETRIC_MEAN)	Dispersion
Part II: Encorafenib + Binimetinib + Ribociclib	Measured Concentration at the End of a Dosing Interval at Steady State (Ctrough, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Binimetinib metabolite, AR00426032	3.14 Nanogram per milliliter	Geometric Coefficient of Variation 74.5
Part II: Encorafenib + Binimetinib + Ribociclib	Measured Concentration at the End of a Dosing Interval at Steady State (Ctrough, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Binimetinib	32.0 Nanogram per milliliter	Geometric Coefficient of Variation 17.1
Part II: Encorafenib + Binimetinib + Ribociclib	Measured Concentration at the End of a Dosing Interval at Steady State (Ctrough, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Buparlisib	49.7 Nanogram per milliliter	Geometric Coefficient of Variation 115.9
Part II: Encorafenib + Binimetinib + Ribociclib	Measured Concentration at the End of a Dosing Interval at Steady State (Ctrough, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Encorafenib	11.2 Nanogram per milliliter	Geometric Coefficient of Variation 106.3
Part II: Encorafenib + Binimetinib + Infigratinib	Measured Concentration at the End of a Dosing Interval at Steady State (Ctrough, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Binimetinib metabolite, AR00426032	3.80 Nanogram per milliliter	Geometric Coefficient of Variation 111.9
Part II: Encorafenib + Binimetinib + Infigratinib	Measured Concentration at the End of a Dosing Interval at Steady State (Ctrough, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Binimetinib	39.1 Nanogram per milliliter	Geometric Coefficient of Variation 57.4
Part II: Encorafenib + Binimetinib + Infigratinib	Measured Concentration at the End of a Dosing Interval at Steady State (Ctrough, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Encorafenib	18.6 Nanogram per milliliter	Geometric Coefficient of Variation 159.4
Part II: Encorafenib + Binimetinib + Infigratinib	Measured Concentration at the End of a Dosing Interval at Steady State (Ctrough, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Buparlisib	97.3 Nanogram per milliliter	Geometric Coefficient of Variation 16.2
Part II: Encorafenib + Binimetinib + Capmatinib	Measured Concentration at the End of a Dosing Interval at Steady State (Ctrough, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Infigratinib metabolite, BHS697	1.64 Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Capmatinib	Measured Concentration at the End of a Dosing Interval at Steady State (Ctrough, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Encorafenib	7.74 Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Capmatinib	Measured Concentration at the End of a Dosing Interval at Steady State (Ctrough, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Binimetinib	33.9 Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Capmatinib	Measured Concentration at the End of a Dosing Interval at Steady State (Ctrough, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Binimetinib metabolite, AR00426032	1.21 Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Capmatinib	Measured Concentration at the End of a Dosing Interval at Steady State (Ctrough, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Infigratinib	2.49 Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Capmatinib	Measured Concentration at the End of a Dosing Interval at Steady State (Ctrough, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Infigratinib metabolite, CQM157	11.1 Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Buparlisib	Measured Concentration at the End of a Dosing Interval at Steady State (Ctrough, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Binimetinib metabolite, AR00426032	8.22 Nanogram per milliliter	Geometric Coefficient of Variation 84.6
Part II: Encorafenib + Binimetinib + Buparlisib	Measured Concentration at the End of a Dosing Interval at Steady State (Ctrough, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Capmatinib	83.9 Nanogram per milliliter	Geometric Coefficient of Variation 34
Part II: Encorafenib + Binimetinib + Buparlisib	Measured Concentration at the End of a Dosing Interval at Steady State (Ctrough, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Encorafenib	11.6 Nanogram per milliliter	Geometric Coefficient of Variation 51.3
Part II: Encorafenib + Binimetinib + Buparlisib	Measured Concentration at the End of a Dosing Interval at Steady State (Ctrough, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Binimetinib	81.2 Nanogram per milliliter	Geometric Coefficient of Variation 47.5
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 300 mg	Measured Concentration at the End of a Dosing Interval at Steady State (Ctrough, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Binimetinib	47.3 Nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 300 mg	Measured Concentration at the End of a Dosing Interval at Steady State (Ctrough, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Encorafenib	7.95 Nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 300 mg	Measured Concentration at the End of a Dosing Interval at Steady State (Ctrough, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Binimetinib metabolite, AR00426032	4.36 Nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 300 mg	Measured Concentration at the End of a Dosing Interval at Steady State (Ctrough, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Capmatinib	71.4 Nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 400 mg	Measured Concentration at the End of a Dosing Interval at Steady State (Ctrough, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Binimetinib	50.9 Nanogram per milliliter	Geometric Coefficient of Variation 34.4
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 400 mg	Measured Concentration at the End of a Dosing Interval at Steady State (Ctrough, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Binimetinib metabolite, AR00426032	5.45 Nanogram per milliliter	Geometric Coefficient of Variation 42.2
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 400 mg	Measured Concentration at the End of a Dosing Interval at Steady State (Ctrough, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Capmatinib	173 Nanogram per milliliter	Geometric Coefficient of Variation 41.2
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 400 mg	Measured Concentration at the End of a Dosing Interval at Steady State (Ctrough, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Encorafenib	13.5 Nanogram per milliliter	Geometric Coefficient of Variation 35
Part II: Encorafenib 100 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Measured Concentration at the End of a Dosing Interval at Steady State (Ctrough, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Encorafenib	9.28 Nanogram per milliliter	—
Part II: Encorafenib 100 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Measured Concentration at the End of a Dosing Interval at Steady State (Ctrough, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Binimetinib	54.3 Nanogram per milliliter	—
Part II: Encorafenib 100 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Measured Concentration at the End of a Dosing Interval at Steady State (Ctrough, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Binimetinib metabolite, AR00426032	4.16 Nanogram per milliliter	—
Part II: Encorafenib 100 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Measured Concentration at the End of a Dosing Interval at Steady State (Ctrough, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Ribociclib	98.4 Nanogram per milliliter	—
Part II: Encorafenib 100 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Measured Concentration at the End of a Dosing Interval at Steady State (Ctrough, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Ribociclib metabolite, LEQ803	76.0 Nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 400 mg	Measured Concentration at the End of a Dosing Interval at Steady State (Ctrough, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Ribociclib	28.2 Nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 400 mg	Measured Concentration at the End of a Dosing Interval at Steady State (Ctrough, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Encorafenib	10.3 Nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 400 mg	Measured Concentration at the End of a Dosing Interval at Steady State (Ctrough, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Binimetinib	28.3 Nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 400 mg	Measured Concentration at the End of a Dosing Interval at Steady State (Ctrough, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Ribociclib metabolite, LEQ803	37.1 Nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 400 mg	Measured Concentration at the End of a Dosing Interval at Steady State (Ctrough, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Binimetinib metabolite, AR00426032	NA Nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Measured Concentration at the End of a Dosing Interval at Steady State (Ctrough, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Ribociclib metabolite, LEQ803	32.9 Nanogram per milliliter	Geometric Coefficient of Variation 25.7
Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Measured Concentration at the End of a Dosing Interval at Steady State (Ctrough, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Encorafenib	7.75 Nanogram per milliliter	Geometric Coefficient of Variation 37.3
Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Measured Concentration at the End of a Dosing Interval at Steady State (Ctrough, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Ribociclib	30.7 Nanogram per milliliter	Geometric Coefficient of Variation 24.9
Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Measured Concentration at the End of a Dosing Interval at Steady State (Ctrough, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Binimetinib metabolite, AR00426032	3.81 Nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Measured Concentration at the End of a Dosing Interval at Steady State (Ctrough, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Binimetinib	21.1 Nanogram per milliliter	Geometric Coefficient of Variation 23.7
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 400 mg	Measured Concentration at the End of a Dosing Interval at Steady State (Ctrough, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Binimetinib	31.5 Nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 400 mg	Measured Concentration at the End of a Dosing Interval at Steady State (Ctrough, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Ribociclib	36.4 Nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 400 mg	Measured Concentration at the End of a Dosing Interval at Steady State (Ctrough, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Encorafenib	10.4 Nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 400 mg	Measured Concentration at the End of a Dosing Interval at Steady State (Ctrough, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Ribociclib metabolite, LEQ803	22.8 Nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 400 mg	Measured Concentration at the End of a Dosing Interval at Steady State (Ctrough, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Binimetinib metabolite, AR00426032	1.72 Nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 600 mg	Measured Concentration at the End of a Dosing Interval at Steady State (Ctrough, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Binimetinib	51.0 Nanogram per milliliter	Geometric Coefficient of Variation 76.1
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 600 mg	Measured Concentration at the End of a Dosing Interval at Steady State (Ctrough, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Ribociclib metabolite, LEQ803	55.1 Nanogram per milliliter	Geometric Coefficient of Variation 33.9
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 600 mg	Measured Concentration at the End of a Dosing Interval at Steady State (Ctrough, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Encorafenib	21.7 Nanogram per milliliter	Geometric Coefficient of Variation 185.4
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 600 mg	Measured Concentration at the End of a Dosing Interval at Steady State (Ctrough, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Binimetinib metabolite, AR00426032	4.34 Nanogram per milliliter	Geometric Coefficient of Variation 79.9
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 600 mg	Measured Concentration at the End of a Dosing Interval at Steady State (Ctrough, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Ribociclib	104 Nanogram per milliliter	Geometric Coefficient of Variation 54.2
Part II: Encorafenib 300 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Measured Concentration at the End of a Dosing Interval at Steady State (Ctrough, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Ribociclib	64.7 Nanogram per milliliter	—
Part II: Encorafenib 300 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Measured Concentration at the End of a Dosing Interval at Steady State (Ctrough, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Binimetinib	36.2 Nanogram per milliliter	—
Part II: Encorafenib 300 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Measured Concentration at the End of a Dosing Interval at Steady State (Ctrough, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Ribociclib metabolite, LEQ803	49.2 Nanogram per milliliter	—
Part II: Encorafenib 300 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Measured Concentration at the End of a Dosing Interval at Steady State (Ctrough, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Binimetinib metabolite, AR00426032	1.09 Nanogram per milliliter	—

Secondary

Number of Participants With Adverse Events (AEs) and Serious AEs (SAEs): Part I

An AE was defined as the appearance of (or worsening of any pre-existing) undesirable sign(s), symptom(s), or medical condition(s) that occurred after participants' signed informed consent has been obtained. An SAE was an AE resulting in any of the following outcomes: was fatal or life-threatening; resulted in persistent or significant disability/incapacity; constituted a congenital anomaly/birth defect; was medically significant; required inpatient hospitalization or prolongation of existing hospitalization. AEs included both SAEs and all Non-SAEs.

Time frame: Day 1 up to 30 days after last dose (maximum treatment exposure for Part I was 403.7 weeks)

Population: Safety set included all participants who received at least 1 dose of encorafenib or binimetinib for Part I and had at least 1 valid post-baseline safety assessment.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Adverse Events (AEs) and Serious AEs (SAEs): Part I	AEs	75 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Adverse Events (AEs) and Serious AEs (SAEs): Part I	SAEs	47 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Adverse Events (AEs) and Serious AEs (SAEs): Part I	AEs	78 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Adverse Events (AEs) and Serious AEs (SAEs): Part I	SAEs	37 Participants

Secondary

Number of Participants With AEs and SAEs: Part II

Time frame: Day 1 up to 30 days after last dose (maximum treatment exposure for Part II was 97.0 weeks)

Population: Safety set included all participants who received at least 1 dose of 3rd combination agent for Part II and had at least 1 valid post-baseline safety assessment.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With AEs and SAEs: Part II	AEs	37 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With AEs and SAEs: Part II	SAEs	19 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With AEs and SAEs: Part II	SAEs	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With AEs and SAEs: Part II	AEs	1 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With AEs and SAEs: Part II	AEs	12 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With AEs and SAEs: Part II	SAEs	6 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With AEs and SAEs: Part II	AEs	6 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With AEs and SAEs: Part II	SAEs	4 Participants

Secondary

Number of Participants With At Least One Dose Interruption: Part I

In this outcome measure number of participants with at least 1 dose interruption for encorafenib and binimetinib were reported.

Time frame: During study treatment (maximum treatment exposure for Part I was 403.7 weeks)

Population: Safety set included all participants who received at least 1 dose of encorafenib or binimetinib for Part I and had at least 1 valid post-baseline safety assessment.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With At Least One Dose Interruption: Part I	Encorafenib	46 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With At Least One Dose Interruption: Part I	Binimetinib	44 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With At Least One Dose Interruption: Part I	Encorafenib	40 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With At Least One Dose Interruption: Part I	Binimetinib	41 Participants

Secondary

Number of Participants With At Least One Dose Interruption: Part II

In this outcome measure number of participants with at least 1 dose interruption for encorafenib, binimetinib, and each third combination agent were reported.

Time frame: During study treatment (maximum treatment exposure for Part II was 97.0 weeks)

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With At Least One Dose Interruption: Part II	Encorafenib	14 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With At Least One Dose Interruption: Part II	Ribociclib	11 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With At Least One Dose Interruption: Part II	Binimetinib	13 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With At Least One Dose Interruption: Part II	Encorafenib	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With At Least One Dose Interruption: Part II	Infigratinib	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With At Least One Dose Interruption: Part II	Binimetinib	0 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With At Least One Dose Interruption: Part II	Binimetinib	5 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With At Least One Dose Interruption: Part II	Encorafenib	4 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With At Least One Dose Interruption: Part II	Capmatinib	5 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With At Least One Dose Interruption: Part II	Encorafenib	2 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With At Least One Dose Interruption: Part II	Buparlisib	2 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With At Least One Dose Interruption: Part II	Binimetinib	3 Participants

Secondary

Number of Participants With At Least One Dose Reduction: Part I

In this outcome measure number of participants with at least 1 dose reduction for encorafenib and binimetinib were reported.

Time frame: During study treatment (maximum treatment exposure for Part I was 403.7 weeks)

Population: Safety set included all participants who received at least 1 dose of encorafenib or binimetinib for Part I and had at least 1 valid post-baseline safety assessment.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With At Least One Dose Reduction: Part I	Encorafenib	9 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With At Least One Dose Reduction: Part I	Binimetinib	32 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With At Least One Dose Reduction: Part I	Encorafenib	14 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With At Least One Dose Reduction: Part I	Binimetinib	28 Participants

Secondary

Number of Participants With At Least One Dose Reduction: Part II

In this outcome measure number of participants with at least 1 dose reduction for encorafenib, binimetinib, and each third combination agent were reported.

Time frame: During study treatment (maximum treatment exposure for Part II was 97.0 weeks)

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With At Least One Dose Reduction: Part II	Encorafenib	1 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With At Least One Dose Reduction: Part II	Ribociclib	1 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With At Least One Dose Reduction: Part II	Binimetinib	11 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With At Least One Dose Reduction: Part II	Encorafenib	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With At Least One Dose Reduction: Part II	Infigratinib	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With At Least One Dose Reduction: Part II	Binimetinib	0 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With At Least One Dose Reduction: Part II	Binimetinib	5 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With At Least One Dose Reduction: Part II	Encorafenib	0 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With At Least One Dose Reduction: Part II	Capmatinib	7 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With At Least One Dose Reduction: Part II	Encorafenib	1 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With At Least One Dose Reduction: Part II	Buparlisib	1 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With At Least One Dose Reduction: Part II	Binimetinib	3 Participants

Secondary

Number of Participants With Dose Limiting Toxicities (DLTs) in Cycle 1: Part II

DLT was defined as an adverse event or abnormal laboratory value assessed as unrelated to disease, disease progression, inter-current illness, or concomitant medications that occurred within the first cycle (first 21 days for infigratinib and capmatinib; 28 days for ribociclib and buparlisib) of treatment initiation and met the defined criteria for study.

Time frame: Cycle 1 (21 days following the first dose of the combination treatment with buparlisib and capmatinib; 28 days for the combination with ribociclib and infigratinib)

Population: Dose-determining analysis set (DDS) consisted of all participants from the safety set for Part II who met the minimum requirements for safety evaluation and minimum exposure or experienced DLT during the first cycle of the assigned triple combination treatment. No participants were included in the dose-determining analysis set in the encorafenib/binimetinib+ infigratinib or buparlisib arm, hence no participants analyzed for these reporting arms for this outcome measure.

Arm	Measure	Value (COUNT_OF_PARTICIPANTS)
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Dose Limiting Toxicities (DLTs) in Cycle 1: Part II	1 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Dose Limiting Toxicities (DLTs) in Cycle 1: Part II	0 Participants

Secondary

Number of Participants With Newly Occurring Notably Abnormal Vital Signs: Part I

Vital signs evaluated were: Low/high systolic blood pressure (BP) (millimeter of Mercury \[mmHg\]): less than or equal to (\<=) 90 mmHg with decrease from baseline of \>=20 mmHg / \>=160 mmHg with increase from baseline of \>=20 mmHg; low/high diastolic BP \[mmHg\]: \<=50 mmHg with decrease from baseline of \>=15 mmHg / \>=100 mmHg with increase from baseline of \>=15 mmHg; low/high pulse rate (beats per minute \[bpm\]): \<=50 bpm with decrease from baseline of \>=15 bpm / \>=120 bpm with increase from baseline of \>=15 bpm; low/high weight (kilogram \[kg\]): \>=20% decrease/increase from baseline; and low/high body temperature (degree Celsius \[C\]): \<=36 C / \>= 37.5 C.

Time frame: During study treatment (maximum treatment exposure for Part I was 403.7 weeks)

Population: Safety set included all participants who received at least 1 dose of encorafenib or binimetinib for Part I and had at least 1 valid post-baseline safety assessment. All participants reported under 'Overall Number of Participants Analyzed' contributed data to the table but may not have evaluable data for every row. Here, Number Analyzed signifies number of participants evaluable for specified rows.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Newly Occurring Notably Abnormal Vital Signs: Part I	Sitting Pulse Rate: High	2 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Newly Occurring Notably Abnormal Vital Signs: Part I	Sitting Pulse Rate: Low	5 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Newly Occurring Notably Abnormal Vital Signs: Part I	Sitting Systolic BP: High	18 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Newly Occurring Notably Abnormal Vital Signs: Part I	Sitting Systolic BP: Low	3 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Newly Occurring Notably Abnormal Vital Signs: Part I	Sitting Diastolic BP: High	11 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Newly Occurring Notably Abnormal Vital Signs: Part I	Sitting Diastolic BP: Low	5 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Newly Occurring Notably Abnormal Vital Signs: Part I	Weight: High	0 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Newly Occurring Notably Abnormal Vital Signs: Part I	Weight: Low	0 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Newly Occurring Notably Abnormal Vital Signs: Part I	Body temperature: High	14 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Newly Occurring Notably Abnormal Vital Signs: Part I	Body temperature: Low	44 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Newly Occurring Notably Abnormal Vital Signs: Part I	Weight: Low	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Newly Occurring Notably Abnormal Vital Signs: Part I	Sitting Pulse Rate: High	8 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Newly Occurring Notably Abnormal Vital Signs: Part I	Sitting Diastolic BP: Low	3 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Newly Occurring Notably Abnormal Vital Signs: Part I	Sitting Pulse Rate: Low	4 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Newly Occurring Notably Abnormal Vital Signs: Part I	Body temperature: Low	36 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Newly Occurring Notably Abnormal Vital Signs: Part I	Sitting Systolic BP: High	5 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Newly Occurring Notably Abnormal Vital Signs: Part I	Weight: High	2 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Newly Occurring Notably Abnormal Vital Signs: Part I	Sitting Systolic BP: Low	2 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Newly Occurring Notably Abnormal Vital Signs: Part I	Body temperature: High	14 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Newly Occurring Notably Abnormal Vital Signs: Part I	Sitting Diastolic BP: High	4 Participants

Secondary

Number of Participants With Newly Occurring Notably Abnormal Vital Signs: Part II

Vital signs evaluated were: Low/high systolic BP (mmHg): \<=90 mmHg with decrease from baseline of \>=20 mmHg / \>=160 mmHg with increase from baseline of \>=20 mmHg; low/high diastolic BP \[mmHg\]: \<=50 mmHg with decrease from baseline of \>=15 mmHg / \>=100 mmHg with increase from baseline of \>=15 mmHg; low/high pulse rate (bpm): \<=50 bpm with decrease from baseline of \>=15 bpm / \>=120 bpm with increase from baseline of \>=15 bpm; low/high weight (kg): \>=20% decrease/increase from baseline; and low/high body temperature (C): \<=36 C / \>= 37.5 C.

Time frame: During study treatment (maximum treatment exposure for Part II was 97.0 weeks)

Population: Safety set included all participants who received at least 1 dose of 3rd combination agent for Part II and had at least 1 valid post-baseline safety assessment. All participants reported under 'Overall Number of Participants Analyzed' contributed data to the table but may not have evaluable data for every row. Here, Number Analyzed signifies number of participants evaluable for specified rows.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Newly Occurring Notably Abnormal Vital Signs: Part II	Weight: High	0 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Newly Occurring Notably Abnormal Vital Signs: Part II	Sitting Diastolic BP: Low	1 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Newly Occurring Notably Abnormal Vital Signs: Part II	Sitting Diastolic BP: High	2 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Newly Occurring Notably Abnormal Vital Signs: Part II	Sitting Pulse Rate: High	2 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Newly Occurring Notably Abnormal Vital Signs: Part II	Body temperature: Low	14 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Newly Occurring Notably Abnormal Vital Signs: Part II	Sitting Systolic BP: High	2 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Newly Occurring Notably Abnormal Vital Signs: Part II	Body temperature: High	3 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Newly Occurring Notably Abnormal Vital Signs: Part II	Sitting Systolic BP: Low	0 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Newly Occurring Notably Abnormal Vital Signs: Part II	Weight: Low	1 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Newly Occurring Notably Abnormal Vital Signs: Part II	Sitting Pulse Rate: Low	1 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Newly Occurring Notably Abnormal Vital Signs: Part II	Weight: Low	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Newly Occurring Notably Abnormal Vital Signs: Part II	Sitting Diastolic BP: Low	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Newly Occurring Notably Abnormal Vital Signs: Part II	Sitting Pulse Rate: Low	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Newly Occurring Notably Abnormal Vital Signs: Part II	Weight: High	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Newly Occurring Notably Abnormal Vital Signs: Part II	Sitting Systolic BP: Low	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Newly Occurring Notably Abnormal Vital Signs: Part II	Body temperature: Low	1 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Newly Occurring Notably Abnormal Vital Signs: Part II	Body temperature: High	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Newly Occurring Notably Abnormal Vital Signs: Part II	Sitting Pulse Rate: High	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Newly Occurring Notably Abnormal Vital Signs: Part II	Sitting Diastolic BP: High	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Newly Occurring Notably Abnormal Vital Signs: Part II	Sitting Systolic BP: High	0 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Newly Occurring Notably Abnormal Vital Signs: Part II	Weight: High	0 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Newly Occurring Notably Abnormal Vital Signs: Part II	Sitting Pulse Rate: Low	0 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Newly Occurring Notably Abnormal Vital Signs: Part II	Sitting Systolic BP: High	4 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Newly Occurring Notably Abnormal Vital Signs: Part II	Sitting Systolic BP: Low	0 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Newly Occurring Notably Abnormal Vital Signs: Part II	Sitting Pulse Rate: High	0 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Newly Occurring Notably Abnormal Vital Signs: Part II	Sitting Diastolic BP: High	1 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Newly Occurring Notably Abnormal Vital Signs: Part II	Sitting Diastolic BP: Low	0 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Newly Occurring Notably Abnormal Vital Signs: Part II	Weight: Low	0 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Newly Occurring Notably Abnormal Vital Signs: Part II	Body temperature: High	1 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Newly Occurring Notably Abnormal Vital Signs: Part II	Body temperature: Low	6 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Newly Occurring Notably Abnormal Vital Signs: Part II	Sitting Pulse Rate: Low	0 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Newly Occurring Notably Abnormal Vital Signs: Part II	Weight: Low	0 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Newly Occurring Notably Abnormal Vital Signs: Part II	Sitting Pulse Rate: High	1 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Newly Occurring Notably Abnormal Vital Signs: Part II	Sitting Systolic BP: Low	0 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Newly Occurring Notably Abnormal Vital Signs: Part II	Body temperature: Low	3 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Newly Occurring Notably Abnormal Vital Signs: Part II	Body temperature: High	1 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Newly Occurring Notably Abnormal Vital Signs: Part II	Sitting Systolic BP: High	0 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Newly Occurring Notably Abnormal Vital Signs: Part II	Weight: High	0 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Newly Occurring Notably Abnormal Vital Signs: Part II	Sitting Diastolic BP: Low	0 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Newly Occurring Notably Abnormal Vital Signs: Part II	Sitting Diastolic BP: High	0 Participants

Secondary

Number of Participants With Notable ECG Values: Part II

Number of participants with notable ECG values were reported in this outcome measure. Abnormality categories were: HR: increase from baseline \>25% and to a value \>100 bpm, decrease from baseline \>25% and to a value \<60 bpm; PR: increase from baseline \>25% and to a value \>200 ms; QRS: increase from baseline \>25% and to a value \>110 ms; QT: increase from baseline \>30 ms, increase from baseline \>60 ms, new interval \>450 ms, new interval \>480 ms, new interval \>500 ms; and QTcF: increase from baseline \>30 ms, increase from baseline \>60 ms, new interval \>450 ms, new interval \>480 ms, new interval \>500 ms. New = newly occurred post-baseline value.

Time frame: During study treatment (maximum treatment exposure for Part II was 97.0 weeks)

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Notable ECG Values: Part II	QT: New Interval >480 ms	1 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Notable ECG Values: Part II	QT: New Interval >450 ms	3 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Notable ECG Values: Part II	QT: Increase from baseline >30 ms	24 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Notable ECG Values: Part II	QTcF: New Interval >500 ms	0 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Notable ECG Values: Part II	HR: Increase from baseline >25% & to a value >100 bpm	3 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Notable ECG Values: Part II	QT: Increase from baseline >60 ms	2 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Notable ECG Values: Part II	QTcF: New Interval >450 ms	14 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Notable ECG Values: Part II	QTcF: Increase from baseline >60 ms	0 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Notable ECG Values: Part II	PR: Increase from baseline >25% & to a value >200 ms	1 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Notable ECG Values: Part II	QTcF: New Interval >480 ms	0 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Notable ECG Values: Part II	QTcF: Increase from baseline >30 ms	11 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Notable ECG Values: Part II	QT: New Interval >500 ms	0 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Notable ECG Values: Part II	QRS: Increase from baseline >25% & to a value >110 ms	0 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Notable ECG Values: Part II	HR: Decrease from baseline >25% & to a value <60 bpm	14 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Notable ECG Values: Part II	QT: Increase from baseline >60 ms	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Notable ECG Values: Part II	HR: Increase from baseline >25% & to a value >100 bpm	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Notable ECG Values: Part II	HR: Decrease from baseline >25% & to a value <60 bpm	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Notable ECG Values: Part II	PR: Increase from baseline >25% & to a value >200 ms	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Notable ECG Values: Part II	QRS: Increase from baseline >25% & to a value >110 ms	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Notable ECG Values: Part II	QT: Increase from baseline >30 ms	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Notable ECG Values: Part II	QT: New Interval >480 ms	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Notable ECG Values: Part II	QT: New Interval >500 ms	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Notable ECG Values: Part II	QTcF: Increase from baseline >30 ms	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Notable ECG Values: Part II	QTcF: Increase from baseline >60 ms	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Notable ECG Values: Part II	QTcF: New Interval >450 ms	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Notable ECG Values: Part II	QTcF: New Interval >480 ms	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Notable ECG Values: Part II	QTcF: New Interval >500 ms	0 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Notable ECG Values: Part II	QRS: Increase from baseline >25% & to a value >110 ms	0 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Notable ECG Values: Part II	QTcF: New Interval >500 ms	0 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Notable ECG Values: Part II	QT: New Interval >480 ms	0 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Notable ECG Values: Part II	QTcF: New Interval >480 ms	0 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Notable ECG Values: Part II	QT: New Interval >500 ms	0 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Notable ECG Values: Part II	PR: Increase from baseline >25% & to a value >200 ms	2 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Notable ECG Values: Part II	QTcF: Increase from baseline >30 ms	2 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Notable ECG Values: Part II	HR: Increase from baseline >25% & to a value >100 bpm	2 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Notable ECG Values: Part II	QTcF: Increase from baseline >60 ms	0 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Notable ECG Values: Part II	HR: Decrease from baseline >25% & to a value <60 bpm	7 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Notable ECG Values: Part II	QTcF: New Interval >450 ms	3 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Notable ECG Values: Part II	QT: Increase from baseline >30 ms	9 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Notable ECG Values: Part II	QT: Increase from baseline >60 ms	0 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Notable ECG Values: Part II	QT: New Interval >450 ms	3 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Notable ECG Values: Part II	QRS: Increase from baseline >25% & to a value >110 ms	0 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Notable ECG Values: Part II	QTcF: Increase from baseline >60 ms	0 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Notable ECG Values: Part II	QT: New Interval >450 ms	0 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Notable ECG Values: Part II	QT: New Interval >480 ms	0 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Notable ECG Values: Part II	PR: Increase from baseline >25% & to a value >200 ms	0 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Notable ECG Values: Part II	QTcF: New Interval >500 ms	0 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Notable ECG Values: Part II	QT: Increase from baseline >60 ms	0 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Notable ECG Values: Part II	QT: New Interval >500 ms	0 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Notable ECG Values: Part II	QTcF: New Interval >450 ms	0 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Notable ECG Values: Part II	QTcF: New Interval >480 ms	0 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Notable ECG Values: Part II	HR: Increase from baseline >25% & to a value >100 bpm	1 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Notable ECG Values: Part II	QTcF: Increase from baseline >30 ms	1 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Notable ECG Values: Part II	HR: Decrease from baseline >25% & to a value <60 bpm	0 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Notable ECG Values: Part II	QT: Increase from baseline >30 ms	0 Participants

Secondary

Number of Participants With Notable Electrocardiograms (ECG) Values: Part I

Number of participants with notable ECG values were reported in this outcome measure. Abnormality categories were: Heart rate (HR): increase from baseline \>25% and to a value \>100 bpm, decrease from baseline \>25% and to a value \<60 bpm; PR: increase from baseline \>25% and to a value \>200 millisecond (ms); QRS: increase from baseline \>25% and to a value \>110 ms; QT: increase from baseline \>30 ms, increase from baseline \>60 ms, new interval \>450 ms, new interval \>480 ms, new interval \>500 ms; and Corrected QT interval by Fridericia (QTcF): increase from baseline \>30 ms, increase from baseline \>60 ms, new interval \>450 ms, new interval \>480 ms, new interval \>500 ms. New = newly occurred post-baseline value.

Time frame: During study treatment (maximum treatment exposure for Part I was 403.7 weeks)

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Notable Electrocardiograms (ECG) Values: Part I	HR: Increase from baseline >25% & to a value >100 bpm	10 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Notable Electrocardiograms (ECG) Values: Part I	HR: Decrease from baseline >25% & to a value <60 bpm	37 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Notable Electrocardiograms (ECG) Values: Part I	PR: Increase from baseline >25% & to a value >200 ms	5 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Notable Electrocardiograms (ECG) Values: Part I	QRS: Increase from baseline >25% & to a value >110 ms	3 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Notable Electrocardiograms (ECG) Values: Part I	QT: Increase from baseline >30 ms	61 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Notable Electrocardiograms (ECG) Values: Part I	QT: Increase from baseline >60 ms	29 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Notable Electrocardiograms (ECG) Values: Part I	QT: New Interval >450 ms	24 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Notable Electrocardiograms (ECG) Values: Part I	QT: New Interval >480 ms	5 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Notable Electrocardiograms (ECG) Values: Part I	QT: New Interval >500 ms	3 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Notable Electrocardiograms (ECG) Values: Part I	QTcF: Increase from baseline >30 ms	46 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Notable Electrocardiograms (ECG) Values: Part I	QTcF: Increase from baseline >60 ms	4 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Notable Electrocardiograms (ECG) Values: Part I	QTcF: New Interval >450 ms	28 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Notable Electrocardiograms (ECG) Values: Part I	QTcF: New Interval >480 ms	4 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Notable Electrocardiograms (ECG) Values: Part I	QTcF: New Interval >500 ms	1 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Notable Electrocardiograms (ECG) Values: Part I	QTcF: Increase from baseline >60 ms	2 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Notable Electrocardiograms (ECG) Values: Part I	HR: Increase from baseline >25% & to a value >100 bpm	5 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Notable Electrocardiograms (ECG) Values: Part I	QT: New Interval >480 ms	3 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Notable Electrocardiograms (ECG) Values: Part I	HR: Decrease from baseline >25% & to a value <60 bpm	23 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Notable Electrocardiograms (ECG) Values: Part I	QTcF: New Interval >480 ms	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Notable Electrocardiograms (ECG) Values: Part I	PR: Increase from baseline >25% & to a value >200 ms	1 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Notable Electrocardiograms (ECG) Values: Part I	QT: New Interval >500 ms	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Notable Electrocardiograms (ECG) Values: Part I	QRS: Increase from baseline >25% & to a value >110 ms	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Notable Electrocardiograms (ECG) Values: Part I	QTcF: New Interval >450 ms	15 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Notable Electrocardiograms (ECG) Values: Part I	QT: Increase from baseline >30 ms	48 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Notable Electrocardiograms (ECG) Values: Part I	QTcF: Increase from baseline >30 ms	31 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Notable Electrocardiograms (ECG) Values: Part I	QT: Increase from baseline >60 ms	15 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Notable Electrocardiograms (ECG) Values: Part I	QTcF: New Interval >500 ms	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Notable Electrocardiograms (ECG) Values: Part I	QT: New Interval >450 ms	4 Participants

Secondary

Number of Participants With Worst Post-baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03 Grade: Part I

Parameters evaluated were: Activated partial thromboplastin time (APTT) (seconds \[sec\]) - CTCAE graded high, fibrinogen (gram per liter \[g/L\]) - CTCAE graded low, hemoglobin (g/L) - CTCAE graded low, hemoglobin (g/L) - CTCAE graded high, prothrombin international normalized ratio (PINR) - CTCAE graded high, lymphocytes (10\^9 cells/L) - CTCAE graded low, lymphocytes (10\^9 cells/L) - CTCAE graded high, neutrophils (10\^9 cells/L) - CTCAE graded low, platelets (10\^9 cells/L) - CTCAE graded low, leukocytes (10\^9 cells/L) - CTCAE graded low, leukocytes (10\^9 cells/L) - CTCAE graded high. CTCAE version 4.03 was used: grade 1 = mild, grade 2 = moderate, grade 3 = severe, grade 4 = life-threatening consequences; grade 0 = values not meeting any of the criteria for grade 1 or higher. Baseline = last non-missing value prior to the first dose of study treatment.

Time frame: Baseline up to last dose (maximum treatment exposure for Part I was 403.7 weeks)

Population: Safety set included all participants who received at least 1 dose of encorafenib or binimetinib for Part I and had at least 1 valid post-baseline safety assessment.

Arm	Measure	Group	Category	Value (COUNT_OF_PARTICIPANTS)
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03 Grade: Part I	Hemoglobin - CTCAE graded low	Worst post-baseline value Grade 4	0 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03 Grade: Part I	APTT -CTCAE graded high	Worst post-baseline value Grade 1	1 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03 Grade: Part I	APTT -CTCAE graded high	Worst post-baseline value Grade 2	0 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03 Grade: Part I	APTT -CTCAE graded high	Worst post-baseline value Grade 3	0 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03 Grade: Part I	APTT -CTCAE graded high	Worst post-baseline value Grade 4	0 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03 Grade: Part I	APTT -CTCAE graded high	Worst post-baseline value Missing	28 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03 Grade: Part I	Fibrinogen - CTCAE graded low	Worst post-baseline value Grade 0	28 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03 Grade: Part I	Fibrinogen - CTCAE graded low	Worst post-baseline value Grade 1	8 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03 Grade: Part I	Fibrinogen - CTCAE graded low	Worst post-baseline value Grade 2	5 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03 Grade: Part I	Fibrinogen - CTCAE graded low	Worst post-baseline value Grade 3	4 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03 Grade: Part I	Fibrinogen - CTCAE graded low	Worst post-baseline value Grade 4	0 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03 Grade: Part I	Fibrinogen - CTCAE graded low	Worst post-baseline value Missing	30 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03 Grade: Part I	Hemoglobin - CTCAE graded low	Worst post-baseline value Grade 0	21 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03 Grade: Part I	Hemoglobin - CTCAE graded low	Worst post-baseline value Grade 1	28 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03 Grade: Part I	Hemoglobin - CTCAE graded low	Worst post-baseline value Grade 2	18 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03 Grade: Part I	Hemoglobin - CTCAE graded low	Worst post-baseline value Grade 3	8 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03 Grade: Part I	APTT -CTCAE graded high	Worst post-baseline value Grade 0	46 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03 Grade: Part I	Hemoglobin - CTCAE graded low	Worst post-baseline value Missing	0 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03 Grade: Part I	Hemoglobin - CTCAE graded high	Worst post-baseline value Grade 0	70 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03 Grade: Part I	Hemoglobin - CTCAE graded high	Worst post-baseline value Grade 1	4 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03 Grade: Part I	Hemoglobin - CTCAE graded high	Worst post-baseline value Grade 2	0 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03 Grade: Part I	Hemoglobin - CTCAE graded high	Worst post-baseline value Grade 3	1 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03 Grade: Part I	Hemoglobin - CTCAE graded high	Worst post-baseline value Grade 4	0 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03 Grade: Part I	Hemoglobin - CTCAE graded high	Worst post-baseline value Missing	0 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03 Grade: Part I	PINR -CTCAE graded high	Worst post-baseline value Grade 0	44 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03 Grade: Part I	PINR -CTCAE graded high	Worst post-baseline value Grade 1	0 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03 Grade: Part I	PINR -CTCAE graded high	Worst post-baseline value Grade 2	0 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03 Grade: Part I	PINR -CTCAE graded high	Worst post-baseline value Grade 3	0 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03 Grade: Part I	PINR -CTCAE graded high	Worst post-baseline value Grade 4	0 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03 Grade: Part I	PINR -CTCAE graded high	Worst post-baseline value Missing	31 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03 Grade: Part I	Lymphocytes - CTCAE graded low	Worst post-baseline value Grade 0	23 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03 Grade: Part I	Lymphocytes - CTCAE graded low	Worst post-baseline value Grade 1	22 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03 Grade: Part I	Lymphocytes - CTCAE graded low	Worst post-baseline value Grade 2	13 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03 Grade: Part I	Lymphocytes - CTCAE graded low	Worst post-baseline value Grade 3	6 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03 Grade: Part I	Lymphocytes - CTCAE graded low	Worst post-baseline value Grade 4	0 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03 Grade: Part I	Lymphocytes - CTCAE graded low	Worst post-baseline value Missing	11 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03 Grade: Part I	Lymphocytes - CTCAE graded high	Worst post-baseline value Grade 0	61 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03 Grade: Part I	Lymphocytes - CTCAE graded high	Worst post-baseline value Grade 1	0 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03 Grade: Part I	Lymphocytes - CTCAE graded high	Worst post-baseline value Grade 2	2 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03 Grade: Part I	Lymphocytes - CTCAE graded high	Worst post-baseline value Grade 3	1 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03 Grade: Part I	Lymphocytes - CTCAE graded high	Worst post-baseline value Grade 4	0 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03 Grade: Part I	Lymphocytes - CTCAE graded high	Worst post-baseline value Missing	11 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03 Grade: Part I	Neutrophils - CTCAE graded low	Worst post-baseline value Grade 0	52 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03 Grade: Part I	Neutrophils - CTCAE graded low	Worst post-baseline value Grade 1	4 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03 Grade: Part I	Neutrophils - CTCAE graded low	Worst post-baseline value Grade 2	5 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03 Grade: Part I	Neutrophils - CTCAE graded low	Worst post-baseline value Grade 3	3 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03 Grade: Part I	Neutrophils - CTCAE graded low	Worst post-baseline value Grade 4	0 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03 Grade: Part I	Neutrophils - CTCAE graded low	Worst post-baseline value Missing	11 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03 Grade: Part I	Platelets - CTCAE graded low	Worst post-baseline value Grade 0	59 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03 Grade: Part I	Platelets - CTCAE graded low	Worst post-baseline value Grade 1	14 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03 Grade: Part I	Platelets - CTCAE graded low	Worst post-baseline value Grade 2	2 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03 Grade: Part I	Platelets - CTCAE graded low	Worst post-baseline value Grade 3	0 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03 Grade: Part I	Platelets - CTCAE graded low	Worst post-baseline value Grade 4	0 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03 Grade: Part I	Platelets - CTCAE graded low	Worst post-baseline value Missing	0 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03 Grade: Part I	Leukocytes - CTCAE graded low	Worst post-baseline value Grade 0	52 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03 Grade: Part I	Leukocytes - CTCAE graded low	Worst post-baseline value Grade 1	11 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03 Grade: Part I	Leukocytes - CTCAE graded low	Worst post-baseline value Grade 2	3 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03 Grade: Part I	Leukocytes - CTCAE graded low	Worst post-baseline value Grade 3	0 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03 Grade: Part I	Leukocytes - CTCAE graded low	Worst post-baseline value Grade 4	0 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03 Grade: Part I	Leukocytes - CTCAE graded low	Worst post-baseline value Missing	9 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03 Grade: Part I	Leukocytes - CTCAE graded high	Worst post-baseline value Grade 0	66 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03 Grade: Part I	Leukocytes - CTCAE graded high	Worst post-baseline value Grade 1	0 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03 Grade: Part I	Leukocytes - CTCAE graded high	Worst post-baseline value Grade 2	0 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03 Grade: Part I	Leukocytes - CTCAE graded high	Worst post-baseline value Grade 3	0 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03 Grade: Part I	Leukocytes - CTCAE graded high	Worst post-baseline value Grade 4	0 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03 Grade: Part I	Leukocytes - CTCAE graded high	Worst post-baseline value Missing	9 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03 Grade: Part I	Platelets - CTCAE graded low	Worst post-baseline value Grade 1	11 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03 Grade: Part I	APTT -CTCAE graded high	Worst post-baseline value Grade 0	54 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03 Grade: Part I	Lymphocytes - CTCAE graded low	Worst post-baseline value Grade 3	10 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03 Grade: Part I	APTT -CTCAE graded high	Worst post-baseline value Grade 1	4 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03 Grade: Part I	Leukocytes - CTCAE graded high	Worst post-baseline value Missing	5 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03 Grade: Part I	APTT -CTCAE graded high	Worst post-baseline value Grade 2	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03 Grade: Part I	Lymphocytes - CTCAE graded low	Worst post-baseline value Grade 4	1 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03 Grade: Part I	APTT -CTCAE graded high	Worst post-baseline value Grade 3	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03 Grade: Part I	Platelets - CTCAE graded low	Worst post-baseline value Grade 2	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03 Grade: Part I	APTT -CTCAE graded high	Worst post-baseline value Grade 4	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03 Grade: Part I	Lymphocytes - CTCAE graded low	Worst post-baseline value Missing	9 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03 Grade: Part I	APTT -CTCAE graded high	Worst post-baseline value Missing	25 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03 Grade: Part I	Leukocytes - CTCAE graded low	Worst post-baseline value Grade 4	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03 Grade: Part I	Fibrinogen - CTCAE graded low	Worst post-baseline value Grade 0	36 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03 Grade: Part I	Lymphocytes - CTCAE graded high	Worst post-baseline value Grade 0	68 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03 Grade: Part I	Fibrinogen - CTCAE graded low	Worst post-baseline value Grade 1	9 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03 Grade: Part I	Platelets - CTCAE graded low	Worst post-baseline value Grade 3	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03 Grade: Part I	Fibrinogen - CTCAE graded low	Worst post-baseline value Grade 2	7 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03 Grade: Part I	Lymphocytes - CTCAE graded high	Worst post-baseline value Grade 1	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03 Grade: Part I	Fibrinogen - CTCAE graded low	Worst post-baseline value Grade 3	1 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03 Grade: Part I	Leukocytes - CTCAE graded high	Worst post-baseline value Grade 2	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03 Grade: Part I	Fibrinogen - CTCAE graded low	Worst post-baseline value Grade 4	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03 Grade: Part I	Lymphocytes - CTCAE graded high	Worst post-baseline value Grade 2	6 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03 Grade: Part I	Fibrinogen - CTCAE graded low	Worst post-baseline value Missing	30 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03 Grade: Part I	Platelets - CTCAE graded low	Worst post-baseline value Grade 4	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03 Grade: Part I	Hemoglobin - CTCAE graded low	Worst post-baseline value Grade 0	17 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03 Grade: Part I	Lymphocytes - CTCAE graded high	Worst post-baseline value Grade 3	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03 Grade: Part I	Hemoglobin - CTCAE graded low	Worst post-baseline value Grade 1	39 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03 Grade: Part I	Leukocytes - CTCAE graded low	Worst post-baseline value Missing	5 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03 Grade: Part I	Hemoglobin - CTCAE graded low	Worst post-baseline value Grade 2	20 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03 Grade: Part I	Lymphocytes - CTCAE graded high	Worst post-baseline value Grade 4	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03 Grade: Part I	Hemoglobin - CTCAE graded low	Worst post-baseline value Grade 3	6 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03 Grade: Part I	Platelets - CTCAE graded low	Worst post-baseline value Missing	1 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03 Grade: Part I	Hemoglobin - CTCAE graded low	Worst post-baseline value Grade 4	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03 Grade: Part I	Lymphocytes - CTCAE graded high	Worst post-baseline value Missing	9 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03 Grade: Part I	Hemoglobin - CTCAE graded low	Worst post-baseline value Missing	1 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03 Grade: Part I	Leukocytes - CTCAE graded high	Worst post-baseline value Grade 4	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03 Grade: Part I	Hemoglobin - CTCAE graded high	Worst post-baseline value Grade 0	80 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03 Grade: Part I	Neutrophils - CTCAE graded low	Worst post-baseline value Grade 0	62 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03 Grade: Part I	Hemoglobin - CTCAE graded high	Worst post-baseline value Grade 1	2 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03 Grade: Part I	Leukocytes - CTCAE graded low	Worst post-baseline value Grade 0	61 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03 Grade: Part I	Hemoglobin - CTCAE graded high	Worst post-baseline value Grade 2	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03 Grade: Part I	Neutrophils - CTCAE graded low	Worst post-baseline value Grade 1	6 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03 Grade: Part I	Hemoglobin - CTCAE graded high	Worst post-baseline value Grade 3	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03 Grade: Part I	Leukocytes - CTCAE graded high	Worst post-baseline value Grade 0	78 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03 Grade: Part I	Hemoglobin - CTCAE graded high	Worst post-baseline value Grade 4	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03 Grade: Part I	Neutrophils - CTCAE graded low	Worst post-baseline value Grade 2	4 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03 Grade: Part I	Hemoglobin - CTCAE graded high	Worst post-baseline value Missing	1 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03 Grade: Part I	Leukocytes - CTCAE graded low	Worst post-baseline value Grade 1	14 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03 Grade: Part I	PINR -CTCAE graded high	Worst post-baseline value Grade 0	34 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03 Grade: Part I	Neutrophils - CTCAE graded low	Worst post-baseline value Grade 3	1 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03 Grade: Part I	PINR -CTCAE graded high	Worst post-baseline value Grade 1	2 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03 Grade: Part I	Leukocytes - CTCAE graded high	Worst post-baseline value Grade 3	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03 Grade: Part I	PINR -CTCAE graded high	Worst post-baseline value Grade 2	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03 Grade: Part I	Neutrophils - CTCAE graded low	Worst post-baseline value Grade 4	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03 Grade: Part I	PINR -CTCAE graded high	Worst post-baseline value Grade 3	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03 Grade: Part I	Leukocytes - CTCAE graded low	Worst post-baseline value Grade 2	3 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03 Grade: Part I	PINR -CTCAE graded high	Worst post-baseline value Grade 4	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03 Grade: Part I	Neutrophils - CTCAE graded low	Worst post-baseline value Missing	10 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03 Grade: Part I	PINR -CTCAE graded high	Worst post-baseline value Missing	47 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03 Grade: Part I	Leukocytes - CTCAE graded high	Worst post-baseline value Grade 1	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03 Grade: Part I	Lymphocytes - CTCAE graded low	Worst post-baseline value Grade 0	27 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03 Grade: Part I	Platelets - CTCAE graded low	Worst post-baseline value Grade 0	71 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03 Grade: Part I	Lymphocytes - CTCAE graded low	Worst post-baseline value Grade 1	24 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03 Grade: Part I	Leukocytes - CTCAE graded low	Worst post-baseline value Grade 3	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03 Grade: Part I	Lymphocytes - CTCAE graded low	Worst post-baseline value Grade 2	12 Participants

Secondary

Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II

Parameters evaluated were: APTT (sec) - CTCAE graded high, fibrinogen (g/L) - CTCAE graded low, hemoglobin (g/L) - CTCAE graded low, hemoglobin (g/L) - CTCAE graded high, PINR - CTCAE graded high, lymphocytes (10\^9 cells/L) - CTCAE graded low, lymphocytes (10\^9 cells/L) - CTCAE graded high, neutrophils (10\^9 cells/L) - CTCAE graded low, platelets (10\^9 cells/L) - CTCAE graded low, leukocytes (10\^9 cells/L) - CTCAE graded low, leukocytes (10\^9 cells/L) - CTCAE graded high. CTCAE version 4.03 was used: grade 1 = mild, grade 2 = moderate, grade 3 = severe, grade 4 = life-threatening consequences; grade 0 = values not meeting any of the criteria for grade 1 or higher. Baseline = last non-missing value prior to the first dose of study treatment in Part II.

Time frame: Baseline up to last dose (maximum treatment exposure for Part II was 97.0 weeks)

Population: Safety set included all participants who received at least 1 dose of 3rd combination agent for Part II and had at least 1 valid post-baseline safety assessment.

Arm	Measure	Group	Category	Value (COUNT_OF_PARTICIPANTS)
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Lymphocytes -CTCAE graded low	Worst post-baseline value Grade 0	5 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	PINR- CTCAE graded high	Worst post-baseline value Missing	24 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	PINR- CTCAE graded high	Worst post-baseline value Grade 4	0 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Hemoglobin- CTCAE graded low	Worst post-baseline value Grade 3	4 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Leukocytes- CTCAE graded low	Worst post-baseline value Grade 1	8 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	PINR- CTCAE graded high	Worst post-baseline value Grade 3	0 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	PINR- CTCAE graded high	Worst post-baseline value Grade 2	0 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Hemoglobin- CTCAE graded low	Worst post-baseline value Grade 4	0 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	APTT- CTCAE graded high	Worst post-baseline value Grade 2	0 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	PINR- CTCAE graded high	Worst post-baseline value Grade 1	0 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	PINR- CTCAE graded high	Worst post-baseline value Grade 0	14 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Hemoglobin- CTCAE graded low	Worst post-baseline value Missing	1 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Leukocytes - CTCAE graded high	Worst post-baseline value Missing	7 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Hemoglobin- CTCAE graded high	Worst post-baseline value Missing	1 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Hemoglobin- CTCAE graded high	Worst post-baseline value Grade 4	0 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Hemoglobin- CTCAE graded high	Worst post-baseline value Grade 0	37 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Leukocytes- CTCAE graded low	Worst post-baseline value Grade 0	8 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Hemoglobin- CTCAE graded high	Worst post-baseline value Grade 3	0 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Hemoglobin- CTCAE graded high	Worst post-baseline value Grade 2	0 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Hemoglobin- CTCAE graded high	Worst post-baseline value Grade 1	0 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Platelets- CTCAE graded low	Worst post-baseline value Missing	1 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	APTT- CTCAE graded high	Worst post-baseline value Grade 3	0 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Leukocytes - CTCAE graded high	Worst post-baseline value Grade 3	0 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Platelets- CTCAE graded low	Worst post-baseline value Grade 4	0 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Platelets- CTCAE graded low	Worst post-baseline value Grade 3	0 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	APTT- CTCAE graded high	Worst post-baseline value Grade 4	0 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Leukocytes - CTCAE graded high	Worst post-baseline value Grade 2	0 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Platelets- CTCAE graded low	Worst post-baseline value Grade 2	0 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Platelets- CTCAE graded low	Worst post-baseline value Grade 1	4 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	APTT- CTCAE graded high	Worst post-baseline value Missing	11 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Leukocytes - CTCAE graded high	Worst post-baseline value Grade 1	0 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Platelets- CTCAE graded low	Worst post-baseline value Grade 0	33 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Neutrophils- CTCAE graded low	Worst post-baseline value Missing	11 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Fibrinogen: CTCAE graded low	Worst post-baseline value Grade 0	13 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Leukocytes - CTCAE graded high	Worst post-baseline value Grade 0	31 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Neutrophils- CTCAE graded low	Worst post-baseline value Grade 4	1 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Neutrophils- CTCAE graded low	Worst post-baseline value Grade 3	1 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Fibrinogen: CTCAE graded low	Worst post-baseline value Grade 1	3 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	APTT- CTCAE graded high	Worst post-baseline value Grade 0	27 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Neutrophils- CTCAE graded low	Worst post-baseline value Grade 2	6 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Neutrophils- CTCAE graded low	Worst post-baseline value Grade 1	9 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Fibrinogen: CTCAE graded low	Worst post-baseline value Grade 2	2 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Leukocytes - CTCAE graded high	Worst post-baseline value Grade 4	0 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Neutrophils- CTCAE graded low	Worst post-baseline value Grade 0	10 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Lymphocytes- CTCAE graded high	Worst post-baseline value Missing	9 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Fibrinogen: CTCAE graded low	Worst post-baseline value Grade 3	1 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Leukocytes- CTCAE graded low	Worst post-baseline value Missing	7 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Lymphocytes- CTCAE graded high	Worst post-baseline value Grade 4	0 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Lymphocytes- CTCAE graded high	Worst post-baseline value Grade 3	0 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Fibrinogen: CTCAE graded low	Worst post-baseline value Grade 4	0 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Leukocytes- CTCAE graded low	Worst post-baseline value Grade 3	3 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Lymphocytes- CTCAE graded high	Worst post-baseline value Grade 2	0 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Lymphocytes- CTCAE graded high	Worst post-baseline value Grade 1	0 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Fibrinogen: CTCAE graded low	Worst post-baseline value Missing	19 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	APTT- CTCAE graded high	Worst post-baseline value Grade 1	0 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Lymphocytes- CTCAE graded high	Worst post-baseline value Grade 0	29 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Lymphocytes -CTCAE graded low	Worst post-baseline value Missing	9 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Hemoglobin- CTCAE graded low	Worst post-baseline value Grade 0	4 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Leukocytes- CTCAE graded low	Worst post-baseline value Grade 4	0 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Lymphocytes -CTCAE graded low	Worst post-baseline value Grade 4	1 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Lymphocytes -CTCAE graded low	Worst post-baseline value Grade 3	7 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Hemoglobin- CTCAE graded low	Worst post-baseline value Grade 1	15 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Leukocytes- CTCAE graded low	Worst post-baseline value Grade 2	12 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Lymphocytes -CTCAE graded low	Worst post-baseline value Grade 2	9 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Lymphocytes -CTCAE graded low	Worst post-baseline value Grade 1	7 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Hemoglobin- CTCAE graded low	Worst post-baseline value Grade 2	14 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Hemoglobin- CTCAE graded low	Worst post-baseline value Grade 2	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Leukocytes- CTCAE graded low	Worst post-baseline value Grade 4	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	APTT- CTCAE graded high	Worst post-baseline value Grade 0	1 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	APTT- CTCAE graded high	Worst post-baseline value Grade 1	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	APTT- CTCAE graded high	Worst post-baseline value Grade 2	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	APTT- CTCAE graded high	Worst post-baseline value Grade 3	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	APTT- CTCAE graded high	Worst post-baseline value Grade 4	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	APTT- CTCAE graded high	Worst post-baseline value Missing	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Fibrinogen: CTCAE graded low	Worst post-baseline value Grade 0	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Fibrinogen: CTCAE graded low	Worst post-baseline value Grade 1	1 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Fibrinogen: CTCAE graded low	Worst post-baseline value Grade 2	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Fibrinogen: CTCAE graded low	Worst post-baseline value Grade 3	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Fibrinogen: CTCAE graded low	Worst post-baseline value Grade 4	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Fibrinogen: CTCAE graded low	Worst post-baseline value Missing	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Hemoglobin- CTCAE graded low	Worst post-baseline value Grade 0	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Hemoglobin- CTCAE graded low	Worst post-baseline value Grade 1	1 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Hemoglobin- CTCAE graded low	Worst post-baseline value Grade 3	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Hemoglobin- CTCAE graded low	Worst post-baseline value Grade 4	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Hemoglobin- CTCAE graded low	Worst post-baseline value Missing	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Hemoglobin- CTCAE graded high	Worst post-baseline value Grade 0	1 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Hemoglobin- CTCAE graded high	Worst post-baseline value Grade 1	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Hemoglobin- CTCAE graded high	Worst post-baseline value Grade 2	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Hemoglobin- CTCAE graded high	Worst post-baseline value Grade 3	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Hemoglobin- CTCAE graded high	Worst post-baseline value Grade 4	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Hemoglobin- CTCAE graded high	Worst post-baseline value Missing	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	PINR- CTCAE graded high	Worst post-baseline value Grade 0	1 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	PINR- CTCAE graded high	Worst post-baseline value Grade 1	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	PINR- CTCAE graded high	Worst post-baseline value Grade 2	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	PINR- CTCAE graded high	Worst post-baseline value Grade 3	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	PINR- CTCAE graded high	Worst post-baseline value Grade 4	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	PINR- CTCAE graded high	Worst post-baseline value Missing	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Lymphocytes -CTCAE graded low	Worst post-baseline value Grade 0	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Lymphocytes -CTCAE graded low	Worst post-baseline value Grade 1	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Lymphocytes -CTCAE graded low	Worst post-baseline value Grade 2	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Lymphocytes -CTCAE graded low	Worst post-baseline value Grade 3	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Lymphocytes -CTCAE graded low	Worst post-baseline value Grade 4	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Lymphocytes -CTCAE graded low	Worst post-baseline value Missing	1 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Lymphocytes- CTCAE graded high	Worst post-baseline value Grade 0	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Lymphocytes- CTCAE graded high	Worst post-baseline value Grade 1	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Lymphocytes- CTCAE graded high	Worst post-baseline value Grade 2	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Lymphocytes- CTCAE graded high	Worst post-baseline value Grade 3	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Lymphocytes- CTCAE graded high	Worst post-baseline value Grade 4	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Lymphocytes- CTCAE graded high	Worst post-baseline value Missing	1 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Neutrophils- CTCAE graded low	Worst post-baseline value Grade 0	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Neutrophils- CTCAE graded low	Worst post-baseline value Grade 1	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Neutrophils- CTCAE graded low	Worst post-baseline value Grade 2	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Neutrophils- CTCAE graded low	Worst post-baseline value Grade 3	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Neutrophils- CTCAE graded low	Worst post-baseline value Grade 4	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Neutrophils- CTCAE graded low	Worst post-baseline value Missing	1 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Platelets- CTCAE graded low	Worst post-baseline value Grade 0	1 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Platelets- CTCAE graded low	Worst post-baseline value Grade 1	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Platelets- CTCAE graded low	Worst post-baseline value Grade 2	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Platelets- CTCAE graded low	Worst post-baseline value Grade 3	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Platelets- CTCAE graded low	Worst post-baseline value Grade 4	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Platelets- CTCAE graded low	Worst post-baseline value Missing	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Leukocytes- CTCAE graded low	Worst post-baseline value Grade 0	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Leukocytes- CTCAE graded low	Worst post-baseline value Grade 1	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Leukocytes- CTCAE graded low	Worst post-baseline value Grade 2	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Leukocytes- CTCAE graded low	Worst post-baseline value Grade 3	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Leukocytes- CTCAE graded low	Worst post-baseline value Missing	1 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Leukocytes - CTCAE graded high	Worst post-baseline value Grade 0	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Leukocytes - CTCAE graded high	Worst post-baseline value Grade 1	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Leukocytes - CTCAE graded high	Worst post-baseline value Grade 2	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Leukocytes - CTCAE graded high	Worst post-baseline value Grade 3	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Leukocytes - CTCAE graded high	Worst post-baseline value Grade 4	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Leukocytes - CTCAE graded high	Worst post-baseline value Missing	1 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Lymphocytes -CTCAE graded low	Worst post-baseline value Grade 0	4 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	APTT- CTCAE graded high	Worst post-baseline value Grade 1	0 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Lymphocytes -CTCAE graded low	Worst post-baseline value Grade 1	4 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Hemoglobin- CTCAE graded low	Worst post-baseline value Grade 1	5 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Leukocytes - CTCAE graded high	Worst post-baseline value Grade 3	0 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Lymphocytes -CTCAE graded low	Worst post-baseline value Grade 2	3 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Leukocytes- CTCAE graded low	Worst post-baseline value Grade 2	0 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Lymphocytes -CTCAE graded low	Worst post-baseline value Grade 3	0 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Hemoglobin- CTCAE graded low	Worst post-baseline value Grade 0	4 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Lymphocytes -CTCAE graded low	Worst post-baseline value Grade 4	0 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Lymphocytes -CTCAE graded low	Worst post-baseline value Missing	2 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Fibrinogen: CTCAE graded low	Worst post-baseline value Missing	5 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Lymphocytes- CTCAE graded high	Worst post-baseline value Grade 0	11 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Leukocytes- CTCAE graded low	Worst post-baseline value Grade 3	0 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Lymphocytes- CTCAE graded high	Worst post-baseline value Grade 1	0 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Fibrinogen: CTCAE graded low	Worst post-baseline value Grade 4	0 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Lymphocytes- CTCAE graded high	Worst post-baseline value Grade 2	0 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	APTT- CTCAE graded high	Worst post-baseline value Grade 0	9 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Lymphocytes- CTCAE graded high	Worst post-baseline value Grade 3	0 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Fibrinogen: CTCAE graded low	Worst post-baseline value Grade 3	0 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Platelets- CTCAE graded low	Worst post-baseline value Grade 2	0 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Lymphocytes- CTCAE graded high	Worst post-baseline value Grade 4	0 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Leukocytes- CTCAE graded low	Worst post-baseline value Missing	2 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Lymphocytes- CTCAE graded high	Worst post-baseline value Missing	2 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Fibrinogen: CTCAE graded low	Worst post-baseline value Grade 2	1 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Neutrophils- CTCAE graded low	Worst post-baseline value Grade 0	11 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Leukocytes - CTCAE graded high	Worst post-baseline value Missing	2 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Neutrophils- CTCAE graded low	Worst post-baseline value Grade 1	0 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Fibrinogen: CTCAE graded low	Worst post-baseline value Grade 1	1 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Neutrophils- CTCAE graded low	Worst post-baseline value Grade 2	0 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Neutrophils- CTCAE graded low	Worst post-baseline value Grade 3	0 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Fibrinogen: CTCAE graded low	Worst post-baseline value Grade 0	6 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Leukocytes - CTCAE graded high	Worst post-baseline value Grade 0	11 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Neutrophils- CTCAE graded low	Worst post-baseline value Grade 4	0 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Leukocytes - CTCAE graded high	Worst post-baseline value Grade 4	0 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Neutrophils- CTCAE graded low	Worst post-baseline value Missing	2 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	APTT- CTCAE graded high	Worst post-baseline value Missing	4 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Leukocytes - CTCAE graded high	Worst post-baseline value Grade 1	0 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Platelets- CTCAE graded low	Worst post-baseline value Grade 0	11 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Platelets- CTCAE graded low	Worst post-baseline value Grade 1	1 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	APTT- CTCAE graded high	Worst post-baseline value Grade 4	0 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Platelets- CTCAE graded low	Worst post-baseline value Grade 3	0 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	APTT- CTCAE graded high	Worst post-baseline value Grade 3	0 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Leukocytes - CTCAE graded high	Worst post-baseline value Grade 2	0 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Platelets- CTCAE graded low	Worst post-baseline value Grade 4	0 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Hemoglobin- CTCAE graded high	Worst post-baseline value Grade 1	1 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Hemoglobin- CTCAE graded high	Worst post-baseline value Grade 2	0 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Hemoglobin- CTCAE graded high	Worst post-baseline value Grade 0	11 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Platelets- CTCAE graded low	Worst post-baseline value Missing	1 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Hemoglobin- CTCAE graded high	Worst post-baseline value Grade 3	0 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Hemoglobin- CTCAE graded high	Worst post-baseline value Grade 4	0 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Hemoglobin- CTCAE graded low	Worst post-baseline value Missing	1 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	APTT- CTCAE graded high	Worst post-baseline value Grade 2	0 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Hemoglobin- CTCAE graded high	Worst post-baseline value Missing	1 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Leukocytes- CTCAE graded low	Worst post-baseline value Grade 4	0 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	PINR- CTCAE graded high	Worst post-baseline value Grade 0	8 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Hemoglobin- CTCAE graded low	Worst post-baseline value Grade 4	0 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Leukocytes- CTCAE graded low	Worst post-baseline value Grade 0	11 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	PINR- CTCAE graded high	Worst post-baseline value Grade 1	0 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	PINR- CTCAE graded high	Worst post-baseline value Grade 2	0 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Hemoglobin- CTCAE graded low	Worst post-baseline value Grade 3	1 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	PINR- CTCAE graded high	Worst post-baseline value Grade 3	0 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	PINR- CTCAE graded high	Worst post-baseline value Grade 4	0 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Hemoglobin- CTCAE graded low	Worst post-baseline value Grade 2	2 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Leukocytes- CTCAE graded low	Worst post-baseline value Grade 1	0 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	PINR- CTCAE graded high	Worst post-baseline value Missing	5 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Leukocytes- CTCAE graded low	Worst post-baseline value Grade 1	0 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Hemoglobin- CTCAE graded low	Worst post-baseline value Grade 1	1 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Neutrophils- CTCAE graded low	Worst post-baseline value Missing	0 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	APTT- CTCAE graded high	Worst post-baseline value Grade 1	0 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Lymphocytes -CTCAE graded low	Worst post-baseline value Grade 1	3 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Lymphocytes -CTCAE graded low	Worst post-baseline value Grade 0	2 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Hemoglobin- CTCAE graded high	Worst post-baseline value Missing	0 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	APTT- CTCAE graded high	Worst post-baseline value Grade 4	0 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Lymphocytes -CTCAE graded low	Worst post-baseline value Grade 2	1 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Hemoglobin- CTCAE graded low	Worst post-baseline value Grade 0	2 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Leukocytes - CTCAE graded high	Worst post-baseline value Grade 1	0 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Hemoglobin- CTCAE graded low	Worst post-baseline value Grade 4	0 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Lymphocytes -CTCAE graded low	Worst post-baseline value Grade 3	0 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Platelets- CTCAE graded low	Worst post-baseline value Grade 1	0 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Leukocytes- CTCAE graded low	Worst post-baseline value Grade 2	0 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	PINR- CTCAE graded high	Worst post-baseline value Grade 3	0 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Lymphocytes -CTCAE graded low	Worst post-baseline value Grade 4	0 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Fibrinogen: CTCAE graded low	Worst post-baseline value Missing	3 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	APTT- CTCAE graded high	Worst post-baseline value Grade 0	4 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Leukocytes- CTCAE graded low	Worst post-baseline value Grade 4	0 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Lymphocytes -CTCAE graded low	Worst post-baseline value Missing	0 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Platelets- CTCAE graded low	Worst post-baseline value Grade 2	0 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Leukocytes - CTCAE graded high	Worst post-baseline value Grade 3	0 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	APTT- CTCAE graded high	Worst post-baseline value Grade 3	0 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Lymphocytes- CTCAE graded high	Worst post-baseline value Grade 0	6 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Fibrinogen: CTCAE graded low	Worst post-baseline value Grade 4	0 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Leukocytes - CTCAE graded high	Worst post-baseline value Grade 4	0 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Hemoglobin- CTCAE graded low	Worst post-baseline value Grade 2	1 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Lymphocytes- CTCAE graded high	Worst post-baseline value Grade 1	0 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Platelets- CTCAE graded low	Worst post-baseline value Grade 3	0 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Leukocytes- CTCAE graded low	Worst post-baseline value Grade 3	0 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	PINR- CTCAE graded high	Worst post-baseline value Grade 0	1 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Lymphocytes- CTCAE graded high	Worst post-baseline value Grade 2	0 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Fibrinogen: CTCAE graded low	Worst post-baseline value Grade 3	0 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Platelets- CTCAE graded low	Worst post-baseline value Grade 0	6 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	PINR- CTCAE graded high	Worst post-baseline value Missing	5 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Lymphocytes- CTCAE graded high	Worst post-baseline value Grade 3	0 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Platelets- CTCAE graded low	Worst post-baseline value Grade 4	0 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	APTT- CTCAE graded high	Worst post-baseline value Grade 2	0 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	PINR- CTCAE graded high	Worst post-baseline value Grade 4	0 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Lymphocytes- CTCAE graded high	Worst post-baseline value Grade 4	0 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Fibrinogen: CTCAE graded low	Worst post-baseline value Grade 2	0 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Hemoglobin- CTCAE graded high	Worst post-baseline value Grade 1	0 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Hemoglobin- CTCAE graded high	Worst post-baseline value Grade 0	6 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Leukocytes - CTCAE graded high	Worst post-baseline value Grade 2	0 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Leukocytes- CTCAE graded low	Worst post-baseline value Missing	0 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	PINR- CTCAE graded high	Worst post-baseline value Grade 1	0 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Neutrophils- CTCAE graded low	Worst post-baseline value Grade 0	6 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Fibrinogen: CTCAE graded low	Worst post-baseline value Grade 1	0 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Hemoglobin- CTCAE graded high	Worst post-baseline value Grade 2	0 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Hemoglobin- CTCAE graded low	Worst post-baseline value Grade 3	2 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Neutrophils- CTCAE graded low	Worst post-baseline value Grade 1	0 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Leukocytes- CTCAE graded low	Worst post-baseline value Grade 0	6 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Leukocytes - CTCAE graded high	Worst post-baseline value Missing	0 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Lymphocytes- CTCAE graded high	Worst post-baseline value Missing	0 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Neutrophils- CTCAE graded low	Worst post-baseline value Grade 2	0 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Fibrinogen: CTCAE graded low	Worst post-baseline value Grade 0	3 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Leukocytes - CTCAE graded high	Worst post-baseline value Grade 0	6 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Hemoglobin- CTCAE graded high	Worst post-baseline value Grade 3	0 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Neutrophils- CTCAE graded low	Worst post-baseline value Grade 3	0 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Hemoglobin- CTCAE graded low	Worst post-baseline value Missing	0 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Platelets- CTCAE graded low	Worst post-baseline value Missing	0 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	PINR- CTCAE graded high	Worst post-baseline value Grade 2	0 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Neutrophils- CTCAE graded low	Worst post-baseline value Grade 4	0 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	APTT- CTCAE graded high	Worst post-baseline value Missing	2 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II	Hemoglobin- CTCAE graded high	Worst post-baseline value Grade 4	0 Participants

Secondary

Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I

Parameters evaluated were: albumin (g/L)- CTCAE graded low, alkaline phosphatase (units per liter \[U/L\])- CTCAE graded high, alanine aminotransferase (U/L)- CTCAE graded high, amylase (U/L - CTCAE graded high, aspartate aminotransferase(U/L)- CTCAE graded high, bilirubin (micromole per liter \[umol/L\])- CTCAE graded high, creatinine (umol/L) - CTCAE graded high, creatine kinase (U/L)- CTCAE graded high, gamma glutamyl transferase (U/L)- CTCAE graded high, glucose (millimole per liter \[mmol/L\])- CTCAE graded low, high, potassium (mmol/L)- CTCAE graded low, potassium (mmol/L)- CTCAE graded high, magnesium (mmol/L)- CTCAE graded low, high, phosphate (mmol/L)- CTCAE graded low, sodium (mmol/L)- CTCAE graded low, sodium (mmol/L)- CTCAE graded high, urate (umol/L)- CTCAE graded high. CTCAE version 4.03 was used: grade 1 = mild, grade 2 = moderate, grade 3 = severe, grade 4 = life-threatening consequences; grade 0 = values not meeting any of the criteria for grade 1 or higher.

Time frame: Baseline up to last dose (maximum treatment exposure for Part I was 403.7 weeks)

Population: Safety set included all participants who received at least 1 dose of encorafenib or binimetinib for Part I and had at least 1 valid post-baseline safety assessment.

Arm	Measure	Group	Category	Value (COUNT_OF_PARTICIPANTS)
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Albumin - CTCAE graded low	Worst post-baseline value Grade 0	32 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Alanine Aminotransferase - CTCAE graded high	Worst post-baseline value Grade 3	5 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Creatinine - CTCAE graded high	Worst post-baseline value Grade 1	57 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Glucose - CTCAE graded low	Worst post-baseline value Grade 2	1 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Glucose - CTCAE graded high	Worst post-baseline value Grade 0	56 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Glucose - CTCAE graded high	Worst post-baseline value Grade 1	4 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Glucose - CTCAE graded high	Worst post-baseline value Grade 3	7 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Glucose - CTCAE graded high	Worst post-baseline value Grade 4	1 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Glucose - CTCAE graded high	Worst post-baseline value Missing	4 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Potassium - CTCAE graded low	Worst post-baseline value Grade 0	65 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Potassium - CTCAE graded low	Worst post-baseline value Grade 1	7 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Potassium - CTCAE graded low	Worst post-baseline value Grade 4	0 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Potassium - CTCAE graded high	Worst post-baseline value Grade 1	18 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Potassium - CTCAE graded high	Worst post-baseline value Grade 3	1 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Potassium - CTCAE graded high	Worst post-baseline value Grade 4	0 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Magnesium - CTCAE graded high	Worst post-baseline value Grade 0	74 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Magnesium - CTCAE graded low	Worst post-baseline value Missing	0 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Creatine Kinase - CTCAE graded high	Worst post-baseline value Grade 2	18 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Creatine Kinase - CTCAE graded high	Worst post-baseline value Grade 3	4 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Creatine Kinase - CTCAE graded high	Worst post-baseline value Grade 4	1 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Creatine Kinase - CTCAE graded high	Worst post-baseline value Missing	0 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Creatinine - CTCAE graded high	Worst post-baseline value Grade 0	2 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Creatinine - CTCAE graded high	Worst post-baseline value Grade 2	14 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Creatinine - CTCAE graded high	Worst post-baseline value Grade 3	2 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Creatinine - CTCAE graded high	Worst post-baseline value Grade 4	0 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Creatinine - CTCAE graded high	Worst post-baseline value Missing	0 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Gamma Glutamyl Transferase - CTCAE graded high	Worst post-baseline value Grade 0	20 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Gamma Glutamyl Transferase - CTCAE graded high	Worst post-baseline value Grade 1	19 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Gamma Glutamyl Transferase - CTCAE graded high	Worst post-baseline value Grade 2	14 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Gamma Glutamyl Transferase - CTCAE graded high	Worst post-baseline value Grade 3	20 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Gamma Glutamyl Transferase - CTCAE graded high	Worst post-baseline value Grade 4	2 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Gamma Glutamyl Transferase - CTCAE graded high	Worst post-baseline value Missing	0 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Glucose - CTCAE graded low	Worst post-baseline value Grade 0	55 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Albumin - CTCAE graded low	Worst post-baseline value Grade 1	35 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Albumin - CTCAE graded low	Worst post-baseline value Grade 2	8 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Albumin - CTCAE graded low	Worst post-baseline value Grade 3	0 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Albumin - CTCAE graded low	Worst post-baseline value Grade 4	0 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Albumin - CTCAE graded low	Worst post-baseline value Missing	0 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Alkaline Phosphatase - CTCAE graded high	Worst post-baseline value Grade 0	39 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Alkaline Phosphatase - CTCAE graded high	Worst post-baseline value Grade 1	28 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Alkaline Phosphatase - CTCAE graded high	Worst post-baseline value Grade 2	5 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Alkaline Phosphatase - CTCAE graded high	Worst post-baseline value Grade 3	3 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Alkaline Phosphatase - CTCAE graded high	Worst post-baseline value Grade 4	0 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Alkaline Phosphatase - CTCAE graded high	Worst post-baseline value Missing	0 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Alanine Aminotransferase - CTCAE graded high	Worst post-baseline value Grade 0	38 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Alanine Aminotransferase - CTCAE graded high	Worst post-baseline value Grade 1	27 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Alanine Aminotransferase - CTCAE graded high	Worst post-baseline value Grade 2	5 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Alanine Aminotransferase - CTCAE graded high	Worst post-baseline value Grade 4	0 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Alanine Aminotransferase - CTCAE graded high	Worst post-baseline value Missing	0 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Amylase - CTCAE graded high	Worst post-baseline value Grade 0	53 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Amylase - CTCAE graded high	Worst post-baseline value Grade 1	14 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Amylase - CTCAE graded high	Worst post-baseline value Grade 2	5 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Amylase - CTCAE graded high	Worst post-baseline value Grade 3	2 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Amylase - CTCAE graded high	Worst post-baseline value Grade 4	0 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Amylase - CTCAE graded high	Worst post-baseline value Missing	1 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Aspartate Aminotransferase - CTCAE graded high	Worst post-baseline value Grade 0	38 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Aspartate Aminotransferase - CTCAE graded high	Worst post-baseline value Grade 1	30 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Aspartate Aminotransferase - CTCAE graded high	Worst post-baseline value Grade 2	4 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Aspartate Aminotransferase - CTCAE graded high	Worst post-baseline value Grade 3	3 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Aspartate Aminotransferase - CTCAE graded high	Worst post-baseline value Grade 4	0 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Aspartate Aminotransferase - CTCAE graded high	Worst post-baseline value Missing	0 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Bilirubin - CTCAE graded high	Worst post-baseline value Grade 0	73 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Bilirubin - CTCAE graded high	Worst post-baseline value Grade 1	1 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Bilirubin - CTCAE graded high	Worst post-baseline value Grade 2	1 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Bilirubin - CTCAE graded high	Worst post-baseline value Grade 3	0 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Bilirubin - CTCAE graded high	Worst post-baseline value Grade 4	0 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Bilirubin - CTCAE graded high	Worst post-baseline value Missing	0 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Creatine Kinase - CTCAE graded high	Worst post-baseline value Grade 0	22 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Creatine Kinase - CTCAE graded high	Worst post-baseline value Grade 1	30 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Glucose - CTCAE graded low	Worst post-baseline value Grade 1	15 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Glucose - CTCAE graded low	Worst post-baseline value Grade 3	0 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Glucose - CTCAE graded low	Worst post-baseline value Grade 4	0 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Glucose - CTCAE graded low	Worst post-baseline value Missing	4 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Glucose - CTCAE graded high	Worst post-baseline value Grade 2	3 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Potassium - CTCAE graded low	Worst post-baseline value Grade 2	0 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Potassium - CTCAE graded low	Worst post-baseline value Grade 3	3 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Potassium - CTCAE graded low	Worst post-baseline value Missing	0 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Potassium - CTCAE graded high	Worst post-baseline value Grade 0	54 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Potassium - CTCAE graded high	Worst post-baseline value Grade 2	2 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Potassium - CTCAE graded high	Worst post-baseline value Missing	0 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Magnesium - CTCAE graded low	Worst post-baseline value Grade 0	66 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Magnesium - CTCAE graded low	Worst post-baseline value Grade 1	8 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Magnesium - CTCAE graded low	Worst post-baseline value Grade 2	0 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Magnesium - CTCAE graded low	Worst post-baseline value Grade 3	1 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Magnesium - CTCAE graded low	Worst post-baseline value Grade 4	0 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Magnesium - CTCAE graded high	Worst post-baseline value Grade 1	1 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Magnesium - CTCAE graded high	Worst post-baseline value Grade 2	0 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Magnesium - CTCAE graded high	Worst post-baseline value Grade 3	0 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Magnesium - CTCAE graded high	Worst post-baseline value Grade 4	0 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Magnesium - CTCAE graded high	Worst post-baseline value Missing	0 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Phosphate - CTCAE graded low	Worst post-baseline value Grade 0	40 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Phosphate - CTCAE graded low	Worst post-baseline value Grade 1	3 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Phosphate - CTCAE graded low	Worst post-baseline value Grade 2	24 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Phosphate - CTCAE graded low	Worst post-baseline value Grade 3	8 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Phosphate - CTCAE graded low	Worst post-baseline value Grade 4	0 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Phosphate - CTCAE graded low	Worst post-baseline value Missing	0 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Sodium - CTCAE graded low	Worst post-baseline value Grade 0	54 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Sodium - CTCAE graded low	Worst post-baseline value Grade 1	21 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Sodium - CTCAE graded low	Worst post-baseline value Grade 2	0 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Sodium - CTCAE graded low	Worst post-baseline value Grade 3	0 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Sodium - CTCAE graded low	Worst post-baseline value Grade 4	0 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Sodium - CTCAE graded low	Worst post-baseline value Missing	0 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Sodium - CTCAE graded high	Worst post-baseline value Grade 0	66 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Sodium - CTCAE graded high	Worst post-baseline value Grade 1	9 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Sodium - CTCAE graded high	Worst post-baseline value Grade 2	0 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Sodium - CTCAE graded high	Worst post-baseline value Grade 3	0 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Sodium - CTCAE graded high	Worst post-baseline value Grade 4	0 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Sodium - CTCAE graded high	Worst post-baseline value Missing	0 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Urate - CTCAE graded high	Worst post-baseline value Grade 0	75 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Urate - CTCAE graded high	Worst post-baseline value Grade 1	0 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Urate - CTCAE graded high	Worst post-baseline value Grade 2	0 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Urate - CTCAE graded high	Worst post-baseline value Grade 3	0 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Urate - CTCAE graded high	Worst post-baseline value Grade 4	0 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Urate - CTCAE graded high	Worst post-baseline value Missing	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Aspartate Aminotransferase - CTCAE graded high	Worst post-baseline value Grade 2	2 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Alkaline Phosphatase - CTCAE graded high	Worst post-baseline value Grade 2	5 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Urate - CTCAE graded high	Worst post-baseline value Grade 2	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Amylase - CTCAE graded high	Worst post-baseline value Grade 2	2 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Aspartate Aminotransferase - CTCAE graded high	Worst post-baseline value Grade 1	29 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Aspartate Aminotransferase - CTCAE graded high	Worst post-baseline value Grade 3	1 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Creatinine - CTCAE graded high	Worst post-baseline value Grade 1	56 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Creatinine - CTCAE graded high	Worst post-baseline value Grade 4	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Gamma Glutamyl Transferase - CTCAE graded high	Worst post-baseline value Grade 3	15 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Glucose - CTCAE graded low	Worst post-baseline value Grade 0	67 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Glucose - CTCAE graded low	Worst post-baseline value Grade 1	7 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Magnesium - CTCAE graded high	Worst post-baseline value Grade 2	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Glucose - CTCAE graded low	Worst post-baseline value Grade 3	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Aspartate Aminotransferase - CTCAE graded high	Worst post-baseline value Grade 4	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Sodium - CTCAE graded low	Worst post-baseline value Grade 4	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Aspartate Aminotransferase - CTCAE graded high	Worst post-baseline value Missing	1 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Magnesium - CTCAE graded high	Worst post-baseline value Grade 3	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Glucose - CTCAE graded high	Worst post-baseline value Grade 4	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Bilirubin - CTCAE graded high	Worst post-baseline value Grade 0	81 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Sodium - CTCAE graded high	Worst post-baseline value Missing	1 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Potassium - CTCAE graded low	Worst post-baseline value Grade 0	74 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Bilirubin - CTCAE graded high	Worst post-baseline value Grade 1	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Potassium - CTCAE graded low	Worst post-baseline value Grade 1	5 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Potassium - CTCAE graded low	Worst post-baseline value Grade 2	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Potassium - CTCAE graded low	Worst post-baseline value Grade 3	3 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Magnesium - CTCAE graded high	Worst post-baseline value Grade 4	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Potassium - CTCAE graded high	Worst post-baseline value Grade 0	66 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Bilirubin - CTCAE graded high	Worst post-baseline value Grade 2	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Potassium - CTCAE graded high	Worst post-baseline value Grade 1	15 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Sodium - CTCAE graded low	Worst post-baseline value Missing	1 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Potassium - CTCAE graded high	Worst post-baseline value Grade 3	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Bilirubin - CTCAE graded high	Worst post-baseline value Grade 3	1 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Magnesium - CTCAE graded low	Worst post-baseline value Grade 0	68 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Magnesium - CTCAE graded high	Worst post-baseline value Missing	1 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Bilirubin - CTCAE graded high	Worst post-baseline value Grade 4	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Magnesium - CTCAE graded low	Worst post-baseline value Missing	1 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Magnesium - CTCAE graded high	Worst post-baseline value Grade 0	79 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Urate - CTCAE graded high	Worst post-baseline value Grade 4	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Creatine Kinase - CTCAE graded high	Worst post-baseline value Grade 2	8 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Bilirubin - CTCAE graded high	Worst post-baseline value Missing	1 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Creatine Kinase - CTCAE graded high	Worst post-baseline value Grade 3	2 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Phosphate - CTCAE graded low	Worst post-baseline value Grade 0	62 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Creatine Kinase - CTCAE graded high	Worst post-baseline value Grade 4	1 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Creatine Kinase - CTCAE graded high	Worst post-baseline value Grade 0	56 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Creatine Kinase - CTCAE graded high	Worst post-baseline value Missing	1 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Sodium - CTCAE graded high	Worst post-baseline value Grade 0	75 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Creatinine - CTCAE graded high	Worst post-baseline value Grade 0	4 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Creatine Kinase - CTCAE graded high	Worst post-baseline value Grade 1	15 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Creatinine - CTCAE graded high	Worst post-baseline value Grade 2	22 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Phosphate - CTCAE graded low	Worst post-baseline value Grade 1	3 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Creatinine - CTCAE graded high	Worst post-baseline value Grade 3	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Glucose - CTCAE graded low	Worst post-baseline value Grade 2	1 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Urate - CTCAE graded high	Worst post-baseline value Grade 0	82 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Creatinine - CTCAE graded high	Worst post-baseline value Missing	1 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Phosphate - CTCAE graded low	Worst post-baseline value Grade 2	12 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Gamma Glutamyl Transferase - CTCAE graded high	Worst post-baseline value Grade 0	33 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Glucose - CTCAE graded low	Worst post-baseline value Grade 4	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Gamma Glutamyl Transferase - CTCAE graded high	Worst post-baseline value Grade 1	18 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Sodium - CTCAE graded high	Worst post-baseline value Grade 1	6 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Gamma Glutamyl Transferase - CTCAE graded high	Worst post-baseline value Grade 2	13 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Glucose - CTCAE graded low	Worst post-baseline value Missing	8 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Glucose - CTCAE graded high	Worst post-baseline value Grade 0	60 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Gamma Glutamyl Transferase - CTCAE graded high	Worst post-baseline value Grade 4	3 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Glucose - CTCAE graded high	Worst post-baseline value Grade 1	10 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Gamma Glutamyl Transferase - CTCAE graded high	Worst post-baseline value Missing	1 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Phosphate - CTCAE graded low	Worst post-baseline value Grade 3	4 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Albumin - CTCAE graded low	Worst post-baseline value Grade 0	40 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Glucose - CTCAE graded high	Worst post-baseline value Grade 2	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Albumin - CTCAE graded low	Worst post-baseline value Grade 1	29 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Glucose - CTCAE graded high	Worst post-baseline value Grade 3	5 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Albumin - CTCAE graded low	Worst post-baseline value Grade 2	12 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Glucose - CTCAE graded high	Worst post-baseline value Missing	8 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Albumin - CTCAE graded low	Worst post-baseline value Grade 3	1 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Urate - CTCAE graded high	Worst post-baseline value Grade 3	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Albumin - CTCAE graded low	Worst post-baseline value Grade 4	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Phosphate - CTCAE graded low	Worst post-baseline value Grade 4	1 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Albumin - CTCAE graded low	Worst post-baseline value Missing	1 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Potassium - CTCAE graded low	Worst post-baseline value Grade 4	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Alkaline Phosphatase - CTCAE graded high	Worst post-baseline value Grade 0	43 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Sodium - CTCAE graded high	Worst post-baseline value Grade 2	1 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Alkaline Phosphatase - CTCAE graded high	Worst post-baseline value Grade 1	31 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Potassium - CTCAE graded low	Worst post-baseline value Missing	1 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Phosphate - CTCAE graded low	Worst post-baseline value Missing	1 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Alkaline Phosphatase - CTCAE graded high	Worst post-baseline value Grade 3	3 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Urate - CTCAE graded high	Worst post-baseline value Grade 1	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Alkaline Phosphatase - CTCAE graded high	Worst post-baseline value Grade 4	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Potassium - CTCAE graded high	Worst post-baseline value Grade 2	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Alkaline Phosphatase - CTCAE graded high	Worst post-baseline value Missing	1 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Potassium - CTCAE graded high	Worst post-baseline value Grade 4	1 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Alanine Aminotransferase - CTCAE graded high	Worst post-baseline value Grade 0	51 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Sodium - CTCAE graded low	Worst post-baseline value Grade 0	53 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Alanine Aminotransferase - CTCAE graded high	Worst post-baseline value Grade 1	28 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Potassium - CTCAE graded high	Worst post-baseline value Missing	1 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Alanine Aminotransferase - CTCAE graded high	Worst post-baseline value Grade 2	2 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Alanine Aminotransferase - CTCAE graded high	Worst post-baseline value Grade 3	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Sodium - CTCAE graded high	Worst post-baseline value Grade 3	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Alanine Aminotransferase - CTCAE graded high	Worst post-baseline value Grade 4	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Sodium - CTCAE graded low	Worst post-baseline value Grade 1	24 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Alanine Aminotransferase - CTCAE graded high	Worst post-baseline value Missing	2 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Magnesium - CTCAE graded low	Worst post-baseline value Grade 1	14 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Amylase - CTCAE graded high	Worst post-baseline value Grade 0	52 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Urate - CTCAE graded high	Worst post-baseline value Missing	1 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Amylase - CTCAE graded high	Worst post-baseline value Grade 1	6 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Magnesium - CTCAE graded low	Worst post-baseline value Grade 2	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Sodium - CTCAE graded low	Worst post-baseline value Grade 2	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Amylase - CTCAE graded high	Worst post-baseline value Grade 3	2 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Magnesium - CTCAE graded low	Worst post-baseline value Grade 3	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Amylase - CTCAE graded high	Worst post-baseline value Grade 4	1 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Sodium - CTCAE graded high	Worst post-baseline value Grade 4	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Amylase - CTCAE graded high	Worst post-baseline value Missing	20 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Magnesium - CTCAE graded low	Worst post-baseline value Grade 4	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Aspartate Aminotransferase - CTCAE graded high	Worst post-baseline value Grade 0	50 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Sodium - CTCAE graded low	Worst post-baseline value Grade 3	5 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I	Magnesium - CTCAE graded high	Worst post-baseline value Grade 1	3 Participants

Secondary

Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II

Parameters evaluated were: albumin (g/L)- CTCAE graded low, alkaline phosphatase (U/L)- CTCAE graded high, alanine aminotransferase (U/L)- CTCAE graded high, amylase (U/L) - CTCAE graded high, aspartate aminotransferase(U/L)- CTCAE graded high, bilirubin (umol/L)- CTCAE graded high, creatinine (umol/L) - CTCAE graded high, creatine kinase (U/L)- CTCAE graded high, gamma glutamyl transferase (U/L)- CTCAE graded high, glucose (mmol/L)- CTCAE graded low, high, potassium (mmol/L)- CTCAE graded low, potassium (mmol/L)- CTCAE graded high, magnesium (mmol/L)- CTCAE graded low, high, phosphate (mmol/L)- CTCAE graded low, sodium (mmol/L)- CTCAE graded low, sodium (mmol/L)- CTCAE graded high, urate (umol/L)- CTCAE graded high. CTCAE version 4.03 was used: grade 1 = mild, grade 2 = moderate, grade 3 = severe, grade 4 = life-threatening consequences; grade 0 = values not meeting any of the criteria for grade 1 or higher.

Time frame: Baseline up to last dose (maximum treatment exposure for Part II was 97.0 weeks)

Population: Safety set included all participants who received at least 1 dose of 3rd combination agent for Part II and had at least 1 valid post-baseline safety assessment.

Arm	Measure	Group	Category	Value (COUNT_OF_PARTICIPANTS)
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Glucose - CTCAE graded low	Worst post-baseline value Grade 4	0 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Sodium -CTCAE graded low	Worst post-baseline value Missing	1 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Aspartate Aminotransferase - CTCAE graded high	Worst post-baseline value Grade 2	3 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Alanine Aminotransferase - CTCAE graded high	Worst post-baseline value Grade 3	1 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Glucose - CTCAE graded low	Worst post-baseline value Missing	8 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Phosphate - CTCAE graded low	Worst post-baseline value Grade 4	2 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Creatine Kinase - CTCAE graded high	Worst post-baseline value Grade 1	14 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Bilirubin - CTCAE graded high	Worst post-baseline value Grade 4	0 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Glucose - CTCAE graded high	Worst post-baseline value Grade 0	26 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Amylase - CTCAE graded high	Worst post-baseline value Grade 4	2 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Sodium - CTCAE graded high	Worst post-baseline value Grade 0	35 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Alanine Aminotransferase - CTCAE graded high	Worst post-baseline value Grade 2	2 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Glucose - CTCAE graded high	Worst post-baseline value Grade 1	2 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Urate - CTCAE graded high	Worst post-baseline value Missing	1 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Bilirubin - CTCAE graded high	Worst post-baseline value Grade 0	37 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Urate - CTCAE graded high	Worst post-baseline value Grade 3	0 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Glucose - CTCAE graded high	Worst post-baseline value Grade 2	0 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Sodium - CTCAE graded high	Worst post-baseline value Missing	1 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Sodium - CTCAE graded high	Worst post-baseline value Grade 1	2 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Alanine Aminotransferase - CTCAE graded high	Worst post-baseline value Grade 1	6 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Glucose - CTCAE graded high	Worst post-baseline value Grade 3	1 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Phosphate - CTCAE graded low	Worst post-baseline value Missing	1 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Creatine Kinase - CTCAE graded high	Worst post-baseline value Grade 2	3 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Gamma Glutamyl Transferase - CTCAE graded high	Worst post-baseline value Grade 0	20 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Glucose - CTCAE graded high	Worst post-baseline value Grade 4	1 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Phosphate - CTCAE graded low	Worst post-baseline value Grade 1	2 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Sodium - CTCAE graded high	Worst post-baseline value Grade 2	0 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Alanine Aminotransferase - CTCAE graded high	Worst post-baseline value Grade 0	27 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Glucose - CTCAE graded high	Worst post-baseline value Missing	8 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Creatinine - CTCAE graded high	Worst post-baseline value Grade 4	0 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Albumin- CTCAE graded low	Worst post-baseline value Grade 0	16 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Sodium - CTCAE graded high	Worst post-baseline value Grade 4	0 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Potassium - CTCAE graded low	Worst post-baseline value Grade 0	34 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Sodium - CTCAE graded high	Worst post-baseline value Grade 3	0 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Aspartate Aminotransferase - CTCAE graded high	Worst post-baseline value Grade 1	6 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Alkaline Phosphatase - CTCAE graded high	Worst post-baseline value Missing	1 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Potassium - CTCAE graded low	Worst post-baseline value Grade 1	3 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Sodium -CTCAE graded low	Worst post-baseline value Grade 0	28 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Creatine Kinase - CTCAE graded high	Worst post-baseline value Grade 3	0 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Creatinine - CTCAE graded high	Worst post-baseline value Grade 3	0 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Potassium - CTCAE graded low	Worst post-baseline value Grade 2	0 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Amylase - CTCAE graded high	Worst post-baseline value Grade 2	0 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Gamma Glutamyl Transferase - CTCAE graded high	Worst post-baseline value Grade 1	9 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Alkaline Phosphatase - CTCAE graded high	Worst post-baseline value Grade 4	0 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Potassium - CTCAE graded low	Worst post-baseline value Grade 3	0 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Magnesium - CTCAE graded high	Worst post-baseline value Missing	1 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Bilirubin - CTCAE graded high	Worst post-baseline value Grade 2	0 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Aspartate Aminotransferase - CTCAE graded high	Worst post-baseline value Missing	1 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Potassium - CTCAE graded low	Worst post-baseline value Grade 4	0 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Urate - CTCAE graded high	Worst post-baseline value Grade 2	0 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Gamma Glutamyl Transferase - CTCAE graded high	Worst post-baseline value Grade 2	1 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Alkaline Phosphatase - CTCAE graded high	Worst post-baseline value Grade 3	2 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Potassium - CTCAE graded low	Worst post-baseline value Missing	1 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Sodium -CTCAE graded low	Worst post-baseline value Grade 1	7 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Creatine Kinase - CTCAE graded high	Worst post-baseline value Grade 4	0 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Aspartate Aminotransferase - CTCAE graded high	Worst post-baseline value Grade 3	1 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Potassium - CTCAE graded high	Worst post-baseline value Grade 0	32 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Amylase - CTCAE graded high	Worst post-baseline value Grade 1	1 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Gamma Glutamyl Transferase - CTCAE graded high	Worst post-baseline value Grade 3	7 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Alkaline Phosphatase - CTCAE graded high	Worst post-baseline value Grade 2	3 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Potassium - CTCAE graded high	Worst post-baseline value Grade 1	4 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Phosphate - CTCAE graded low	Worst post-baseline value Grade 2	7 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Bilirubin - CTCAE graded high	Worst post-baseline value Missing	1 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Magnesium - CTCAE graded high	Worst post-baseline value Grade 3	0 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Potassium - CTCAE graded high	Worst post-baseline value Grade 2	1 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Gamma Glutamyl Transferase - CTCAE graded high	Worst post-baseline value Grade 4	0 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Aspartate Aminotransferase - CTCAE graded high	Worst post-baseline value Grade 0	27 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Alkaline Phosphatase - CTCAE graded high	Worst post-baseline value Grade 1	10 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Potassium - CTCAE graded high	Worst post-baseline value Grade 3	0 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Magnesium - CTCAE graded high	Worst post-baseline value Grade 4	0 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Creatine Kinase - CTCAE graded high	Worst post-baseline value Missing	1 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Sodium -CTCAE graded low	Worst post-baseline value Grade 2	0 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Potassium - CTCAE graded high	Worst post-baseline value Grade 4	0 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Amylase - CTCAE graded high	Worst post-baseline value Grade 0	27 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Gamma Glutamyl Transferase - CTCAE graded high	Worst post-baseline value Missing	1 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Alkaline Phosphatase - CTCAE graded high	Worst post-baseline value Grade 0	22 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Potassium - CTCAE graded high	Worst post-baseline value Missing	1 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Urate - CTCAE graded high	Worst post-baseline value Grade 4	0 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Bilirubin - CTCAE graded high	Worst post-baseline value Grade 1	0 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Amylase - CTCAE graded high	Worst post-baseline value Grade 3	0 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Magnesium - CTCAE graded low	Worst post-baseline value Grade 0	35 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Glucose - CTCAE graded low	Worst post-baseline value Grade 0	24 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Urate - CTCAE graded high	Worst post-baseline value Grade 1	0 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Albumin- CTCAE graded low	Worst post-baseline value Missing	1 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Magnesium - CTCAE graded low	Worst post-baseline value Grade 1	2 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Sodium -CTCAE graded low	Worst post-baseline value Grade 3	2 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Creatinine - CTCAE graded high	Worst post-baseline value Grade 0	1 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Alanine Aminotransferase - CTCAE graded high	Worst post-baseline value Missing	1 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Magnesium - CTCAE graded low	Worst post-baseline value Grade 2	0 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Glucose - CTCAE graded low	Worst post-baseline value Grade 1	6 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Phosphate - CTCAE graded low	Worst post-baseline value Grade 3	1 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Albumin- CTCAE graded low	Worst post-baseline value Grade 4	0 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Magnesium - CTCAE graded low	Worst post-baseline value Grade 3	0 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Creatine Kinase - CTCAE graded high	Worst post-baseline value Grade 0	20 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Aspartate Aminotransferase - CTCAE graded high	Worst post-baseline value Grade 4	0 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Creatinine - CTCAE graded high	Worst post-baseline value Missing	1 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Magnesium - CTCAE graded low	Worst post-baseline value Grade 4	0 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Glucose - CTCAE graded low	Worst post-baseline value Grade 2	0 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Amylase - CTCAE graded high	Worst post-baseline value Missing	8 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Albumin- CTCAE graded low	Worst post-baseline value Grade 3	1 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Magnesium - CTCAE graded low	Worst post-baseline value Missing	1 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Albumin- CTCAE graded low	Worst post-baseline value Grade 1	13 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Creatinine - CTCAE graded high	Worst post-baseline value Grade 1	25 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Sodium -CTCAE graded low	Worst post-baseline value Grade 4	0 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Magnesium - CTCAE graded high	Worst post-baseline value Grade 0	36 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Alanine Aminotransferase - CTCAE graded high	Worst post-baseline value Grade 4	1 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Glucose - CTCAE graded low	Worst post-baseline value Grade 3	0 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Albumin- CTCAE graded low	Worst post-baseline value Grade 2	7 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Magnesium - CTCAE graded high	Worst post-baseline value Grade 1	1 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Phosphate - CTCAE graded low	Worst post-baseline value Grade 0	25 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Bilirubin - CTCAE graded high	Worst post-baseline value Grade 3	0 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Creatinine - CTCAE graded high	Worst post-baseline value Grade 2	11 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Magnesium - CTCAE graded high	Worst post-baseline value Grade 2	0 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Urate - CTCAE graded high	Worst post-baseline value Grade 0	37 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Magnesium - CTCAE graded high	Worst post-baseline value Grade 2	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Magnesium - CTCAE graded high	Worst post-baseline value Grade 3	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Albumin- CTCAE graded low	Worst post-baseline value Grade 0	1 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Magnesium - CTCAE graded high	Worst post-baseline value Grade 4	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Creatinine - CTCAE graded high	Worst post-baseline value Grade 2	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Magnesium - CTCAE graded high	Worst post-baseline value Missing	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Bilirubin - CTCAE graded high	Worst post-baseline value Grade 3	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Urate - CTCAE graded high	Worst post-baseline value Missing	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Phosphate - CTCAE graded low	Worst post-baseline value Grade 0	1 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Phosphate - CTCAE graded low	Worst post-baseline value Grade 1	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Urate - CTCAE graded high	Worst post-baseline value Grade 4	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Phosphate - CTCAE graded low	Worst post-baseline value Grade 2	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Creatinine - CTCAE graded high	Worst post-baseline value Grade 3	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Phosphate - CTCAE graded low	Worst post-baseline value Grade 3	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Aspartate Aminotransferase - CTCAE graded high	Worst post-baseline value Missing	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Urate - CTCAE graded high	Worst post-baseline value Grade 3	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Phosphate - CTCAE graded low	Worst post-baseline value Grade 4	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Amylase - CTCAE graded high	Worst post-baseline value Grade 3	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Phosphate - CTCAE graded low	Worst post-baseline value Missing	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Urate - CTCAE graded high	Worst post-baseline value Grade 2	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Sodium -CTCAE graded low	Worst post-baseline value Grade 0	1 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Creatinine - CTCAE graded high	Worst post-baseline value Grade 4	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Sodium -CTCAE graded low	Worst post-baseline value Grade 1	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Aspartate Aminotransferase - CTCAE graded high	Worst post-baseline value Grade 3	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Urate - CTCAE graded high	Worst post-baseline value Grade 1	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Sodium -CTCAE graded low	Worst post-baseline value Grade 2	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Sodium -CTCAE graded low	Worst post-baseline value Grade 3	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Urate - CTCAE graded high	Worst post-baseline value Grade 0	1 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Sodium -CTCAE graded low	Worst post-baseline value Grade 4	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Creatinine - CTCAE graded high	Worst post-baseline value Missing	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Sodium -CTCAE graded low	Worst post-baseline value Missing	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Sodium - CTCAE graded high	Worst post-baseline value Missing	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Sodium - CTCAE graded high	Worst post-baseline value Grade 0	1 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Amylase - CTCAE graded high	Worst post-baseline value Grade 2	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Sodium - CTCAE graded high	Worst post-baseline value Grade 1	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Sodium - CTCAE graded high	Worst post-baseline value Grade 4	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Sodium - CTCAE graded high	Worst post-baseline value Grade 2	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Gamma Glutamyl Transferase - CTCAE graded high	Worst post-baseline value Grade 0	1 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Sodium - CTCAE graded high	Worst post-baseline value Grade 3	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Bilirubin - CTCAE graded high	Worst post-baseline value Grade 4	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Gamma Glutamyl Transferase - CTCAE graded high	Worst post-baseline value Grade 1	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Amylase - CTCAE graded high	Worst post-baseline value Grade 1	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Gamma Glutamyl Transferase - CTCAE graded high	Worst post-baseline value Grade 2	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Gamma Glutamyl Transferase - CTCAE graded high	Worst post-baseline value Grade 3	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Amylase - CTCAE graded high	Worst post-baseline value Grade 0	1 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Gamma Glutamyl Transferase - CTCAE graded high	Worst post-baseline value Grade 4	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Bilirubin - CTCAE graded high	Worst post-baseline value Missing	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Gamma Glutamyl Transferase - CTCAE graded high	Worst post-baseline value Missing	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Alanine Aminotransferase - CTCAE graded high	Worst post-baseline value Missing	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Glucose - CTCAE graded low	Worst post-baseline value Grade 0	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Aspartate Aminotransferase - CTCAE graded high	Worst post-baseline value Grade 2	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Glucose - CTCAE graded low	Worst post-baseline value Grade 1	1 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Alanine Aminotransferase - CTCAE graded high	Worst post-baseline value Grade 4	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Glucose - CTCAE graded low	Worst post-baseline value Grade 2	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Creatine Kinase - CTCAE graded high	Worst post-baseline value Grade 0	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Glucose - CTCAE graded low	Worst post-baseline value Grade 3	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Bilirubin - CTCAE graded high	Worst post-baseline value Grade 1	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Alanine Aminotransferase - CTCAE graded high	Worst post-baseline value Grade 3	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Glucose - CTCAE graded low	Worst post-baseline value Grade 4	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Glucose - CTCAE graded low	Worst post-baseline value Missing	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Alanine Aminotransferase - CTCAE graded high	Worst post-baseline value Grade 2	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Glucose - CTCAE graded high	Worst post-baseline value Grade 0	1 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Creatine Kinase - CTCAE graded high	Worst post-baseline value Grade 1	1 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Glucose - CTCAE graded high	Worst post-baseline value Grade 1	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Alanine Aminotransferase - CTCAE graded high	Worst post-baseline value Grade 1	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Glucose - CTCAE graded high	Worst post-baseline value Grade 2	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Aspartate Aminotransferase - CTCAE graded high	Worst post-baseline value Grade 1	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Glucose - CTCAE graded high	Worst post-baseline value Grade 3	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Alanine Aminotransferase - CTCAE graded high	Worst post-baseline value Grade 0	1 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Glucose - CTCAE graded high	Worst post-baseline value Grade 4	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Creatine Kinase - CTCAE graded high	Worst post-baseline value Grade 2	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Glucose - CTCAE graded high	Worst post-baseline value Missing	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Aspartate Aminotransferase - CTCAE graded high	Worst post-baseline value Grade 4	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Alkaline Phosphatase - CTCAE graded high	Worst post-baseline value Missing	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Potassium - CTCAE graded low	Worst post-baseline value Grade 0	1 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Potassium - CTCAE graded low	Worst post-baseline value Grade 1	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Alkaline Phosphatase - CTCAE graded high	Worst post-baseline value Grade 4	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Potassium - CTCAE graded low	Worst post-baseline value Grade 2	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Creatine Kinase - CTCAE graded high	Worst post-baseline value Grade 3	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Potassium - CTCAE graded low	Worst post-baseline value Grade 3	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Alkaline Phosphatase - CTCAE graded high	Worst post-baseline value Grade 3	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Potassium - CTCAE graded low	Worst post-baseline value Grade 4	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Aspartate Aminotransferase - CTCAE graded high	Worst post-baseline value Grade 0	1 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Potassium - CTCAE graded low	Worst post-baseline value Missing	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Alkaline Phosphatase - CTCAE graded high	Worst post-baseline value Grade 2	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Potassium - CTCAE graded high	Worst post-baseline value Grade 0	1 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Creatine Kinase - CTCAE graded high	Worst post-baseline value Grade 4	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Potassium - CTCAE graded high	Worst post-baseline value Grade 1	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Bilirubin - CTCAE graded high	Worst post-baseline value Grade 2	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Alkaline Phosphatase - CTCAE graded high	Worst post-baseline value Grade 1	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Potassium - CTCAE graded high	Worst post-baseline value Grade 2	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Potassium - CTCAE graded high	Worst post-baseline value Grade 3	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Alkaline Phosphatase - CTCAE graded high	Worst post-baseline value Grade 0	1 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Potassium - CTCAE graded high	Worst post-baseline value Grade 4	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Creatine Kinase - CTCAE graded high	Worst post-baseline value Missing	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Potassium - CTCAE graded high	Worst post-baseline value Missing	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Bilirubin - CTCAE graded high	Worst post-baseline value Grade 0	1 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Albumin- CTCAE graded low	Worst post-baseline value Missing	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Magnesium - CTCAE graded low	Worst post-baseline value Grade 0	1 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Amylase - CTCAE graded high	Worst post-baseline value Missing	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Magnesium - CTCAE graded low	Worst post-baseline value Grade 1	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Albumin- CTCAE graded low	Worst post-baseline value Grade 4	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Magnesium - CTCAE graded low	Worst post-baseline value Grade 2	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Creatinine - CTCAE graded high	Worst post-baseline value Grade 0	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Magnesium - CTCAE graded low	Worst post-baseline value Grade 3	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Albumin- CTCAE graded low	Worst post-baseline value Grade 3	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Magnesium - CTCAE graded low	Worst post-baseline value Grade 4	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Magnesium - CTCAE graded low	Worst post-baseline value Missing	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Albumin- CTCAE graded low	Worst post-baseline value Grade 2	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Magnesium - CTCAE graded high	Worst post-baseline value Grade 0	1 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Creatinine - CTCAE graded high	Worst post-baseline value Grade 1	1 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Magnesium - CTCAE graded high	Worst post-baseline value Grade 1	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Albumin- CTCAE graded low	Worst post-baseline value Grade 1	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Amylase - CTCAE graded high	Worst post-baseline value Grade 4	0 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Magnesium - CTCAE graded high	Worst post-baseline value Grade 2	0 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Bilirubin - CTCAE graded high	Worst post-baseline value Grade 0	12 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Bilirubin - CTCAE graded high	Worst post-baseline value Grade 1	0 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Bilirubin - CTCAE graded high	Worst post-baseline value Grade 2	0 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Bilirubin - CTCAE graded high	Worst post-baseline value Grade 3	0 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Bilirubin - CTCAE graded high	Worst post-baseline value Grade 4	0 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Bilirubin - CTCAE graded high	Worst post-baseline value Missing	1 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Creatine Kinase - CTCAE graded high	Worst post-baseline value Grade 0	6 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Creatine Kinase - CTCAE graded high	Worst post-baseline value Grade 1	4 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Creatine Kinase - CTCAE graded high	Worst post-baseline value Grade 2	0 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Creatine Kinase - CTCAE graded high	Worst post-baseline value Grade 3	2 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Creatine Kinase - CTCAE graded high	Worst post-baseline value Grade 4	0 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Creatine Kinase - CTCAE graded high	Worst post-baseline value Missing	1 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Creatinine - CTCAE graded high	Worst post-baseline value Grade 0	0 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Creatinine - CTCAE graded high	Worst post-baseline value Grade 1	4 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Creatinine - CTCAE graded high	Worst post-baseline value Grade 2	8 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Creatinine - CTCAE graded high	Worst post-baseline value Grade 3	0 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Creatinine - CTCAE graded high	Worst post-baseline value Grade 4	0 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Creatinine - CTCAE graded high	Worst post-baseline value Missing	1 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Gamma Glutamyl Transferase - CTCAE graded high	Worst post-baseline value Grade 0	5 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Gamma Glutamyl Transferase - CTCAE graded high	Worst post-baseline value Grade 1	2 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Gamma Glutamyl Transferase - CTCAE graded high	Worst post-baseline value Grade 2	2 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Gamma Glutamyl Transferase - CTCAE graded high	Worst post-baseline value Grade 3	3 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Gamma Glutamyl Transferase - CTCAE graded high	Worst post-baseline value Grade 4	0 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Gamma Glutamyl Transferase - CTCAE graded high	Worst post-baseline value Missing	1 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Glucose - CTCAE graded low	Worst post-baseline value Grade 0	11 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Glucose - CTCAE graded low	Worst post-baseline value Grade 1	1 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Glucose - CTCAE graded low	Worst post-baseline value Grade 2	0 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Glucose - CTCAE graded low	Worst post-baseline value Grade 3	0 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Glucose - CTCAE graded low	Worst post-baseline value Grade 4	0 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Glucose - CTCAE graded low	Worst post-baseline value Missing	1 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Glucose - CTCAE graded high	Worst post-baseline value Grade 0	10 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Glucose - CTCAE graded high	Worst post-baseline value Grade 1	1 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Glucose - CTCAE graded high	Worst post-baseline value Grade 2	0 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Glucose - CTCAE graded high	Worst post-baseline value Grade 3	1 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Glucose - CTCAE graded high	Worst post-baseline value Grade 4	0 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Glucose - CTCAE graded high	Worst post-baseline value Missing	1 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Potassium - CTCAE graded low	Worst post-baseline value Grade 0	11 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Potassium - CTCAE graded low	Worst post-baseline value Grade 1	1 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Potassium - CTCAE graded low	Worst post-baseline value Grade 2	0 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Potassium - CTCAE graded low	Worst post-baseline value Grade 3	0 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Potassium - CTCAE graded low	Worst post-baseline value Grade 4	0 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Potassium - CTCAE graded low	Worst post-baseline value Missing	1 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Potassium - CTCAE graded high	Worst post-baseline value Grade 0	9 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Potassium - CTCAE graded high	Worst post-baseline value Grade 1	3 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Potassium - CTCAE graded high	Worst post-baseline value Grade 2	0 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Potassium - CTCAE graded high	Worst post-baseline value Grade 3	0 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Potassium - CTCAE graded high	Worst post-baseline value Grade 4	0 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Potassium - CTCAE graded high	Worst post-baseline value Missing	1 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Magnesium - CTCAE graded low	Worst post-baseline value Grade 0	10 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Magnesium - CTCAE graded low	Worst post-baseline value Grade 1	2 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Magnesium - CTCAE graded low	Worst post-baseline value Grade 2	0 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Magnesium - CTCAE graded low	Worst post-baseline value Grade 3	0 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Magnesium - CTCAE graded low	Worst post-baseline value Grade 4	0 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Magnesium - CTCAE graded low	Worst post-baseline value Missing	1 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Magnesium - CTCAE graded high	Worst post-baseline value Grade 0	12 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Magnesium - CTCAE graded high	Worst post-baseline value Grade 1	0 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Aspartate Aminotransferase - CTCAE graded high	Worst post-baseline value Missing	1 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Magnesium - CTCAE graded high	Worst post-baseline value Grade 3	0 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Magnesium - CTCAE graded high	Worst post-baseline value Grade 4	0 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Magnesium - CTCAE graded high	Worst post-baseline value Missing	1 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Phosphate - CTCAE graded low	Worst post-baseline value Grade 0	7 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Phosphate - CTCAE graded low	Worst post-baseline value Grade 1	1 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Phosphate - CTCAE graded low	Worst post-baseline value Grade 2	3 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Phosphate - CTCAE graded low	Worst post-baseline value Grade 3	1 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Phosphate - CTCAE graded low	Worst post-baseline value Grade 4	0 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Phosphate - CTCAE graded low	Worst post-baseline value Missing	1 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Sodium -CTCAE graded low	Worst post-baseline value Grade 0	10 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Sodium -CTCAE graded low	Worst post-baseline value Grade 1	2 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Sodium -CTCAE graded low	Worst post-baseline value Grade 2	0 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Sodium -CTCAE graded low	Worst post-baseline value Grade 3	0 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Sodium -CTCAE graded low	Worst post-baseline value Grade 4	0 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Sodium -CTCAE graded low	Worst post-baseline value Missing	1 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Sodium - CTCAE graded high	Worst post-baseline value Grade 0	12 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Sodium - CTCAE graded high	Worst post-baseline value Grade 1	0 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Sodium - CTCAE graded high	Worst post-baseline value Grade 2	0 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Sodium - CTCAE graded high	Worst post-baseline value Grade 3	0 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Sodium - CTCAE graded high	Worst post-baseline value Grade 4	0 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Sodium - CTCAE graded high	Worst post-baseline value Missing	1 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Urate - CTCAE graded high	Worst post-baseline value Grade 0	12 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Urate - CTCAE graded high	Worst post-baseline value Grade 1	0 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Urate - CTCAE graded high	Worst post-baseline value Grade 2	0 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Urate - CTCAE graded high	Worst post-baseline value Grade 3	0 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Urate - CTCAE graded high	Worst post-baseline value Grade 4	0 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Urate - CTCAE graded high	Worst post-baseline value Missing	1 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Albumin- CTCAE graded low	Worst post-baseline value Grade 0	1 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Albumin- CTCAE graded low	Worst post-baseline value Grade 1	6 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Albumin- CTCAE graded low	Worst post-baseline value Grade 2	3 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Albumin- CTCAE graded low	Worst post-baseline value Grade 3	2 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Albumin- CTCAE graded low	Worst post-baseline value Grade 4	0 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Albumin- CTCAE graded low	Worst post-baseline value Missing	1 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Alkaline Phosphatase - CTCAE graded high	Worst post-baseline value Grade 0	7 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Alkaline Phosphatase - CTCAE graded high	Worst post-baseline value Grade 1	3 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Alkaline Phosphatase - CTCAE graded high	Worst post-baseline value Grade 2	2 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Alkaline Phosphatase - CTCAE graded high	Worst post-baseline value Grade 3	0 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Alkaline Phosphatase - CTCAE graded high	Worst post-baseline value Grade 4	0 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Alkaline Phosphatase - CTCAE graded high	Worst post-baseline value Missing	1 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Alanine Aminotransferase - CTCAE graded high	Worst post-baseline value Grade 0	9 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Alanine Aminotransferase - CTCAE graded high	Worst post-baseline value Grade 1	2 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Alanine Aminotransferase - CTCAE graded high	Worst post-baseline value Grade 2	0 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Alanine Aminotransferase - CTCAE graded high	Worst post-baseline value Grade 3	1 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Alanine Aminotransferase - CTCAE graded high	Worst post-baseline value Grade 4	0 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Alanine Aminotransferase - CTCAE graded high	Worst post-baseline value Missing	1 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Amylase - CTCAE graded high	Worst post-baseline value Grade 0	9 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Amylase - CTCAE graded high	Worst post-baseline value Grade 1	2 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Amylase - CTCAE graded high	Worst post-baseline value Grade 2	0 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Amylase - CTCAE graded high	Worst post-baseline value Grade 3	0 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Amylase - CTCAE graded high	Worst post-baseline value Grade 4	0 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Amylase - CTCAE graded high	Worst post-baseline value Missing	2 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Aspartate Aminotransferase - CTCAE graded high	Worst post-baseline value Grade 0	8 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Aspartate Aminotransferase - CTCAE graded high	Worst post-baseline value Grade 1	4 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Aspartate Aminotransferase - CTCAE graded high	Worst post-baseline value Grade 2	0 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Aspartate Aminotransferase - CTCAE graded high	Worst post-baseline value Grade 3	0 Participants
Part II: Encorafenib + Binimetinib + Capmatinib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Aspartate Aminotransferase - CTCAE graded high	Worst post-baseline value Grade 4	0 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Magnesium - CTCAE graded high	Worst post-baseline value Grade 2	0 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Magnesium - CTCAE graded high	Worst post-baseline value Grade 1	0 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Aspartate Aminotransferase - CTCAE graded high	Worst post-baseline value Grade 3	1 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Albumin- CTCAE graded low	Worst post-baseline value Grade 1	0 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Magnesium - CTCAE graded high	Worst post-baseline value Grade 0	5 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Magnesium - CTCAE graded low	Worst post-baseline value Missing	1 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Amylase - CTCAE graded high	Worst post-baseline value Grade 4	0 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Albumin- CTCAE graded low	Worst post-baseline value Grade 2	1 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Magnesium - CTCAE graded low	Worst post-baseline value Grade 4	0 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Magnesium - CTCAE graded low	Worst post-baseline value Grade 3	0 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Creatinine - CTCAE graded high	Worst post-baseline value Grade 0	1 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Albumin- CTCAE graded low	Worst post-baseline value Grade 3	1 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Magnesium - CTCAE graded low	Worst post-baseline value Grade 2	0 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Magnesium - CTCAE graded low	Worst post-baseline value Grade 1	1 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Creatine Kinase - CTCAE graded high	Worst post-baseline value Missing	1 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Albumin- CTCAE graded low	Worst post-baseline value Grade 4	0 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Magnesium - CTCAE graded low	Worst post-baseline value Grade 0	4 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Potassium - CTCAE graded high	Worst post-baseline value Missing	1 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Bilirubin - CTCAE graded high	Worst post-baseline value Grade 2	0 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Albumin- CTCAE graded low	Worst post-baseline value Missing	1 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Potassium - CTCAE graded high	Worst post-baseline value Grade 4	0 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Potassium - CTCAE graded high	Worst post-baseline value Grade 3	0 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Amylase - CTCAE graded high	Worst post-baseline value Missing	4 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Alkaline Phosphatase - CTCAE graded high	Worst post-baseline value Grade 0	1 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Potassium - CTCAE graded high	Worst post-baseline value Grade 2	0 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Potassium - CTCAE graded high	Worst post-baseline value Grade 1	2 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Creatine Kinase - CTCAE graded high	Worst post-baseline value Grade 4	0 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Alkaline Phosphatase - CTCAE graded high	Worst post-baseline value Grade 1	4 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Potassium - CTCAE graded high	Worst post-baseline value Grade 0	3 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Potassium - CTCAE graded low	Worst post-baseline value Missing	1 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Creatine Kinase - CTCAE graded high	Worst post-baseline value Grade 3	0 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Alkaline Phosphatase - CTCAE graded high	Worst post-baseline value Grade 2	1 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Potassium - CTCAE graded low	Worst post-baseline value Grade 4	0 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Potassium - CTCAE graded low	Worst post-baseline value Grade 3	0 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Bilirubin - CTCAE graded high	Worst post-baseline value Grade 1	0 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Alkaline Phosphatase - CTCAE graded high	Worst post-baseline value Grade 3	0 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Potassium - CTCAE graded low	Worst post-baseline value Grade 2	0 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Potassium - CTCAE graded low	Worst post-baseline value Grade 1	0 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Aspartate Aminotransferase - CTCAE graded high	Worst post-baseline value Grade 0	3 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Alkaline Phosphatase - CTCAE graded high	Worst post-baseline value Grade 4	0 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Potassium - CTCAE graded low	Worst post-baseline value Grade 0	5 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Glucose - CTCAE graded high	Worst post-baseline value Missing	1 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Creatine Kinase - CTCAE graded high	Worst post-baseline value Grade 2	0 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Alkaline Phosphatase - CTCAE graded high	Worst post-baseline value Missing	0 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Glucose - CTCAE graded high	Worst post-baseline value Grade 4	0 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Glucose - CTCAE graded high	Worst post-baseline value Grade 3	0 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Creatine Kinase - CTCAE graded high	Worst post-baseline value Grade 1	2 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Alanine Aminotransferase - CTCAE graded high	Worst post-baseline value Grade 0	4 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Glucose - CTCAE graded high	Worst post-baseline value Grade 2	0 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Glucose - CTCAE graded high	Worst post-baseline value Grade 1	1 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Aspartate Aminotransferase - CTCAE graded high	Worst post-baseline value Missing	0 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Alanine Aminotransferase - CTCAE graded high	Worst post-baseline value Grade 1	1 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Glucose - CTCAE graded high	Worst post-baseline value Grade 0	4 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Glucose - CTCAE graded low	Worst post-baseline value Missing	1 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Aspartate Aminotransferase - CTCAE graded high	Worst post-baseline value Grade 1	2 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Alanine Aminotransferase - CTCAE graded high	Worst post-baseline value Grade 2	0 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Glucose - CTCAE graded low	Worst post-baseline value Grade 4	0 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Glucose - CTCAE graded low	Worst post-baseline value Grade 3	0 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Creatine Kinase - CTCAE graded high	Worst post-baseline value Grade 0	3 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Alanine Aminotransferase - CTCAE graded high	Worst post-baseline value Grade 3	0 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Glucose - CTCAE graded low	Worst post-baseline value Grade 2	0 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Glucose - CTCAE graded low	Worst post-baseline value Grade 1	0 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Bilirubin - CTCAE graded high	Worst post-baseline value Missing	0 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Alanine Aminotransferase - CTCAE graded high	Worst post-baseline value Grade 4	1 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Glucose - CTCAE graded low	Worst post-baseline value Grade 0	5 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Gamma Glutamyl Transferase - CTCAE graded high	Worst post-baseline value Missing	0 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Aspartate Aminotransferase - CTCAE graded high	Worst post-baseline value Grade 4	0 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Alanine Aminotransferase - CTCAE graded high	Worst post-baseline value Missing	0 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Gamma Glutamyl Transferase - CTCAE graded high	Worst post-baseline value Grade 4	0 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Gamma Glutamyl Transferase - CTCAE graded high	Worst post-baseline value Grade 3	3 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Aspartate Aminotransferase - CTCAE graded high	Worst post-baseline value Grade 2	0 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Amylase - CTCAE graded high	Worst post-baseline value Grade 0	1 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Gamma Glutamyl Transferase - CTCAE graded high	Worst post-baseline value Grade 2	2 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Gamma Glutamyl Transferase - CTCAE graded high	Worst post-baseline value Grade 1	1 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Bilirubin - CTCAE graded high	Worst post-baseline value Grade 4	0 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Amylase - CTCAE graded high	Worst post-baseline value Grade 1	0 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Gamma Glutamyl Transferase - CTCAE graded high	Worst post-baseline value Grade 0	0 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Sodium - CTCAE graded high	Worst post-baseline value Grade 3	0 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Sodium - CTCAE graded high	Worst post-baseline value Grade 2	0 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Sodium - CTCAE graded high	Worst post-baseline value Grade 1	1 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Creatinine - CTCAE graded high	Worst post-baseline value Missing	1 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Sodium - CTCAE graded high	Worst post-baseline value Grade 4	0 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Sodium - CTCAE graded high	Worst post-baseline value Grade 0	4 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Sodium -CTCAE graded low	Worst post-baseline value Missing	1 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Bilirubin - CTCAE graded high	Worst post-baseline value Grade 3	0 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Sodium - CTCAE graded high	Worst post-baseline value Missing	1 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Sodium -CTCAE graded low	Worst post-baseline value Grade 4	0 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Sodium -CTCAE graded low	Worst post-baseline value Grade 3	0 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Amylase - CTCAE graded high	Worst post-baseline value Grade 2	1 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Urate - CTCAE graded high	Worst post-baseline value Grade 0	5 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Sodium -CTCAE graded low	Worst post-baseline value Grade 2	0 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Sodium -CTCAE graded low	Worst post-baseline value Grade 1	2 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Creatinine - CTCAE graded high	Worst post-baseline value Grade 4	0 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Urate - CTCAE graded high	Worst post-baseline value Grade 1	0 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Sodium -CTCAE graded low	Worst post-baseline value Grade 0	3 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Phosphate - CTCAE graded low	Worst post-baseline value Missing	1 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Creatinine - CTCAE graded high	Worst post-baseline value Grade 3	0 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Urate - CTCAE graded high	Worst post-baseline value Grade 2	0 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Phosphate - CTCAE graded low	Worst post-baseline value Grade 4	0 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Phosphate - CTCAE graded low	Worst post-baseline value Grade 3	0 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Bilirubin - CTCAE graded high	Worst post-baseline value Grade 0	6 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Urate - CTCAE graded high	Worst post-baseline value Grade 3	0 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Phosphate - CTCAE graded low	Worst post-baseline value Grade 2	0 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Phosphate - CTCAE graded low	Worst post-baseline value Grade 1	1 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Amylase - CTCAE graded high	Worst post-baseline value Grade 3	0 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Urate - CTCAE graded high	Worst post-baseline value Grade 4	0 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Phosphate - CTCAE graded low	Worst post-baseline value Grade 0	4 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Magnesium - CTCAE graded high	Worst post-baseline value Missing	1 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Creatinine - CTCAE graded high	Worst post-baseline value Grade 2	1 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Urate - CTCAE graded high	Worst post-baseline value Missing	1 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Magnesium - CTCAE graded high	Worst post-baseline value Grade 4	0 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Magnesium - CTCAE graded high	Worst post-baseline value Grade 3	0 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Creatinine - CTCAE graded high	Worst post-baseline value Grade 1	3 Participants
Part II: Encorafenib + Binimetinib + Buparlisib	Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II	Albumin- CTCAE graded low	Worst post-baseline value Grade 0	3 Participants

Secondary

Overall Survival (OS): Part II

OS was defined as the time from the start date of study treatment (3rd agent combined with encorafenib and binimetinib) to date of death due to any cause. If a participant was not known to have died, survival was censored at the date of last known date participant alive. Kaplan Meier method used for estimation.

Time frame: From date of start of treatment to date of death due to any cause or censoring date (maximum treatment exposure for Part II was 97.0 weeks)

Arm	Measure	Value (MEDIAN)
Part II: Encorafenib + Binimetinib + Ribociclib	Overall Survival (OS): Part II	10.4 Months
Part II: Encorafenib + Binimetinib + Infigratinib	Overall Survival (OS): Part II	20.8 Months
Part II: Encorafenib + Binimetinib + Capmatinib	Overall Survival (OS): Part II	5.6 Months
Part II: Encorafenib + Binimetinib + Buparlisib	Overall Survival (OS): Part II	2.5 Months

Secondary

PFS: Part II

PFS was defined as the time from the start date of study drug in Part II until documented PD or death due to any cause. All participants who had not progressed or died at the time of the data cut-off were censored at the date of last tumor assessment (other than those who were unknown or missing) prior to cut-off date or start date of new anti-neoplastic therapy, whichever is earlier. Per RECIST 1.1, PD= At least a 20% increase in the sum of diameter of all measured target lesions, taking as reference the smallest sum of diameter of all target lesions recorded at or after baseline. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. Kaplan Meier method used for estimation.

Time frame: From start of study drug until documented PD or death due to any cause or censoring date (maximum treatment exposure for Part II was 97.0 weeks)

Arm	Measure	Value (MEDIAN)
Part II: Encorafenib + Binimetinib + Ribociclib	PFS: Part II	2.1 Months
Part II: Encorafenib + Binimetinib + Infigratinib	PFS: Part II	2.1 Months
Part II: Encorafenib + Binimetinib + Capmatinib	PFS: Part II	2.1 Months
Part II: Encorafenib + Binimetinib + Buparlisib	PFS: Part II	1.4 Months

Secondary

Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part I

AR00426032 is metabolite of binimetinib. Maximum treatment exposure for Part I was of 403.7 weeks.

Time frame: C1 (1.5 hrs post-dose on D1; pre-dose, 1.5 hrs post-dose on D15); C2 (pre-dose on D8 and D21); C3 pre-dose on D15; C4 pre-dose on D15; C5 pre-dose on D15; EOT

Population: PAS consisted of all participants who had at least one blood sample providing evaluable PK data. All participants reported under Number of Participants Analyzed contributed data to the table but may not have evaluable data for every row. Here, Number Analyzed signifies number of participants evaluable for specified time points.

Arm	Measure	Group	Value (GEOMETRIC_MEAN)	Dispersion
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part I	Binimetinib: C1 D1, 1.5 hr	551 Nanogram per milliliter	Geometric Coefficient of Variation 88.8
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part I	Binimetinib: C1 D15, Pre-dose	40.3 Nanogram per milliliter	Geometric Coefficient of Variation 63.5
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part I	Binimetinib: C1 D15, 1.5 hr	461 Nanogram per milliliter	Geometric Coefficient of Variation 70.2
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part I	Binimetinib: C2 D8, Pre-dose	39.9 Nanogram per milliliter	Geometric Coefficient of Variation 58.8
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part I	Binimetinib: C2 D21, Pre-dose	38.9 Nanogram per milliliter	Geometric Coefficient of Variation 54.9
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part I	Binimetinib: C3 D15, Pre-dose	41.9 Nanogram per milliliter	Geometric Coefficient of Variation 60.4
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part I	Binimetinib: C4 D15, Pre-dose	36.2 Nanogram per milliliter	Geometric Coefficient of Variation 68.6
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part I	Binimetinib: C5 D15, Pre-dose	41.3 Nanogram per milliliter	Geometric Coefficient of Variation 55.7
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part I	Binimetinib: EOT	33.2 Nanogram per milliliter	Geometric Coefficient of Variation 179.4
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part I	AR00426032: C1 D1, 1.5 hr	57.6 Nanogram per milliliter	Geometric Coefficient of Variation 93.5
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part I	AR00426032: C1 D15, Pre-dose	4.13 Nanogram per milliliter	Geometric Coefficient of Variation 70.8
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part I	AR00426032: C1 D15, 1.5 hr	30.6 Nanogram per milliliter	Geometric Coefficient of Variation 110.9
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part I	AR00426032: C2 D8, Pre-dose	3.63 Nanogram per milliliter	Geometric Coefficient of Variation 60.2
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part I	AR00426032: C2 D21, Pre-dose	4.11 Nanogram per milliliter	Geometric Coefficient of Variation 61
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part I	AR00426032: C3 D15, Pre-dose	3.71 Nanogram per milliliter	Geometric Coefficient of Variation 59.5
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part I	AR00426032: C4 D15, Pre-dose	3.48 Nanogram per milliliter	Geometric Coefficient of Variation 65.8
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part I	AR00426032: C5 D15, Pre-dose	3.77 Nanogram per milliliter	Geometric Coefficient of Variation 66.9
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part I	AR00426032: EOT	4.09 Nanogram per milliliter	Geometric Coefficient of Variation 90.8
Part II: Encorafenib + Binimetinib + Infigratinib	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part I	AR00426032: C2 D21, Pre-dose	4.39 Nanogram per milliliter	Geometric Coefficient of Variation 80.2
Part II: Encorafenib + Binimetinib + Infigratinib	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part I	Binimetinib: C1 D1, 1.5 hr	482 Nanogram per milliliter	Geometric Coefficient of Variation 73.4
Part II: Encorafenib + Binimetinib + Infigratinib	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part I	AR00426032: C1 D1, 1.5 hr	47.5 Nanogram per milliliter	Geometric Coefficient of Variation 101.6
Part II: Encorafenib + Binimetinib + Infigratinib	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part I	Binimetinib: C1 D15, Pre-dose	43.3 Nanogram per milliliter	Geometric Coefficient of Variation 72.9
Part II: Encorafenib + Binimetinib + Infigratinib	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part I	AR00426032: EOT	5.88 Nanogram per milliliter	Geometric Coefficient of Variation 118
Part II: Encorafenib + Binimetinib + Infigratinib	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part I	Binimetinib: C1 D15, 1.5 hr	451 Nanogram per milliliter	Geometric Coefficient of Variation 50.2
Part II: Encorafenib + Binimetinib + Infigratinib	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part I	AR00426032: C1 D15, Pre-dose	4.50 Nanogram per milliliter	Geometric Coefficient of Variation 64
Part II: Encorafenib + Binimetinib + Infigratinib	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part I	Binimetinib: C2 D8, Pre-dose	44.8 Nanogram per milliliter	Geometric Coefficient of Variation 73
Part II: Encorafenib + Binimetinib + Infigratinib	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part I	AR00426032: C3 D15, Pre-dose	3.90 Nanogram per milliliter	Geometric Coefficient of Variation 60.6
Part II: Encorafenib + Binimetinib + Infigratinib	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part I	Binimetinib: C2 D21, Pre-dose	53.1 Nanogram per milliliter	Geometric Coefficient of Variation 78.2
Part II: Encorafenib + Binimetinib + Infigratinib	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part I	AR00426032: C1 D15, 1.5 hr	31.9 Nanogram per milliliter	Geometric Coefficient of Variation 84
Part II: Encorafenib + Binimetinib + Infigratinib	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part I	Binimetinib: C3 D15, Pre-dose	38.7 Nanogram per milliliter	Geometric Coefficient of Variation 94.6
Part II: Encorafenib + Binimetinib + Infigratinib	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part I	AR00426032: C5 D15, Pre-dose	3.36 Nanogram per milliliter	Geometric Coefficient of Variation 67.3
Part II: Encorafenib + Binimetinib + Infigratinib	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part I	Binimetinib: C4 D15, Pre-dose	38.8 Nanogram per milliliter	Geometric Coefficient of Variation 57.4
Part II: Encorafenib + Binimetinib + Infigratinib	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part I	AR00426032: C2 D8, Pre-dose	4.17 Nanogram per milliliter	Geometric Coefficient of Variation 88.1
Part II: Encorafenib + Binimetinib + Infigratinib	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part I	Binimetinib: C5 D15, Pre-dose	39.2 Nanogram per milliliter	Geometric Coefficient of Variation 76.1
Part II: Encorafenib + Binimetinib + Infigratinib	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part I	AR00426032: C4 D15, Pre-dose	3.81 Nanogram per milliliter	Geometric Coefficient of Variation 56.9
Part II: Encorafenib + Binimetinib + Infigratinib	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part I	Binimetinib: EOT	52.8 Nanogram per milliliter	Geometric Coefficient of Variation 180.4

Secondary

Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II

AR00426032 is metabolite of binimetinib. Maximum treatment exposure for Part II was of 97.0 weeks.

Time frame: C1 (1.5, 4 hrs post-dose on D1; pre-dose on D8; pre-dose, 0.5, 1.5, 2.5, 4, 6, 8 hrs post-dose on D15; 24 hrs post-dose on D16; pre-dose on D21); C2 (pre-dose on D1 and D15); C3 pre-dose on D1; C4 pre-dose on D1; C5 pre-dose on D1; EOT

Arm	Measure	Group	Value (GEOMETRIC_MEAN)	Dispersion
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	AR00426032, C2 D15: Pre-dose	9.97 Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	Binimetinib, C1 D15: 8 hrs	74.9 Nanogram per milliliter	Geometric Coefficient of Variation 34.7
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	AR00426032, C5 D1: Pre-dose	6.05 Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	Binimetinib, C3 D1: Pre-dose	50.0 Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	AR00426032b, C1 D15: 8 hrs	5.94 Nanogram per milliliter	Geometric Coefficient of Variation 76.7
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	Binimetinib, C2 D1: Pre-dose	38.8 Nanogram per milliliter	Geometric Coefficient of Variation 62.5
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	AR00426032, EOT	NA Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	Binimetinib, C2 D15: Pre-dose	63.7 Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	AR00426032, C2 D1: Pre-dose	6.23 Nanogram per milliliter	Geometric Coefficient of Variation 82
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	Binimetinib, C1 D15: 1.5 hrs	386 Nanogram per milliliter	Geometric Coefficient of Variation 41.1
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	Binimetinib, EOT	NA Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	AR00426032, C1 D15: Pre-dose	3.14 Nanogram per milliliter	Geometric Coefficient of Variation 74.5
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	Binimetinib, C1 D15: 0.5 hr	150 Nanogram per milliliter	Geometric Coefficient of Variation 36.1
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	Binimetinib, C1 D15: 6 hrs	79.0 Nanogram per milliliter	Geometric Coefficient of Variation 36.1
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	Binimetinib, C1 D15: 2.5 hrs	250 Nanogram per milliliter	Geometric Coefficient of Variation 17.1
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	Binimetinib, C1 D15: 4 hrs	147 Nanogram per milliliter	Geometric Coefficient of Variation 21.4
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	AR00426032, C1 D8: Pre-dose	3.98 Nanogram per milliliter	Geometric Coefficient of Variation 31.9
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	AR00426032, C1 D15: 1.5 hrs	24.9 Nanogram per milliliter	Geometric Coefficient of Variation 92.2
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	AR00426032, C1 D15: 0.5 hr	6.66 Nanogram per milliliter	Geometric Coefficient of Variation 43.2
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	AR00426032 C3 D1: Pre-dose	9.74 Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	Binimetinib, C4 D1: Pre-dose	46.1 Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	Binimetinib, C1 D15: Pre-dose	32.0 Nanogram per milliliter	Geometric Coefficient of Variation 17.1
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	Binimetinib, C1 D16: 24 hrs	44.1 Nanogram per milliliter	Geometric Coefficient of Variation 19.1
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	AR00426032, C1 D15: 2.5 hrs	18.5 Nanogram per milliliter	Geometric Coefficient of Variation 77
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	AR00426032, C1 D16: 24 hrs	3.99 Nanogram per milliliter	Geometric Coefficient of Variation 61.8
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	Binimetinib, C1 D8: Pre-dose	41.6 Nanogram per milliliter	Geometric Coefficient of Variation 21.7
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	AR00426032, C1 D15: 4 hrs	11.8 Nanogram per milliliter	Geometric Coefficient of Variation 40.3
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	AR00426032, C4 D1: Pre-dose	7.10 Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	Binimetinib, C5 D1: Pre-dose	60.0 Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	AR00426032, C1 D15: 6 hrs	6.86 Nanogram per milliliter	Geometric Coefficient of Variation 61.8
Part II: Encorafenib + Binimetinib + Infigratinib	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	Binimetinib, EOT	NA Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Infigratinib	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	AR00426032, C1 D15: Pre-dose	3.80 Nanogram per milliliter	Geometric Coefficient of Variation 111.9
Part II: Encorafenib + Binimetinib + Infigratinib	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	Binimetinib, C1 D15: 4 hrs	125 Nanogram per milliliter	Geometric Coefficient of Variation 62.1
Part II: Encorafenib + Binimetinib + Infigratinib	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	Binimetinib, C1 D15: 6 hrs	97.3 Nanogram per milliliter	Geometric Coefficient of Variation 32.8
Part II: Encorafenib + Binimetinib + Infigratinib	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	Binimetinib, C2 D15: Pre-dose	73.0 Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Infigratinib	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	Binimetinib, C2 D1: Pre-dose	42.7 Nanogram per milliliter	Geometric Coefficient of Variation 27.8
Part II: Encorafenib + Binimetinib + Infigratinib	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	AR00426032b, C1 D15: 8 hrs	5.24 Nanogram per milliliter	Geometric Coefficient of Variation 70.7
Part II: Encorafenib + Binimetinib + Infigratinib	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	AR00426032, C2 D1: Pre-dose	3.51 Nanogram per milliliter	Geometric Coefficient of Variation 36.8
Part II: Encorafenib + Binimetinib + Infigratinib	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	AR00426032, EOT	NA Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Infigratinib	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	AR00426032, C1 D1: 1.5 hrs	22.4 Nanogram per milliliter	Geometric Coefficient of Variation 200.6
Part II: Encorafenib + Binimetinib + Infigratinib	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	AR00426032, C1 D15: 6 hrs	7.66 Nanogram per milliliter	Geometric Coefficient of Variation 117.7
Part II: Encorafenib + Binimetinib + Infigratinib	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	Binimetinib, C1 D1: 1.5 hrs	410 Nanogram per milliliter	Geometric Coefficient of Variation 48.8
Part II: Encorafenib + Binimetinib + Infigratinib	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	AR00426032, C2 D15: Pre-dose	7.52 Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Infigratinib	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	AR00426032, C1 D15: 4 hrs	9.98 Nanogram per milliliter	Geometric Coefficient of Variation 142.4
Part II: Encorafenib + Binimetinib + Infigratinib	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	Binimetinib, C1 D8: Pre-dose	51.1 Nanogram per milliliter	Geometric Coefficient of Variation 9.7
Part II: Encorafenib + Binimetinib + Infigratinib	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	AR00426032, C1 D16: 24 hrs	2.92 Nanogram per milliliter	Geometric Coefficient of Variation 159.3
Part II: Encorafenib + Binimetinib + Infigratinib	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	Binimetinib, C1 D16: 24 hrs	30.2 Nanogram per milliliter	Geometric Coefficient of Variation 59.2
Part II: Encorafenib + Binimetinib + Infigratinib	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	AR00426032, C1 D15: 2.5 hrs	11.3 Nanogram per milliliter	Geometric Coefficient of Variation 447.2
Part II: Encorafenib + Binimetinib + Infigratinib	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	Binimetinib, C1 D15: Pre-dose	39.1 Nanogram per milliliter	Geometric Coefficient of Variation 57.4
Part II: Encorafenib + Binimetinib + Infigratinib	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	AR00426032, C1 D15: 1.5 hrs	13.2 Nanogram per milliliter	Geometric Coefficient of Variation 1550.1
Part II: Encorafenib + Binimetinib + Infigratinib	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	Binimetinib, C1 D15: 0.5 hr	143 Nanogram per milliliter	Geometric Coefficient of Variation 496.2
Part II: Encorafenib + Binimetinib + Infigratinib	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	Binimetinib, C1 D15: 1.5 hrs	187 Nanogram per milliliter	Geometric Coefficient of Variation 351
Part II: Encorafenib + Binimetinib + Infigratinib	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	Binimetinib, C1 D15: 8 hrs	59.7 Nanogram per milliliter	Geometric Coefficient of Variation 12.6
Part II: Encorafenib + Binimetinib + Infigratinib	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	AR00426032, C1 D15: 0.5 hr	7.43 Nanogram per milliliter	Geometric Coefficient of Variation 455.1
Part II: Encorafenib + Binimetinib + Infigratinib	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	AR00426032, C1 D8: Pre-dose	2.95 Nanogram per milliliter	Geometric Coefficient of Variation 165.3
Part II: Encorafenib + Binimetinib + Infigratinib	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	Binimetinib, C1 D15: 2.5 hrs	143 Nanogram per milliliter	Geometric Coefficient of Variation 172.4
Part II: Encorafenib + Binimetinib + Capmatinib	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	AR00426032, C2 D15: Pre-dose	1.07 Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Capmatinib	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	Binimetinib, C2 D15: Pre-dose	63.9 Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Capmatinib	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	Binimetinib, C1 D15: 6 hrs	55.8 Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Capmatinib	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	AR00426032, C1 D15: 2.5 hrs	7.75 Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Capmatinib	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	Binimetinib, C1 D15: 0.5 hr	315 Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Capmatinib	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	Binimetinib, C1 D15: 1.5 hrs	413 Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Capmatinib	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	AR00426032, C1 D21: Pre-dose	NA Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Capmatinib	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	AR00426032, C1 D15: 4 hrs	3.15 Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Capmatinib	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	Binimetinib, EOT	36.3 Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Capmatinib	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	Binimetinib, C3 D1: Pre-dose	47.2 Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Capmatinib	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	Binimetinib, C2 D1: Pre-dose	40.5 Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Capmatinib	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	Binimetinib, C1 D8: Pre-dose	46.0 Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Capmatinib	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	AR00426032, C1 D15: 0.5 hr	8.21 Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Capmatinib	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	AR00426032, C1 D1: 1.5 hrs	12.9 Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Capmatinib	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	AR00426032, EOT	NA Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Capmatinib	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	AR00426032, C1 D15: Pre-dose	1.21 Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Capmatinib	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	Binimetinib, C1 D15: Pre-dose	33.9 Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Capmatinib	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	AR00426032, C1 D15: 6 hrs	1.82 Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Capmatinib	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	Binimetinib, C1 D16: 24 hrs	42.1 Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Capmatinib	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	AR00426032 C3 D1: Pre-dose	NA Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Capmatinib	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	Binimetinib, C1 D1: 1.5 hrs	416 Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Capmatinib	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	Binimetinib, C1 D15: 2.5 hrs	235 Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Capmatinib	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	Binimetinib, C1 D21: Pre-dose	34.0 Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Capmatinib	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	Binimetinib, C1 D15: 4 hrs	98.0 Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Capmatinib	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	AR00426032, C1 D15: 1.5 hrs	15.8 Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Capmatinib	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	AR00426032, C2 D1: Pre-dose	NA Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Capmatinib	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	AR00426032, C1 D8: Pre-dose	1.21 Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Capmatinib	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	AR00426032, C1 D16: 24 hrs	1.27 Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Buparlisib	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	Binimetinib, C1 D15: 8 hrs	107 Nanogram per milliliter	Geometric Coefficient of Variation 40.9
Part II: Encorafenib + Binimetinib + Buparlisib	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	Binimetinib, C1 D15: 1.5 hrs	489 Nanogram per milliliter	Geometric Coefficient of Variation 27.1
Part II: Encorafenib + Binimetinib + Buparlisib	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	AR00426032, C1 D15: 2.5 hrs	18.5 Nanogram per milliliter	Geometric Coefficient of Variation 88.4
Part II: Encorafenib + Binimetinib + Buparlisib	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	Binimetinib, EOT	NA Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Buparlisib	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	Binimetinib, C1 D15: 4 hrs	166 Nanogram per milliliter	Geometric Coefficient of Variation 48.9
Part II: Encorafenib + Binimetinib + Buparlisib	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	Binimetinib, C1 D8: Pre-dose	74.6 Nanogram per milliliter	Geometric Coefficient of Variation 34.5
Part II: Encorafenib + Binimetinib + Buparlisib	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	Binimetinib, C1 D15: 2.5 hrs	295 Nanogram per milliliter	Geometric Coefficient of Variation 29.7
Part II: Encorafenib + Binimetinib + Buparlisib	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	AR00426032, C2 D1: Pre-dose	13.5 Nanogram per milliliter	Geometric Coefficient of Variation 116.8
Part II: Encorafenib + Binimetinib + Buparlisib	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	AR00426032, C1 D15: 1.5 hrs	27.9 Nanogram per milliliter	Geometric Coefficient of Variation 85.6
Part II: Encorafenib + Binimetinib + Buparlisib	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	AR00426032 C3 D1: Pre-dose	6.15 Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Buparlisib	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	Binimetinib, C1 D15: Pre-dose	85.6 Nanogram per milliliter	Geometric Coefficient of Variation 53.7
Part II: Encorafenib + Binimetinib + Buparlisib	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	AR00426032, C1 D1: 1.5 hrs	11.4 Nanogram per milliliter	Geometric Coefficient of Variation 85.7
Part II: Encorafenib + Binimetinib + Buparlisib	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	AR00426032, C2 D15: Pre-dose	3.27 Nanogram per milliliter	Geometric Coefficient of Variation 65.1
Part II: Encorafenib + Binimetinib + Buparlisib	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	Binimetinib, C2 D15: Pre-dose	40.9 Nanogram per milliliter	Geometric Coefficient of Variation 50.8
Part II: Encorafenib + Binimetinib + Buparlisib	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	AR00426032, C1 D15: Pre-dose	11.5 Nanogram per milliliter	Geometric Coefficient of Variation 39.5
Part II: Encorafenib + Binimetinib + Buparlisib	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	Binimetinib, C1 D15: 0.5 hr	430 Nanogram per milliliter	Geometric Coefficient of Variation 26.8
Part II: Encorafenib + Binimetinib + Buparlisib	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	AR00426032, C1 D15: 4 hrs	9.46 Nanogram per milliliter	Geometric Coefficient of Variation 142.7
Part II: Encorafenib + Binimetinib + Buparlisib	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	Binimetinib, C3 D1: Pre-dose	37.8 Nanogram per milliliter	Geometric Coefficient of Variation 189.6
Part II: Encorafenib + Binimetinib + Buparlisib	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	AR00426032, C1 D15: 0.5 hr	13.1 Nanogram per milliliter	Geometric Coefficient of Variation 97.8
Part II: Encorafenib + Binimetinib + Buparlisib	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	AR00426032, EOT	NA Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Buparlisib	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	Binimetinib, C2 D1: Pre-dose	118 Nanogram per milliliter	Geometric Coefficient of Variation 120.1
Part II: Encorafenib + Binimetinib + Buparlisib	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	AR00426032, C1 D15: 6 hrs	6.90 Nanogram per milliliter	Geometric Coefficient of Variation 142.3
Part II: Encorafenib + Binimetinib + Buparlisib	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	Binimetinib, C1 D15: 6 hrs	106 Nanogram per milliliter	Geometric Coefficient of Variation 53.3
Part II: Encorafenib + Binimetinib + Buparlisib	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	AR00426032, C1 D8: Pre-dose	7.10 Nanogram per milliliter	Geometric Coefficient of Variation 122.1
Part II: Encorafenib + Binimetinib + Buparlisib	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	Binimetinib, C1 D1: 1.5 hrs	313 Nanogram per milliliter	Geometric Coefficient of Variation 25.6
Part II: Encorafenib + Binimetinib + Buparlisib	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	AR00426032, C1 D16: 24 hrs	7.79 Nanogram per milliliter	Geometric Coefficient of Variation 87.5
Part II: Encorafenib + Binimetinib + Buparlisib	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	AR00426032b, C1 D15: 8 hrs	6.49 Nanogram per milliliter	Geometric Coefficient of Variation 124.9
Part II: Encorafenib + Binimetinib + Buparlisib	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	Binimetinib, C1 D16: 24 hrs	63.2 Nanogram per milliliter	Geometric Coefficient of Variation 64
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 300 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	AR00426032, EOT	NA Nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 300 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	Binimetinib, C2 D1: Pre-dose	24.6 Nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 300 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	Binimetinib, C2 D15: Pre-dose	18.9 Nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 300 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	AR00426032b, C1 D15: 8 hrs	8.06 Nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 300 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	AR00426032, C1 D15: 6 hrs	8.89 Nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 300 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	Binimetinib, C1 D1: 1.5 hrs	1100 Nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 300 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	AR00426032, C1 D15: 4 hrs	22.6 Nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 300 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	Binimetinib, C1 D8: Pre-dose	27.2 Nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 300 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	Binimetinib, C1 D15: Pre-dose	47.3 Nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 300 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	Binimetinib, C1 D15: 0.5 hr	401 Nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 300 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	AR00426032, C2 D15: Pre-dose	1.74 Nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 300 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	AR00426032, C1 D15: 0.5 hr	11.4 Nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 300 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	Binimetinib, C1 D15: 1.5 hrs	797 Nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 300 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	AR00426032, C1 D15: Pre-dose	4.36 Nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 300 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	Binimetinib, C1 D15: 4 hrs	264 Nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 300 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	Binimetinib, C1 D15: 6 hrs	112 Nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 300 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	Binimetinib, C1 D15: 8 hrs	132 Nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 300 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	AR00426032, C1 D16: 24 hrs	1.44 Nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 300 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	Binimetinib, C1 D16: 24 hrs	17.6 Nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 300 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	Binimetinib, EOT	NA Nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 400 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	AR00426032, C2 D1: Pre-dose	5.71 Nanogram per milliliter	Geometric Coefficient of Variation 44.2
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 400 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	Binimetinib, C1 D15: 2.5 hrs	491 Nanogram per milliliter	Geometric Coefficient of Variation 38
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 400 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	AR00426032, C1 D15: Pre-dose	5.45 Nanogram per milliliter	Geometric Coefficient of Variation 42.2
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 400 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	AR00426032, C2 D15: Pre-dose	4.23 Nanogram per milliliter	Geometric Coefficient of Variation 62.5
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 400 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	Binimetinib, C1 D15: 1.5 hrs	734 Nanogram per milliliter	Geometric Coefficient of Variation 45.6
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 400 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	Binimetinib, C1 D15: 0.5 hr	180 Nanogram per milliliter	Geometric Coefficient of Variation 91.5
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 400 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	AR00426032 C3 D1: Pre-dose	4.35 Nanogram per milliliter	Geometric Coefficient of Variation 42.3
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 400 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	Binimetinib, C1 D15: 8 hrs	102 Nanogram per milliliter	Geometric Coefficient of Variation 12.4
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 400 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	Binimetinib, C2 D15: Pre-dose	49.8 Nanogram per milliliter	Geometric Coefficient of Variation 21.2
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 400 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	AR00426032, C1 D15: 0.5 hr	9.80 Nanogram per milliliter	Geometric Coefficient of Variation 75.7
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 400 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	AR00426032, C1 D1: 1.5 hrs	35.9 Nanogram per milliliter	Geometric Coefficient of Variation 274.1
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 400 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	Binimetinib, C1 D15: Pre-dose	50.9 Nanogram per milliliter	Geometric Coefficient of Variation 34.4
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 400 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	AR00426032, C1 D15: 1.5 hrs	41.1 Nanogram per milliliter	Geometric Coefficient of Variation 25.7
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 400 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	Binimetinib, C1 D8: Pre-dose	67.4 Nanogram per milliliter	Geometric Coefficient of Variation 63.1
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 400 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	AR00426032, C1 D15: 2.5 hrs	34.3 Nanogram per milliliter	Geometric Coefficient of Variation 51.3
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 400 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	AR00426032, C1 D15: 4 hrs	19.3 Nanogram per milliliter	Geometric Coefficient of Variation 76.9
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 400 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	Binimetinib, C3 D1: Pre-dose	41.9 Nanogram per milliliter	Geometric Coefficient of Variation 49
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 400 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	Binimetinib, C1 D16: 24 hrs	55.9 Nanogram per milliliter	Geometric Coefficient of Variation 54
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 400 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	Binimetinib, C1 D1: 1.5 hrs	508 Nanogram per milliliter	Geometric Coefficient of Variation 130.2
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 400 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	AR00426032, EOT	6.68 Nanogram per milliliter	Geometric Coefficient of Variation 80.1
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 400 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	Binimetinib, C4 D1: Pre-dose	53.8 Nanogram per milliliter	Geometric Coefficient of Variation 10.6
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 400 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	Binimetinib, EOT	52.1 Nanogram per milliliter	Geometric Coefficient of Variation 18.3
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 400 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	Binimetinib, C2 D1: Pre-dose	54.2 Nanogram per milliliter	Geometric Coefficient of Variation 32.4
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 400 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	AR00426032, C1 D15: 6 hrs	9.66 Nanogram per milliliter	Geometric Coefficient of Variation 71.5
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 400 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	AR00426032, C4 D1: Pre-dose	5.70 Nanogram per milliliter	Geometric Coefficient of Variation 11.8
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 400 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	AR00426032, C1 D8: Pre-dose	6.34 Nanogram per milliliter	Geometric Coefficient of Variation 54.5
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 400 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	Binimetinib, C1 D15: 4 hrs	266 Nanogram per milliliter	Geometric Coefficient of Variation 32.5
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 400 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	AR00426032b, C1 D15: 8 hrs	8.87 Nanogram per milliliter	Geometric Coefficient of Variation 76.5
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 400 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	Binimetinib, C1 D15: 6 hrs	141 Nanogram per milliliter	Geometric Coefficient of Variation 15.1
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 400 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	AR00426032, C1 D16: 24 hrs	4.75 Nanogram per milliliter	Geometric Coefficient of Variation 25.4
Part II: Encorafenib 100 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	AR00426032, C2 D1: Pre-dose	4.32 Nanogram per milliliter	—
Part II: Encorafenib 100 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	AR00426032, C2 D15: Pre-dose	8.54 Nanogram per milliliter	—
Part II: Encorafenib 100 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	AR00426032 C3 D1: Pre-dose	4.50 Nanogram per milliliter	—
Part II: Encorafenib 100 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	AR00426032, C4 D1: Pre-dose	5.43 Nanogram per milliliter	—
Part II: Encorafenib 100 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	AR00426032, C5 D1: Pre-dose	8.89 Nanogram per milliliter	—
Part II: Encorafenib 100 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	AR00426032, EOT	3.77 Nanogram per milliliter	—
Part II: Encorafenib 100 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	Binimetinib, C1 D1: 1.5 hrs	396 Nanogram per milliliter	—
Part II: Encorafenib 100 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	Binimetinib, C1 D1: 4 hrs	152 Nanogram per milliliter	—
Part II: Encorafenib 100 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	Binimetinib, C1 D8: Pre-dose	63.0 Nanogram per milliliter	—
Part II: Encorafenib 100 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	Binimetinib, C1 D15: Pre-dose	54.3 Nanogram per milliliter	—
Part II: Encorafenib 100 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	Binimetinib, C1 D15: 0.5 hr	229 Nanogram per milliliter	—
Part II: Encorafenib 100 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	Binimetinib, C1 D15: 1.5 hrs	261 Nanogram per milliliter	—
Part II: Encorafenib 100 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	Binimetinib, C1 D15: 2.5 hrs	207 Nanogram per milliliter	—
Part II: Encorafenib 100 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	Binimetinib, C1 D15: 4 hrs	130 Nanogram per milliliter	—
Part II: Encorafenib 100 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	Binimetinib, C1 D15: 6 hrs	167 Nanogram per milliliter	—
Part II: Encorafenib 100 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	Binimetinib, C1 D15: 8 hrs	116 Nanogram per milliliter	—
Part II: Encorafenib 100 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	Binimetinib, C1 D16: 24 hrs	78.3 Nanogram per milliliter	—
Part II: Encorafenib 100 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	Binimetinib, C1 D21: Pre-dose	40.4 Nanogram per milliliter	—
Part II: Encorafenib 100 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	Binimetinib, C2 D1: Pre-dose	58.3 Nanogram per milliliter	—
Part II: Encorafenib 100 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	Binimetinib, C2 D15: Pre-dose	63.1 Nanogram per milliliter	—
Part II: Encorafenib 100 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	Binimetinib, C3 D1: Pre-dose	53.4 Nanogram per milliliter	—
Part II: Encorafenib 100 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	Binimetinib, C4 D1: Pre-dose	63.6 Nanogram per milliliter	—
Part II: Encorafenib 100 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	Binimetinib, C5 D1: Pre-dose	42.3 Nanogram per milliliter	—
Part II: Encorafenib 100 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	Binimetinib, EOT	41.0 Nanogram per milliliter	—
Part II: Encorafenib 100 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	AR00426032, C1 D1: 4 hrs	9.40 Nanogram per milliliter	—
Part II: Encorafenib 100 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	AR00426032, C1 D8: Pre-dose	6.15 Nanogram per milliliter	—
Part II: Encorafenib 100 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	AR00426032, C1 D15: Pre-dose	4.16 Nanogram per milliliter	—
Part II: Encorafenib 100 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	AR00426032, C1 D15: 0.5 hr	7.31 Nanogram per milliliter	—
Part II: Encorafenib 100 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	AR00426032, C1 D15: 1.5 hrs	12.9 Nanogram per milliliter	—
Part II: Encorafenib 100 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	AR00426032, C1 D15: 2.5 hrs	9.71 Nanogram per milliliter	—
Part II: Encorafenib 100 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	AR00426032, C1 D15: 4 hrs	6.76 Nanogram per milliliter	—
Part II: Encorafenib 100 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	AR00426032, C1 D15: 6 hrs	5.82 Nanogram per milliliter	—
Part II: Encorafenib 100 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	AR00426032b, C1 D15: 8 hrs	5.12 Nanogram per milliliter	—
Part II: Encorafenib 100 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	AR00426032, C1 D16: 24 hrs	6.53 Nanogram per milliliter	—
Part II: Encorafenib 100 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	AR00426032, C1 D21: Pre-dose	3.66 Nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 400 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	Binimetinib, C2 D1: Pre-dose	174 Nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 400 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	AR00426032, C2 D15: Pre-dose	1.63 Nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 400 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	Binimetinib, C4 D1: Pre-dose	40.9 Nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 400 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	AR00426032, C2 D1: Pre-dose	2.06 Nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 400 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	Binimetinib, C5 D1: Pre-dose	28.5 Nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 400 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	Binimetinib, C1 D21: Pre-dose	38.8 Nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 400 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	AR00426032, C1 D21: Pre-dose	1.47 Nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 400 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	Binimetinib, EOT	32.3 Nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 400 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	Binimetinib, C1 D16: 24 hrs	29.8 Nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 400 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	AR00426032, C1 D1: 1.5 hrs	22.1 Nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 400 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	AR00426032, C1 D1: 4 hrs	4.09 Nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 400 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	Binimetinib, C1 D15: 8 hrs	65.5 Nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 400 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	Binimetinib, C1 D15: 6 hrs	77.4 Nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 400 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	AR00426032, C1 D8: Pre-dose	1.10 Nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 400 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	Binimetinib, C1 D15: 2.5 hrs	331 Nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 400 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	AR00426032, C1 D15: Pre-dose	NA Nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 400 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	Binimetinib, C1 D15: 1.5 hrs	520 Nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 400 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	Binimetinib, C1 D15: 0.5 hr	389 Nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 400 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	AR00426032, C1 D15: 0.5 hr	4.35 Nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 400 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	Binimetinib, C1 D15: Pre-dose	28.3 Nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 400 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	AR00426032, C1 D15: 1.5 hrs	12.6 Nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 400 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	Binimetinib, C1 D8: Pre-dose	31.5 Nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 400 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	AR00426032, C1 D15: 2.5 hrs	8.51 Nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 400 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	Binimetinib, C1 D1: 4 hrs	106 Nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 400 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	Binimetinib, C1 D1: 1.5 hrs	649 Nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 400 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	AR00426032, EOT	1.48 Nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 400 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	AR00426032, C1 D15: 6 hrs	2.52 Nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 400 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	AR00426032, C5 D1: Pre-dose	1.36 Nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 400 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	AR00426032, C4 D1: Pre-dose	2.78 Nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 400 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	AR00426032b, C1 D15: 8 hrs	1.95 Nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 400 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	AR00426032 C3 D1: Pre-dose	1.09 Nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 400 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	AR00426032, C1 D16: 24 hrs	1.08 Nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 400 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	Binimetinib, C2 D15: Pre-dose	19.4 Nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 400 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	Binimetinib, C3 D1: Pre-dose	4.82 Nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	AR00426032, C2 D15: Pre-dose	1.99 Nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	Binimetinib, EOT	13.8 Nanogram per milliliter	Geometric Coefficient of Variation 205.5
Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	AR00426032, C1 D15: 0.5 hr	6.16 Nanogram per milliliter	Geometric Coefficient of Variation 490.6
Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	AR00426032, C1 D1: 4 hrs	6.71 Nanogram per milliliter	Geometric Coefficient of Variation 145.3
Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	Binimetinib, C1 D15: 4 hrs	98.0 Nanogram per milliliter	Geometric Coefficient of Variation 60
Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	Binimetinib, C1 D15: Pre-dose	21.1 Nanogram per milliliter	Geometric Coefficient of Variation 23.7
Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	AR00426032, C1 D21: Pre-dose	3.18 Nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	AR00426032b, C1 D15: 8 hrs	2.67 Nanogram per milliliter	Geometric Coefficient of Variation 72.9
Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	Binimetinib, C2 D1: Pre-dose	23.3 Nanogram per milliliter	Geometric Coefficient of Variation 20.2
Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	Binimetinib, C1 D15: 2.5 hrs	154 Nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	AR00426032, C1 D15: 1.5 hrs	16.1 Nanogram per milliliter	Geometric Coefficient of Variation 151.9
Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	Binimetinib, C1 D8: Pre-dose	25.1 Nanogram per milliliter	Geometric Coefficient of Variation 1.7
Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	Binimetinib, C2 D15: Pre-dose	15.2 Nanogram per milliliter	Geometric Coefficient of Variation 18.2
Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	Binimetinib, C1 D21: Pre-dose	13.6 Nanogram per milliliter	Geometric Coefficient of Variation 80.7
Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	AR00426032, C1 D15: 2.5 hrs	16.2 Nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	AR00426032, C1 D8: Pre-dose	1.73 Nanogram per milliliter	Geometric Coefficient of Variation 48.7
Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	Binimetinib, C1 D1: 4 hrs	129 Nanogram per milliliter	Geometric Coefficient of Variation 25.8
Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	AR00426032, C2 D1: Pre-dose	4.09 Nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	AR00426032, C1 D15: 6 hrs	3.07 Nanogram per milliliter	Geometric Coefficient of Variation 95
Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	AR00426032, C1 D15: Pre-dose	3.81 Nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	Binimetinib, C1 D1: 1.5 hrs	273 Nanogram per milliliter	Geometric Coefficient of Variation 24.6
Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	AR00426032, EOT	3.65 Nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	AR00426032, C1 D15: 4 hrs	5.21 Nanogram per milliliter	Geometric Coefficient of Variation 81.9
Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	AR00426032, C1 D1: 1.5 hrs	8.05 Nanogram per milliliter	Geometric Coefficient of Variation 68.9
Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	Binimetinib, C1 D15: 1.5 hrs	313 Nanogram per milliliter	Geometric Coefficient of Variation 15.9
Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	Binimetinib, C1 D15: 8 hrs	42.2 Nanogram per milliliter	Geometric Coefficient of Variation 39.2
Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	Binimetinib, C1 D15: 6 hrs	53.3 Nanogram per milliliter	Geometric Coefficient of Variation 36.2
Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	Binimetinib, C1 D15: 0.5 hr	161 Nanogram per milliliter	Geometric Coefficient of Variation 54.7
Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	AR00426032, C1 D16: 24 hrs	3.19 Nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	Binimetinib, C1 D16: 24 hrs	23.1 Nanogram per milliliter	Geometric Coefficient of Variation 5.2
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 400 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	Binimetinib, C1 D8: Pre-dose	27.2 Nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 400 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	AR00426032, EOT	NA Nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 400 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	AR00426032, C1 D21: Pre-dose	1.13 Nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 400 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	AR00426032, C2 D1: Pre-dose	3.99 Nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 400 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	AR00426032, C2 D15: Pre-dose	1.19 Nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 400 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	Binimetinib, C2 D1: Pre-dose	58.3 Nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 400 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	Binimetinib, C2 D15: Pre-dose	14.1 Nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 400 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	Binimetinib, EOT	NA Nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 400 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	AR00426032, C1 D8: Pre-dose	2.09 Nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 400 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	Binimetinib, C1 D21: Pre-dose	19.6 Nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 600 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	AR00426032 C3 D1: Pre-dose	4.46 Nanogram per milliliter	Geometric Coefficient of Variation 70.2
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 600 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	Binimetinib, C1 D15: 6 hrs	134 Nanogram per milliliter	Geometric Coefficient of Variation 46.5
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 600 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	AR00426032, C2 D15: Pre-dose	5.69 Nanogram per milliliter	Geometric Coefficient of Variation 57
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 600 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	Binimetinib, C1 D15: 4 hrs	241 Nanogram per milliliter	Geometric Coefficient of Variation 28.6
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 600 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	AR00426032, C1 D8: Pre-dose	5.50 Nanogram per milliliter	Geometric Coefficient of Variation 62.6
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 600 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	Binimetinib, C1 D15: 2.5 hrs	380 Nanogram per milliliter	Geometric Coefficient of Variation 31.2
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 600 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	Binimetinib, C1 D15: 1.5 hrs	437 Nanogram per milliliter	Geometric Coefficient of Variation 46.5
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 600 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	AR00426032, C1 D21: Pre-dose	6.64 Nanogram per milliliter	Geometric Coefficient of Variation 56.1
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 600 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	AR00426032, C1 D15: Pre-dose	4.19 Nanogram per milliliter	Geometric Coefficient of Variation 79.2
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 600 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	Binimetinib, C1 D15: 0.5 hr	158 Nanogram per milliliter	Geometric Coefficient of Variation 90.1
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 600 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	AR00426032, C1 D15: 0.5 hr	7.81 Nanogram per milliliter	Geometric Coefficient of Variation 119
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 600 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	Binimetinib, C1 D15: Pre-dose	48.2 Nanogram per milliliter	Geometric Coefficient of Variation 70
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 600 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	AR00426032, C1 D16: 24 hrs	4.70 Nanogram per milliliter	Geometric Coefficient of Variation 80.2
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 600 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	Binimetinib, C1 D8: Pre-dose	51.0 Nanogram per milliliter	Geometric Coefficient of Variation 67.8
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 600 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	Binimetinib, C3 D1: Pre-dose	45.0 Nanogram per milliliter	Geometric Coefficient of Variation 91.8
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 600 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	AR00426032, C1 D15: 1.5 hrs	18.3 Nanogram per milliliter	Geometric Coefficient of Variation 135.9
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 600 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	Binimetinib, C1 D1: 4 hrs	215 Nanogram per milliliter	Geometric Coefficient of Variation 44.5
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 600 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	AR00426032, C1 D15: 2.5 hrs	18.5 Nanogram per milliliter	Geometric Coefficient of Variation 81.2
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 600 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	Binimetinib, C2 D15: Pre-dose	58.4 Nanogram per milliliter	Geometric Coefficient of Variation 68.3
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 600 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	Binimetinib, C1 D1: 1.5 hrs	446 Nanogram per milliliter	Geometric Coefficient of Variation 59.8
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 600 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	AR00426032, C1 D15: 4 hrs	12.2 Nanogram per milliliter	Geometric Coefficient of Variation 78.7
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 600 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	AR00426032, EOT	4.24 Nanogram per milliliter	Geometric Coefficient of Variation 85.5
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 600 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	AR00426032, C5 D1: Pre-dose	6.11 Nanogram per milliliter	Geometric Coefficient of Variation 67.8
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 600 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	AR00426032, C2 D1: Pre-dose	4.03 Nanogram per milliliter	Geometric Coefficient of Variation 58.1
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 600 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	AR00426032, C1 D15: 6 hrs	7.41 Nanogram per milliliter	Geometric Coefficient of Variation 80.2
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 600 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	Binimetinib, C2 D1: Pre-dose	46.0 Nanogram per milliliter	Geometric Coefficient of Variation 71.2
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 600 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	AR00426032, C4 D1: Pre-dose	5.78 Nanogram per milliliter	Geometric Coefficient of Variation 83
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 600 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	Binimetinib, C4 D1: Pre-dose	77.5 Nanogram per milliliter	Geometric Coefficient of Variation 32.1
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 600 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	Binimetinib, C5 D1: Pre-dose	73.8 Nanogram per milliliter	Geometric Coefficient of Variation 25.7
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 600 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	Binimetinib, C1 D21: Pre-dose	63.2 Nanogram per milliliter	Geometric Coefficient of Variation 51
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 600 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	Binimetinib, C1 D16: 24 hrs	55.2 Nanogram per milliliter	Geometric Coefficient of Variation 66
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 600 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	Binimetinib, EOT	29.0 Nanogram per milliliter	Geometric Coefficient of Variation 179.7
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 600 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	AR00426032b, C1 D15: 8 hrs	6.73 Nanogram per milliliter	Geometric Coefficient of Variation 75
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 600 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	Binimetinib, C1 D15: 8 hrs	109 Nanogram per milliliter	Geometric Coefficient of Variation 54.8
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 600 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	AR00426032, C1 D1: 1.5 hrs	19.4 Nanogram per milliliter	Geometric Coefficient of Variation 99.3
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 600 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	AR00426032, C1 D1: 4 hrs	12.3 Nanogram per milliliter	Geometric Coefficient of Variation 75.3
Part II: Encorafenib 300 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	Binimetinib, C1 D21: Pre-dose	35.3 Nanogram per milliliter	—
Part II: Encorafenib 300 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	AR00426032, C2 D15: Pre-dose	1.33 Nanogram per milliliter	—
Part II: Encorafenib 300 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	AR00426032, C1 D1: 4 hrs	4.61 Nanogram per milliliter	—
Part II: Encorafenib 300 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	AR00426032, C1 D1: 1.5 hrs	16.3 Nanogram per milliliter	—
Part II: Encorafenib 300 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	AR00426032, C1 D15: 2.5 hrs	4.73 Nanogram per milliliter	—
Part II: Encorafenib 300 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	Binimetinib, C1 D15: Pre-dose	36.2 Nanogram per milliliter	—
Part II: Encorafenib 300 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	Binimetinib, C2 D1: Pre-dose	22.4 Nanogram per milliliter	—
Part II: Encorafenib 300 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	Binimetinib, C1 D1: 1.5 hrs	522 Nanogram per milliliter	—
Part II: Encorafenib 300 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	AR00426032, C1 D8: Pre-dose	2.14 Nanogram per milliliter	—
Part II: Encorafenib 300 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	Binimetinib, C3 D1: Pre-dose	42.0 Nanogram per milliliter	—
Part II: Encorafenib 300 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	AR00426032, C1 D16: 24 hrs	1.56 Nanogram per milliliter	—
Part II: Encorafenib 300 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	AR00426032, C1 D15: Pre-dose	1.09 Nanogram per milliliter	—
Part II: Encorafenib 300 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	AR00426032 C3 D1: Pre-dose	1.73 Nanogram per milliliter	—
Part II: Encorafenib 300 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	Binimetinib, C1 D1: 4 hrs	99.5 Nanogram per milliliter	—
Part II: Encorafenib 300 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	Binimetinib, C1 D16: 24 hrs	40.5 Nanogram per milliliter	—
Part II: Encorafenib 300 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	Binimetinib, C1 D8: Pre-dose	37.3 Nanogram per milliliter	—
Part II: Encorafenib 300 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	AR00426032, C1 D21: Pre-dose	1.65 Nanogram per milliliter	—
Part II: Encorafenib 300 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	Binimetinib, C1 D15: 2.5 hrs	178 Nanogram per milliliter	—
Part II: Encorafenib 300 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	Binimetinib, C2 D15: Pre-dose	27.3 Nanogram per milliliter	—
Part II: Encorafenib 300 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	AR00426032, C2 D1: Pre-dose	NA Nanogram per milliliter	—
Part II: Encorafenib 450 mg/ Binimetinib 45 mg + Ribociclib 600 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	AR00426032, C2 D1: Pre-dose	17.8 Nanogram per milliliter	—
Part II: Encorafenib 450 mg/ Binimetinib 45 mg + Ribociclib 600 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	Binimetinib, C1 D1: 1.5 hrs	1230 Nanogram per milliliter	—
Part II: Encorafenib 450 mg/ Binimetinib 45 mg + Ribociclib 600 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	AR00426032, C2 D15: Pre-dose	3.74 Nanogram per milliliter	—
Part II: Encorafenib 450 mg/ Binimetinib 45 mg + Ribociclib 600 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	AR00426032, C1 D1: 1.5 hrs	64.6 Nanogram per milliliter	—
Part II: Encorafenib 450 mg/ Binimetinib 45 mg + Ribociclib 600 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	AR00426032, C1 D21: Pre-dose	3.11 Nanogram per milliliter	—
Part II: Encorafenib 450 mg/ Binimetinib 45 mg + Ribociclib 600 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	Binimetinib, C1 D21: Pre-dose	8.91 Nanogram per milliliter	—
Part II: Encorafenib 450 mg/ Binimetinib 45 mg + Ribociclib 600 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	Binimetinib, C2 D1: Pre-dose	54.1 Nanogram per milliliter	—
Part II: Encorafenib 450 mg/ Binimetinib 45 mg + Ribociclib 600 mg	Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II	Binimetinib, C2 D15: Pre-dose	34.9 Nanogram per milliliter	—

Secondary

Plasma Concentration for Buparlisib (BKM): Part II

Maximum treatment exposure for Part II was of 97.0 weeks.

Time frame: C1 (1.5 hrs post-dose on D1; pre-dose on D8; pre-dose, 0.5, 1.5, 2.5, 4, 6, 8 hrs post-dose on D15; 24 hrs post-dose on D16); C2 (pre-dose on D1 and D15); C3 pre-dose on D1; C4 pre-dose on D1; C5 pre-dose on D1; EOT

Arm	Measure	Group	Value (GEOMETRIC_MEAN)	Dispersion
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Buparlisib (BKM): Part II	C1 D1: 1.5 hrs	213 Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Buparlisib (BKM): Part II	C1 D15: 8 hrs	87.4 Nanogram per milliliter	Geometric Coefficient of Variation 63.9
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Buparlisib (BKM): Part II	C1 D15: 1.5 hrs	266 Nanogram per milliliter	Geometric Coefficient of Variation 51.5
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Buparlisib (BKM): Part II	C1 D16: 24 hrs	41.8 Nanogram per milliliter	Geometric Coefficient of Variation 82.9
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Buparlisib (BKM): Part II	C1 D15: Pre-dose	49.7 Nanogram per milliliter	Geometric Coefficient of Variation 115.9
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Buparlisib (BKM): Part II	C2 D1: Pre-dose	54.7 Nanogram per milliliter	Geometric Coefficient of Variation 134.9
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Buparlisib (BKM): Part II	C1 D15: 2.5 hrs	176 Nanogram per milliliter	Geometric Coefficient of Variation 42.2
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Buparlisib (BKM): Part II	C2 D15: Pre-dose	99.3 Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Buparlisib (BKM): Part II	C1 D8: Pre-dose	45.0 Nanogram per milliliter	Geometric Coefficient of Variation 75.2
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Buparlisib (BKM): Part II	C3 D1: Pre-dose	81.2 Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Buparlisib (BKM): Part II	C4 D1: Pre-dose	73.2 Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Buparlisib (BKM): Part II	C5 D1: Pre-dose	122 Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Buparlisib (BKM): Part II	EOT	1.84 Nanogram per milliliter	Geometric Coefficient of Variation 53.4
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Buparlisib (BKM): Part II	C1 D15: 4 hrs	115 Nanogram per milliliter	Geometric Coefficient of Variation 44
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Buparlisib (BKM): Part II	C1 D15: 0.5 hr	139 Nanogram per milliliter	Geometric Coefficient of Variation 13.4
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Buparlisib (BKM): Part II	C1 D15: 6 hrs	94.2 Nanogram per milliliter	Geometric Coefficient of Variation 40
Part II: Encorafenib + Binimetinib + Infigratinib	Plasma Concentration for Buparlisib (BKM): Part II	EOT	NA Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Infigratinib	Plasma Concentration for Buparlisib (BKM): Part II	C1 D1: 1.5 hrs	213 Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Infigratinib	Plasma Concentration for Buparlisib (BKM): Part II	C1 D8: Pre-dose	119 Nanogram per milliliter	Geometric Coefficient of Variation 3.6
Part II: Encorafenib + Binimetinib + Infigratinib	Plasma Concentration for Buparlisib (BKM): Part II	C1 D15: Pre-dose	97.3 Nanogram per milliliter	Geometric Coefficient of Variation 16.2
Part II: Encorafenib + Binimetinib + Infigratinib	Plasma Concentration for Buparlisib (BKM): Part II	C1 D15: 0.5 hr	229 Nanogram per milliliter	Geometric Coefficient of Variation 21.5
Part II: Encorafenib + Binimetinib + Infigratinib	Plasma Concentration for Buparlisib (BKM): Part II	C1 D15: 1.5 hrs	312 Nanogram per milliliter	Geometric Coefficient of Variation 10.9
Part II: Encorafenib + Binimetinib + Infigratinib	Plasma Concentration for Buparlisib (BKM): Part II	C1 D15: 2.5 hrs	268 Nanogram per milliliter	Geometric Coefficient of Variation 11.9
Part II: Encorafenib + Binimetinib + Infigratinib	Plasma Concentration for Buparlisib (BKM): Part II	C1 D15: 4 hrs	235 Nanogram per milliliter	Geometric Coefficient of Variation 39.4
Part II: Encorafenib + Binimetinib + Infigratinib	Plasma Concentration for Buparlisib (BKM): Part II	C1 D15: 6 hrs	171 Nanogram per milliliter	Geometric Coefficient of Variation 26.4
Part II: Encorafenib + Binimetinib + Infigratinib	Plasma Concentration for Buparlisib (BKM): Part II	C1 D15: 8 hrs	111 Nanogram per milliliter	Geometric Coefficient of Variation 25.5
Part II: Encorafenib + Binimetinib + Infigratinib	Plasma Concentration for Buparlisib (BKM): Part II	C1 D16: 24 hrs	101 Nanogram per milliliter	Geometric Coefficient of Variation 1.4
Part II: Encorafenib + Binimetinib + Infigratinib	Plasma Concentration for Buparlisib (BKM): Part II	C2 D1: Pre-dose	110 Nanogram per milliliter	Geometric Coefficient of Variation 51.2
Part II: Encorafenib + Binimetinib + Infigratinib	Plasma Concentration for Buparlisib (BKM): Part II	C2 D15: Pre-dose	138 Nanogram per milliliter	—

Secondary

Plasma Concentration for Capmatinib (INC): Part II

Maximum treatment exposure for Part II was of 97.0 weeks.

Population: PAS consisted of all participants who had at least one blood sample providing evaluable PK data. All participants reported under 'Overall Number of Participants Analyzed' contributed data to the table; however, may not have evaluable data for every row. Here, Number Analyzed signifies number of participants evaluable for specified time points.

Arm	Measure	Group	Value (GEOMETRIC_MEAN)	Dispersion
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Capmatinib (INC): Part II	C1 D16: 24 hrs	79.6 Nanogram per milliliter	Geometric Coefficient of Variation 103.1
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Capmatinib (INC): Part II	C1 D15: 2.5 hrs	545 Nanogram per milliliter	Geometric Coefficient of Variation 81.2
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Capmatinib (INC): Part II	C1 D15: 8 hrs	120 Nanogram per milliliter	Geometric Coefficient of Variation 50
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Capmatinib (INC): Part II	C1 D15: 4 hrs	401 Nanogram per milliliter	Geometric Coefficient of Variation 17.3
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Capmatinib (INC): Part II	C3 D1: Pre-dose	114 Nanogram per milliliter	Geometric Coefficient of Variation 113.4
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Capmatinib (INC): Part II	C1 D15: 6 hrs	157 Nanogram per milliliter	Geometric Coefficient of Variation 63.2
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Capmatinib (INC): Part II	C1 D15: Pre-dose	89.3 Nanogram per milliliter	Geometric Coefficient of Variation 35.7
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Capmatinib (INC): Part II	C1 D8: Pre-dose	74.3 Nanogram per milliliter	Geometric Coefficient of Variation 97.2
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Capmatinib (INC): Part II	C2 D15: Pre-dose	65.2 Nanogram per milliliter	Geometric Coefficient of Variation 31
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Capmatinib (INC): Part II	C1 D15: 0.5 hr	196 Nanogram per milliliter	Geometric Coefficient of Variation 103.8
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Capmatinib (INC): Part II	C1 D1: 1.5 hrs	362 Nanogram per milliliter	Geometric Coefficient of Variation 268.6
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Capmatinib (INC): Part II	C2 D1: Pre-dose	151 Nanogram per milliliter	Geometric Coefficient of Variation 107.6
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Capmatinib (INC): Part II	C1 D15: 1.5 hrs	636 Nanogram per milliliter	Geometric Coefficient of Variation 78.2
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Capmatinib (INC): Part II	EOT	NA Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Infigratinib	Plasma Concentration for Capmatinib (INC): Part II	C1 D15: 0.5 hr	1880 Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Infigratinib	Plasma Concentration for Capmatinib (INC): Part II	C1 D1: 1.5 hrs	3600 Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Infigratinib	Plasma Concentration for Capmatinib (INC): Part II	C1 D8: Pre-dose	44.4 Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Infigratinib	Plasma Concentration for Capmatinib (INC): Part II	C1 D15: Pre-dose	71.4 Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Infigratinib	Plasma Concentration for Capmatinib (INC): Part II	C1 D15: 1.5 hrs	3670 Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Infigratinib	Plasma Concentration for Capmatinib (INC): Part II	C1 D15: 4 hrs	1230 Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Infigratinib	Plasma Concentration for Capmatinib (INC): Part II	C1 D15: 6 hrs	264 Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Infigratinib	Plasma Concentration for Capmatinib (INC): Part II	C1 D15: 8 hrs	268 Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Infigratinib	Plasma Concentration for Capmatinib (INC): Part II	C1 D16: 24 hrs	58.1 Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Infigratinib	Plasma Concentration for Capmatinib (INC): Part II	C2 D1: Pre-dose	38.7 Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Infigratinib	Plasma Concentration for Capmatinib (INC): Part II	C2 D15: Pre-dose	50.5 Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Infigratinib	Plasma Concentration for Capmatinib (INC): Part II	C5 D1: Pre-dose	41.8 Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Infigratinib	Plasma Concentration for Capmatinib (INC): Part II	EOT	NA Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Capmatinib	Plasma Concentration for Capmatinib (INC): Part II	C4 D1: Pre-dose	175 Nanogram per milliliter	Geometric Coefficient of Variation 44.8
Part II: Encorafenib + Binimetinib + Capmatinib	Plasma Concentration for Capmatinib (INC): Part II	C1 D16: 24 hrs	269 Nanogram per milliliter	Geometric Coefficient of Variation 68.7
Part II: Encorafenib + Binimetinib + Capmatinib	Plasma Concentration for Capmatinib (INC): Part II	C1 D15: 0.5 hr	314 Nanogram per milliliter	Geometric Coefficient of Variation 49
Part II: Encorafenib + Binimetinib + Capmatinib	Plasma Concentration for Capmatinib (INC): Part II	EOT	65.4 Nanogram per milliliter	Geometric Coefficient of Variation 155
Part II: Encorafenib + Binimetinib + Capmatinib	Plasma Concentration for Capmatinib (INC): Part II	C2 D1: Pre-dose	227 Nanogram per milliliter	Geometric Coefficient of Variation 42
Part II: Encorafenib + Binimetinib + Capmatinib	Plasma Concentration for Capmatinib (INC): Part II	C1 D15: Pre-dose	173 Nanogram per milliliter	Geometric Coefficient of Variation 41.2
Part II: Encorafenib + Binimetinib + Capmatinib	Plasma Concentration for Capmatinib (INC): Part II	C1 D1: 1.5 hrs	715 Nanogram per milliliter	Geometric Coefficient of Variation 133.2
Part II: Encorafenib + Binimetinib + Capmatinib	Plasma Concentration for Capmatinib (INC): Part II	C2 D15: Pre-dose	166 Nanogram per milliliter	Geometric Coefficient of Variation 80.9
Part II: Encorafenib + Binimetinib + Capmatinib	Plasma Concentration for Capmatinib (INC): Part II	C1 D15: 4 hrs	950 Nanogram per milliliter	Geometric Coefficient of Variation 39.1
Part II: Encorafenib + Binimetinib + Capmatinib	Plasma Concentration for Capmatinib (INC): Part II	C1 D8: Pre-dose	129 Nanogram per milliliter	Geometric Coefficient of Variation 49.4
Part II: Encorafenib + Binimetinib + Capmatinib	Plasma Concentration for Capmatinib (INC): Part II	C1 D15: 6 hrs	487 Nanogram per milliliter	Geometric Coefficient of Variation 23.3
Part II: Encorafenib + Binimetinib + Capmatinib	Plasma Concentration for Capmatinib (INC): Part II	C1 D15: 2.5 hrs	1530 Nanogram per milliliter	Geometric Coefficient of Variation 18.4
Part II: Encorafenib + Binimetinib + Capmatinib	Plasma Concentration for Capmatinib (INC): Part II	C3 D1: Pre-dose	96.5 Nanogram per milliliter	Geometric Coefficient of Variation 17.9
Part II: Encorafenib + Binimetinib + Capmatinib	Plasma Concentration for Capmatinib (INC): Part II	C1 D15: 8 hrs	390 Nanogram per milliliter	Geometric Coefficient of Variation 10.5
Part II: Encorafenib + Binimetinib + Capmatinib	Plasma Concentration for Capmatinib (INC): Part II	C1 D15: 1.5 hrs	1830 Nanogram per milliliter	Geometric Coefficient of Variation 38.3

Secondary

Plasma Concentration for Encorafenib (LGX): Part I

In results reported below, following abbreviation have been used: Cycle 1 (C1), Day 1 (D1), Day 8 (D8), Day 15 (D15), Day 21 (D21), Cycle 2 (C2), Cycle 3 (C3), Cycle 4 (C4), Cycle 5 (C5) and end of treatment (EOT). Maximum treatment exposure for Part I was of 403.7 weeks.

Time frame: C1 (1.5 hrs post-dose on D1; pre-dose, 1.5 hrs post-dose on D15); C2 (pre-dose on D8 and D21); C3 pre-dose on D15; C4 pre-dose on D15; C5 pre-dose on D15; EOT

Population: Pharmacokinetic analysis set (PAS) consisted of all participants who had at least one blood sample providing evaluable pharmacokinetic (PK) data. All participants reported under Number of Participants Analyzed contributed data to the table but may not have evaluable data for every row. Here, Number Analyzed signifies number of participants evaluable for specified time points.

Arm	Measure	Group	Value (GEOMETRIC_MEAN)	Dispersion
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Encorafenib (LGX): Part I	C1 D15, Pre-dose	10.0 Nanogram per milliliter	Geometric Coefficient of Variation 81.6
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Encorafenib (LGX): Part I	C3 D15, Pre-dose	8.43 Nanogram per milliliter	Geometric Coefficient of Variation 82.3
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Encorafenib (LGX): Part I	C2 D8, Pre-dose	9.96 Nanogram per milliliter	Geometric Coefficient of Variation 81.7
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Encorafenib (LGX): Part I	C4 D15, Pre-dose	9.21 Nanogram per milliliter	Geometric Coefficient of Variation 100.3
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Encorafenib (LGX): Part I	C1 D15, 1.5 hr	2470 Nanogram per milliliter	Geometric Coefficient of Variation 116.7
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Encorafenib (LGX): Part I	C5 D15, Pre-dose	8.84 Nanogram per milliliter	Geometric Coefficient of Variation 59.4
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Encorafenib (LGX): Part I	C2 D21, Pre-dose	9.04 Nanogram per milliliter	Geometric Coefficient of Variation 84.2
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Encorafenib (LGX): Part I	EOT	19.6 Nanogram per milliliter	Geometric Coefficient of Variation 399.9
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Encorafenib (LGX): Part I	C1 D1, 1.5 hr	4820 Nanogram per milliliter	Geometric Coefficient of Variation 114.2
Part II: Encorafenib + Binimetinib + Infigratinib	Plasma Concentration for Encorafenib (LGX): Part I	EOT	34.5 Nanogram per milliliter	Geometric Coefficient of Variation 890.3
Part II: Encorafenib + Binimetinib + Infigratinib	Plasma Concentration for Encorafenib (LGX): Part I	C1 D1, 1.5 hr	4480 Nanogram per milliliter	Geometric Coefficient of Variation 124.4
Part II: Encorafenib + Binimetinib + Infigratinib	Plasma Concentration for Encorafenib (LGX): Part I	C1 D15, Pre-dose	13.8 Nanogram per milliliter	Geometric Coefficient of Variation 104.4
Part II: Encorafenib + Binimetinib + Infigratinib	Plasma Concentration for Encorafenib (LGX): Part I	C1 D15, 1.5 hr	2910 Nanogram per milliliter	Geometric Coefficient of Variation 91.6
Part II: Encorafenib + Binimetinib + Infigratinib	Plasma Concentration for Encorafenib (LGX): Part I	C2 D8, Pre-dose	14.7 Nanogram per milliliter	Geometric Coefficient of Variation 117.5
Part II: Encorafenib + Binimetinib + Infigratinib	Plasma Concentration for Encorafenib (LGX): Part I	C2 D21, Pre-dose	15.6 Nanogram per milliliter	Geometric Coefficient of Variation 156.3
Part II: Encorafenib + Binimetinib + Infigratinib	Plasma Concentration for Encorafenib (LGX): Part I	C3 D15, Pre-dose	11.2 Nanogram per milliliter	Geometric Coefficient of Variation 114.3
Part II: Encorafenib + Binimetinib + Infigratinib	Plasma Concentration for Encorafenib (LGX): Part I	C4 D15, Pre-dose	12.3 Nanogram per milliliter	Geometric Coefficient of Variation 108.9
Part II: Encorafenib + Binimetinib + Infigratinib	Plasma Concentration for Encorafenib (LGX): Part I	C5 D15, Pre-dose	11.9 Nanogram per milliliter	Geometric Coefficient of Variation 72.7

Secondary

Plasma Concentration for Encorafenib (LGX): Part II

In results reported below, following abbreviation have been used: Cycle 1 (C1), Day 1 (D1), Day 8 (D8), Day 15 (D15), Day 16 (D16), Day 21 (D21), Cycle 2 (C2), Cycle 3 (C3), Cycle 4 (C4), Cycle 5 (C5). Maximum treatment exposure for Part II was of 97.0 weeks.

Population: PAS consisted of all participants who had at least one blood sample providing evaluable PK data. All participants reported under Number of Participants Analyzed contributed data to the table but may not have evaluable data for every row. Here, Number Analyzed signifies number of participants evaluable for specified time points.

Arm	Measure	Group	Value (GEOMETRIC_MEAN)	Dispersion
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Encorafenib (LGX): Part II	C1 D15: 0.5 hr	437 Nanogram per milliliter	Geometric Coefficient of Variation 228.2
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Encorafenib (LGX): Part II	C2 D15: Pre-dose	41.3 Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Encorafenib (LGX): Part II	C4 D1: Pre-dose	30.2 Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Encorafenib (LGX): Part II	EOT	1.77 Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Encorafenib (LGX): Part II	C1 D16: 24 hrs	11.3 Nanogram per milliliter	Geometric Coefficient of Variation 45.3
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Encorafenib (LGX): Part II	C3 D1: Pre-dose	13.9 Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Encorafenib (LGX): Part II	C1 D15: 6 hrs	246 Nanogram per milliliter	Geometric Coefficient of Variation 94.6
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Encorafenib (LGX): Part II	C1 D15: 2.5 hrs	1420 Nanogram per milliliter	Geometric Coefficient of Variation 39.6
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Encorafenib (LGX): Part II	C1 D15: 8 hrs	180 Nanogram per milliliter	Geometric Coefficient of Variation 94.5
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Encorafenib (LGX): Part II	C1 D15: Pre-dose	11.2 Nanogram per milliliter	Geometric Coefficient of Variation 106.3
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Encorafenib (LGX): Part II	C1 D8: Pre-dose	8.97 Nanogram per milliliter	Geometric Coefficient of Variation 89
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Encorafenib (LGX): Part II	C5 D1: Pre-dose	749 Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Encorafenib (LGX): Part II	C1 D15: 4 hrs	649 Nanogram per milliliter	Geometric Coefficient of Variation 37.5
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Encorafenib (LGX): Part II	C2 D1: Pre-dose	13.5 Nanogram per milliliter	Geometric Coefficient of Variation 193
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Encorafenib (LGX): Part II	C1 D15: 1.5 hrs	3050 Nanogram per milliliter	Geometric Coefficient of Variation 59.6
Part II: Encorafenib + Binimetinib + Infigratinib	Plasma Concentration for Encorafenib (LGX): Part II	C1 D15: 6 hrs	433 Nanogram per milliliter	Geometric Coefficient of Variation 45
Part II: Encorafenib + Binimetinib + Infigratinib	Plasma Concentration for Encorafenib (LGX): Part II	C1 D15: 8 hrs	276 Nanogram per milliliter	Geometric Coefficient of Variation 103.8
Part II: Encorafenib + Binimetinib + Infigratinib	Plasma Concentration for Encorafenib (LGX): Part II	C1 D15: 0.5 hr	625 Nanogram per milliliter	Geometric Coefficient of Variation 19.5
Part II: Encorafenib + Binimetinib + Infigratinib	Plasma Concentration for Encorafenib (LGX): Part II	EOT	NA Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Infigratinib	Plasma Concentration for Encorafenib (LGX): Part II	C2 D1: Pre-dose	32.6 Nanogram per milliliter	Geometric Coefficient of Variation 202.9
Part II: Encorafenib + Binimetinib + Infigratinib	Plasma Concentration for Encorafenib (LGX): Part II	C1 D8: Pre-dose	21.3 Nanogram per milliliter	Geometric Coefficient of Variation 150.6
Part II: Encorafenib + Binimetinib + Infigratinib	Plasma Concentration for Encorafenib (LGX): Part II	C1 D15: 1.5 hrs	2150 Nanogram per milliliter	Geometric Coefficient of Variation 54.6
Part II: Encorafenib + Binimetinib + Infigratinib	Plasma Concentration for Encorafenib (LGX): Part II	C1 D1: 1.5 hrs	3430 Nanogram per milliliter	Geometric Coefficient of Variation 17.6
Part II: Encorafenib + Binimetinib + Infigratinib	Plasma Concentration for Encorafenib (LGX): Part II	C1 D15: 4 hrs	770 Nanogram per milliliter	Geometric Coefficient of Variation 6.2
Part II: Encorafenib + Binimetinib + Infigratinib	Plasma Concentration for Encorafenib (LGX): Part II	C1 D15: 2.5 hrs	1320 Nanogram per milliliter	Geometric Coefficient of Variation 30
Part II: Encorafenib + Binimetinib + Infigratinib	Plasma Concentration for Encorafenib (LGX): Part II	C2 D15: Pre-dose	15.6 Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Infigratinib	Plasma Concentration for Encorafenib (LGX): Part II	C1 D15: Pre-dose	18.6 Nanogram per milliliter	Geometric Coefficient of Variation 159.4
Part II: Encorafenib + Binimetinib + Infigratinib	Plasma Concentration for Encorafenib (LGX): Part II	C1 D16: 24 hrs	25.1 Nanogram per milliliter	Geometric Coefficient of Variation 2066.8
Part II: Encorafenib + Binimetinib + Capmatinib	Plasma Concentration for Encorafenib (LGX): Part II	C1 D15: Pre-dose	7.74 Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Capmatinib	Plasma Concentration for Encorafenib (LGX): Part II	C1 D15: 1.5 hrs	2100 Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Capmatinib	Plasma Concentration for Encorafenib (LGX): Part II	C1 D16: 24 hrs	6.76 Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Capmatinib	Plasma Concentration for Encorafenib (LGX): Part II	C1 D8: Pre-dose	12.4 Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Capmatinib	Plasma Concentration for Encorafenib (LGX): Part II	C1 D15: 4 hrs	397 Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Capmatinib	Plasma Concentration for Encorafenib (LGX): Part II	EOT	14.3 Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Capmatinib	Plasma Concentration for Encorafenib (LGX): Part II	C3 D1: Pre-dose	20.5 Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Capmatinib	Plasma Concentration for Encorafenib (LGX): Part II	C2 D15: Pre-dose	13.9 Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Capmatinib	Plasma Concentration for Encorafenib (LGX): Part II	C1 D21: Pre-dose	10.4 Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Capmatinib	Plasma Concentration for Encorafenib (LGX): Part II	C1 D15: 6 hrs	211 Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Capmatinib	Plasma Concentration for Encorafenib (LGX): Part II	C2 D1: Pre-dose	12.7 Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Capmatinib	Plasma Concentration for Encorafenib (LGX): Part II	C1 D15: 0.5 hr	1690 Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Capmatinib	Plasma Concentration for Encorafenib (LGX): Part II	C1 D15: 2.5 hrs	1020 Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Capmatinib	Plasma Concentration for Encorafenib (LGX): Part II	C1 D1: 1.5 hrs	1860 Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Buparlisib	Plasma Concentration for Encorafenib (LGX): Part II	C1 D15: 4 hrs	453 Nanogram per milliliter	Geometric Coefficient of Variation 24.3
Part II: Encorafenib + Binimetinib + Buparlisib	Plasma Concentration for Encorafenib (LGX): Part II	C1 D15: 6 hrs	165 Nanogram per milliliter	Geometric Coefficient of Variation 68.8
Part II: Encorafenib + Binimetinib + Buparlisib	Plasma Concentration for Encorafenib (LGX): Part II	C3 D1: Pre-dose	23.2 Nanogram per milliliter	Geometric Coefficient of Variation 33.1
Part II: Encorafenib + Binimetinib + Buparlisib	Plasma Concentration for Encorafenib (LGX): Part II	C1 D8: Pre-dose	10.3 Nanogram per milliliter	Geometric Coefficient of Variation 54.4
Part II: Encorafenib + Binimetinib + Buparlisib	Plasma Concentration for Encorafenib (LGX): Part II	C1 D1: 1.5 hrs	1130 Nanogram per milliliter	Geometric Coefficient of Variation 3.8
Part II: Encorafenib + Binimetinib + Buparlisib	Plasma Concentration for Encorafenib (LGX): Part II	C2 D15: Pre-dose	9.68 Nanogram per milliliter	Geometric Coefficient of Variation 36.5
Part II: Encorafenib + Binimetinib + Buparlisib	Plasma Concentration for Encorafenib (LGX): Part II	C1 D15: Pre-dose	9.95 Nanogram per milliliter	Geometric Coefficient of Variation 40.1
Part II: Encorafenib + Binimetinib + Buparlisib	Plasma Concentration for Encorafenib (LGX): Part II	C2 D1: Pre-dose	19.9 Nanogram per milliliter	Geometric Coefficient of Variation 210.5
Part II: Encorafenib + Binimetinib + Buparlisib	Plasma Concentration for Encorafenib (LGX): Part II	C1 D15: 0.5 hr	262 Nanogram per milliliter	Geometric Coefficient of Variation 345.5
Part II: Encorafenib + Binimetinib + Buparlisib	Plasma Concentration for Encorafenib (LGX): Part II	C1 D15: 1.5 hrs	1550 Nanogram per milliliter	Geometric Coefficient of Variation 62.4
Part II: Encorafenib + Binimetinib + Buparlisib	Plasma Concentration for Encorafenib (LGX): Part II	C1 D16: 24 hrs	8.10 Nanogram per milliliter	Geometric Coefficient of Variation 43.1
Part II: Encorafenib + Binimetinib + Buparlisib	Plasma Concentration for Encorafenib (LGX): Part II	C1 D15: 2.5 hrs	808 Nanogram per milliliter	Geometric Coefficient of Variation 55
Part II: Encorafenib + Binimetinib + Buparlisib	Plasma Concentration for Encorafenib (LGX): Part II	EOT	NA Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Buparlisib	Plasma Concentration for Encorafenib (LGX): Part II	C1 D15: 8 hrs	115 Nanogram per milliliter	Geometric Coefficient of Variation 55.4
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 300 mg	Plasma Concentration for Encorafenib (LGX): Part II	C1 D15: 0.5 hr	139 Nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 300 mg	Plasma Concentration for Encorafenib (LGX): Part II	C1 D8: Pre-dose	6.21 Nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 300 mg	Plasma Concentration for Encorafenib (LGX): Part II	C1 D15: 6 hrs	266 Nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 300 mg	Plasma Concentration for Encorafenib (LGX): Part II	C2 D1: Pre-dose	2.91 Nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 300 mg	Plasma Concentration for Encorafenib (LGX): Part II	C1 D15: 8 hrs	257 Nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 300 mg	Plasma Concentration for Encorafenib (LGX): Part II	C1 D15: 4 hrs	1160 Nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 300 mg	Plasma Concentration for Encorafenib (LGX): Part II	C1 D1: 1.5 hrs	3750 Nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 300 mg	Plasma Concentration for Encorafenib (LGX): Part II	C1 D15: Pre-dose	7.95 Nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 300 mg	Plasma Concentration for Encorafenib (LGX): Part II	C1 D16: 24 hrs	5.20 Nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 300 mg	Plasma Concentration for Encorafenib (LGX): Part II	EOT	NA Nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 300 mg	Plasma Concentration for Encorafenib (LGX): Part II	C1 D15: 1.5 hrs	2890 Nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 400 mg	Plasma Concentration for Encorafenib (LGX): Part II	C1 D16: 24 hrs	15.0 Nanogram per milliliter	Geometric Coefficient of Variation 20.9
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 400 mg	Plasma Concentration for Encorafenib (LGX): Part II	C1 D1: 1.5 hrs	1770 Nanogram per milliliter	Geometric Coefficient of Variation 62.9
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 400 mg	Plasma Concentration for Encorafenib (LGX): Part II	C1 D8: Pre-dose	11.7 Nanogram per milliliter	Geometric Coefficient of Variation 56.4
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 400 mg	Plasma Concentration for Encorafenib (LGX): Part II	C1 D15: Pre-dose	13.5 Nanogram per milliliter	Geometric Coefficient of Variation 35
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 400 mg	Plasma Concentration for Encorafenib (LGX): Part II	C1 D15: 0.5 hr	127 Nanogram per milliliter	Geometric Coefficient of Variation 216.1
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 400 mg	Plasma Concentration for Encorafenib (LGX): Part II	C1 D15: 1.5 hrs	2500 Nanogram per milliliter	Geometric Coefficient of Variation 27.9
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 400 mg	Plasma Concentration for Encorafenib (LGX): Part II	C1 D15: 2.5 hrs	1550 Nanogram per milliliter	Geometric Coefficient of Variation 34.4
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 400 mg	Plasma Concentration for Encorafenib (LGX): Part II	C1 D15: 4 hrs	667 Nanogram per milliliter	Geometric Coefficient of Variation 20.4
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 400 mg	Plasma Concentration for Encorafenib (LGX): Part II	C1 D15: 6 hrs	317 Nanogram per milliliter	Geometric Coefficient of Variation 26.8
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 400 mg	Plasma Concentration for Encorafenib (LGX): Part II	C1 D15: 8 hrs	217 Nanogram per milliliter	Geometric Coefficient of Variation 34.5
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 400 mg	Plasma Concentration for Encorafenib (LGX): Part II	C2 D1: Pre-dose	14.0 Nanogram per milliliter	Geometric Coefficient of Variation 30.3
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 400 mg	Plasma Concentration for Encorafenib (LGX): Part II	C2 D15: Pre-dose	8.49 Nanogram per milliliter	Geometric Coefficient of Variation 70.5
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 400 mg	Plasma Concentration for Encorafenib (LGX): Part II	C3 D1: Pre-dose	10.1 Nanogram per milliliter	Geometric Coefficient of Variation 72.1
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 400 mg	Plasma Concentration for Encorafenib (LGX): Part II	C4 D1: Pre-dose	12.5 Nanogram per milliliter	Geometric Coefficient of Variation 11.4
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 400 mg	Plasma Concentration for Encorafenib (LGX): Part II	EOT	13.9 Nanogram per milliliter	Geometric Coefficient of Variation 66.6
Part II: Encorafenib 100 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Plasma Concentration for Encorafenib (LGX): Part II	C4 D1: Pre-dose	5.95 Nanogram per milliliter	—
Part II: Encorafenib 100 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Plasma Concentration for Encorafenib (LGX): Part II	C1 D15: 8 hrs	142 Nanogram per milliliter	—
Part II: Encorafenib 100 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Plasma Concentration for Encorafenib (LGX): Part II	C5 D1: Pre-dose	10.7 Nanogram per milliliter	—
Part II: Encorafenib 100 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Plasma Concentration for Encorafenib (LGX): Part II	C1 D16: 24 hrs	10.7 Nanogram per milliliter	—
Part II: Encorafenib 100 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Plasma Concentration for Encorafenib (LGX): Part II	C1 D1: 4 hrs	238 Nanogram per milliliter	—
Part II: Encorafenib 100 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Plasma Concentration for Encorafenib (LGX): Part II	C1 D1: 1.5 hrs	878 Nanogram per milliliter	—
Part II: Encorafenib 100 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Plasma Concentration for Encorafenib (LGX): Part II	C1 D15: 6 hrs	209 Nanogram per milliliter	—
Part II: Encorafenib 100 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Plasma Concentration for Encorafenib (LGX): Part II	C1 D15: 4 hrs	389 Nanogram per milliliter	—
Part II: Encorafenib 100 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Plasma Concentration for Encorafenib (LGX): Part II	C1 D21: Pre-dose	13.6 Nanogram per milliliter	—
Part II: Encorafenib 100 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Plasma Concentration for Encorafenib (LGX): Part II	C1 D15: 0.5 hr	8.55 Nanogram per milliliter	—
Part II: Encorafenib 100 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Plasma Concentration for Encorafenib (LGX): Part II	EOT	8.24 Nanogram per milliliter	—
Part II: Encorafenib 100 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Plasma Concentration for Encorafenib (LGX): Part II	C2 D1: Pre-dose	8.50 Nanogram per milliliter	—
Part II: Encorafenib 100 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Plasma Concentration for Encorafenib (LGX): Part II	C1 D15: 2.5 hrs	622 Nanogram per milliliter	—
Part II: Encorafenib 100 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Plasma Concentration for Encorafenib (LGX): Part II	C1 D15: Pre-dose	9.28 Nanogram per milliliter	—
Part II: Encorafenib 100 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Plasma Concentration for Encorafenib (LGX): Part II	C2 D15: Pre-dose	11.1 Nanogram per milliliter	—
Part II: Encorafenib 100 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Plasma Concentration for Encorafenib (LGX): Part II	C1 D8: Pre-dose	12.5 Nanogram per milliliter	—
Part II: Encorafenib 100 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Plasma Concentration for Encorafenib (LGX): Part II	C1 D15: 1.5 hrs	366 Nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 400 mg	Plasma Concentration for Encorafenib (LGX): Part II	C2 D15: Pre-dose	16.5 Nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 400 mg	Plasma Concentration for Encorafenib (LGX): Part II	C1 D15: 0.5 hr	601 Nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 400 mg	Plasma Concentration for Encorafenib (LGX): Part II	C3 D1: Pre-dose	NA Nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 400 mg	Plasma Concentration for Encorafenib (LGX): Part II	C1 D8: Pre-dose	15.2 Nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 400 mg	Plasma Concentration for Encorafenib (LGX): Part II	C4 D1: Pre-dose	7.28 Nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 400 mg	Plasma Concentration for Encorafenib (LGX): Part II	C1 D1: 1.5 hrs	2030 Nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 400 mg	Plasma Concentration for Encorafenib (LGX): Part II	C1 D1: 4 hrs	297 Nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 400 mg	Plasma Concentration for Encorafenib (LGX): Part II	C1 D15: 2.5 hrs	981 Nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 400 mg	Plasma Concentration for Encorafenib (LGX): Part II	C5 D1: Pre-dose	9.84 Nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 400 mg	Plasma Concentration for Encorafenib (LGX): Part II	EOT	6.81 Nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 400 mg	Plasma Concentration for Encorafenib (LGX): Part II	C1 D16: 24 hrs	7.85 Nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 400 mg	Plasma Concentration for Encorafenib (LGX): Part II	C1 D15: 8 hrs	132 Nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 400 mg	Plasma Concentration for Encorafenib (LGX): Part II	C1 D15: Pre-dose	10.3 Nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 400 mg	Plasma Concentration for Encorafenib (LGX): Part II	C1 D15: 6 hrs	199 Nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 400 mg	Plasma Concentration for Encorafenib (LGX): Part II	C1 D15: 1.5 hrs	1960 Nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 400 mg	Plasma Concentration for Encorafenib (LGX): Part II	C2 D1: Pre-dose	82.5 Nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 400 mg	Plasma Concentration for Encorafenib (LGX): Part II	C1 D21: Pre-dose	13.9 Nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Plasma Concentration for Encorafenib (LGX): Part II	C1 D15: 6 hrs	203 Nanogram per milliliter	Geometric Coefficient of Variation 11.1
Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Plasma Concentration for Encorafenib (LGX): Part II	C1 D15: 0.5 hr	473 Nanogram per milliliter	Geometric Coefficient of Variation 1248.5
Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Plasma Concentration for Encorafenib (LGX): Part II	C1 D15: 1.5 hrs	1450 Nanogram per milliliter	Geometric Coefficient of Variation 3.9
Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Plasma Concentration for Encorafenib (LGX): Part II	C1 D21: Pre-dose	12.4 Nanogram per milliliter	Geometric Coefficient of Variation 60.4
Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Plasma Concentration for Encorafenib (LGX): Part II	C1 D15: 8 hrs	109 Nanogram per milliliter	Geometric Coefficient of Variation 2.6
Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Plasma Concentration for Encorafenib (LGX): Part II	C1 D15: Pre-dose	7.75 Nanogram per milliliter	Geometric Coefficient of Variation 37.3
Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Plasma Concentration for Encorafenib (LGX): Part II	C1 D1: 4 hrs	626 Nanogram per milliliter	Geometric Coefficient of Variation 65.7
Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Plasma Concentration for Encorafenib (LGX): Part II	C2 D1: Pre-dose	8.19 Nanogram per milliliter	Geometric Coefficient of Variation 42.2
Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Plasma Concentration for Encorafenib (LGX): Part II	EOT	24.5 Nanogram per milliliter	Geometric Coefficient of Variation 259.8
Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Plasma Concentration for Encorafenib (LGX): Part II	C1 D15: 2.5 hrs	686 Nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Plasma Concentration for Encorafenib (LGX): Part II	C1 D8: Pre-dose	9.39 Nanogram per milliliter	Geometric Coefficient of Variation 15.9
Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Plasma Concentration for Encorafenib (LGX): Part II	C1 D1: 1.5 hrs	847 Nanogram per milliliter	Geometric Coefficient of Variation 28.1
Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Plasma Concentration for Encorafenib (LGX): Part II	C1 D16: 24 hrs	10.8 Nanogram per milliliter	Geometric Coefficient of Variation 106.1
Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Plasma Concentration for Encorafenib (LGX): Part II	C1 D15: 4 hrs	478 Nanogram per milliliter	Geometric Coefficient of Variation 39.6
Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Plasma Concentration for Encorafenib (LGX): Part II	C2 D15: Pre-dose	12.3 Nanogram per milliliter	Geometric Coefficient of Variation 24.3
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 400 mg	Plasma Concentration for Encorafenib (LGX): Part II	C1 D21: Pre-dose	20.3 Nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 400 mg	Plasma Concentration for Encorafenib (LGX): Part II	EOT	NA Nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 400 mg	Plasma Concentration for Encorafenib (LGX): Part II	C2 D1: Pre-dose	19.2 Nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 400 mg	Plasma Concentration for Encorafenib (LGX): Part II	C1 D8: Pre-dose	7.15 Nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 400 mg	Plasma Concentration for Encorafenib (LGX): Part II	C2 D15: Pre-dose	8.95 Nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 600 mg	Plasma Concentration for Encorafenib (LGX): Part II	C1 D15: 6 hrs	567 Nanogram per milliliter	Geometric Coefficient of Variation 51.5
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 600 mg	Plasma Concentration for Encorafenib (LGX): Part II	C1 D15: 2.5 hrs	1510 Nanogram per milliliter	Geometric Coefficient of Variation 48.2
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 600 mg	Plasma Concentration for Encorafenib (LGX): Part II	EOT	16.6 Nanogram per milliliter	Geometric Coefficient of Variation 265
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 600 mg	Plasma Concentration for Encorafenib (LGX): Part II	C1 D15: 8 hrs	412 Nanogram per milliliter	Geometric Coefficient of Variation 62.3
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 600 mg	Plasma Concentration for Encorafenib (LGX): Part II	C1 D15: 1.5 hrs	1850 Nanogram per milliliter	Geometric Coefficient of Variation 69.7
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 600 mg	Plasma Concentration for Encorafenib (LGX): Part II	C1 D15: 0.5 hr	175 Nanogram per milliliter	Geometric Coefficient of Variation 252.7
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 600 mg	Plasma Concentration for Encorafenib (LGX): Part II	C1 D16: 24 hrs	22.8 Nanogram per milliliter	Geometric Coefficient of Variation 199
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 600 mg	Plasma Concentration for Encorafenib (LGX): Part II	C1 D21: Pre-dose	17.5 Nanogram per milliliter	Geometric Coefficient of Variation 106.4
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 600 mg	Plasma Concentration for Encorafenib (LGX): Part II	C1 D15: Pre-dose	20.9 Nanogram per milliliter	Geometric Coefficient of Variation 188.5
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 600 mg	Plasma Concentration for Encorafenib (LGX): Part II	C2 D1: Pre-dose	11.9 Nanogram per milliliter	Geometric Coefficient of Variation 100.9
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 600 mg	Plasma Concentration for Encorafenib (LGX): Part II	C1 D8: Pre-dose	16.2 Nanogram per milliliter	Geometric Coefficient of Variation 116.1
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 600 mg	Plasma Concentration for Encorafenib (LGX): Part II	C2 D15: Pre-dose	21.3 Nanogram per milliliter	Geometric Coefficient of Variation 115.3
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 600 mg	Plasma Concentration for Encorafenib (LGX): Part II	C1 D1: 4 hrs	596 Nanogram per milliliter	Geometric Coefficient of Variation 51.1
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 600 mg	Plasma Concentration for Encorafenib (LGX): Part II	C3 D1: Pre-dose	9.34 Nanogram per milliliter	Geometric Coefficient of Variation 125.7
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 600 mg	Plasma Concentration for Encorafenib (LGX): Part II	C4 D1: Pre-dose	13.1 Nanogram per milliliter	Geometric Coefficient of Variation 21.8
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 600 mg	Plasma Concentration for Encorafenib (LGX): Part II	C5 D1: Pre-dose	9.15 Nanogram per milliliter	Geometric Coefficient of Variation 44
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 600 mg	Plasma Concentration for Encorafenib (LGX): Part II	C1 D1: 1.5 hrs	1600 Nanogram per milliliter	Geometric Coefficient of Variation 85.6
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 600 mg	Plasma Concentration for Encorafenib (LGX): Part II	C1 D15: 4 hrs	1020 Nanogram per milliliter	Geometric Coefficient of Variation 34.3

Secondary

Plasma Concentration for Infigratinib (BGJ) and Its Metabolites: Part II

BHS697 and CQM157 are metabolites of infigratinib. Maximum treatment exposure for Part II was of 97.0 weeks.

Time frame: C1 (1.5 hrs post-dose on D1; pre-dose on D8; pre-dose, 0.5, 1.5, 2.5, 4, 6 hrs post-dose on D15; 24 hrs post-dose on D16; pre-dose on D21); C2 (pre-dose on D1 and D15); C3 pre-dose on D1; EOT

Population: PAS consisted of all participants who had at least one blood sample providing evaluable PK data. Here, Number Analyzed signifies number of participants evaluable for specified time points.

Arm	Measure	Group	Value (GEOMETRIC_MEAN)
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Infigratinib (BGJ) and Its Metabolites: Part II	Infigratinib, C1 D1: 1.5 hrs	15.0 Nanogram per milliliter
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Infigratinib (BGJ) and Its Metabolites: Part II	Infigratinib, C1 D8: Pre-dose	2.67 Nanogram per milliliter
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Infigratinib (BGJ) and Its Metabolites: Part II	Infigratinib, C1 D15: Pre-dose	2.49 Nanogram per milliliter
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Infigratinib (BGJ) and Its Metabolites: Part II	Infigratinib, C1 D15: 0.5 hr	3.39 Nanogram per milliliter
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Infigratinib (BGJ) and Its Metabolites: Part II	Infigratinib, C1 D15: 1.5 hrs	15.2 Nanogram per milliliter
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Infigratinib (BGJ) and Its Metabolites: Part II	Infigratinib, C1 D15: 2.5 hrs	27.5 Nanogram per milliliter
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Infigratinib (BGJ) and Its Metabolites: Part II	Infigratinib, C1 D15: 4 hrs	24.7 Nanogram per milliliter
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Infigratinib (BGJ) and Its Metabolites: Part II	Infigratinib, C1 D15: 6 hrs	20.5 Nanogram per milliliter
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Infigratinib (BGJ) and Its Metabolites: Part II	Infigratinib, C1 D21: Pre-dose	2.05 Nanogram per milliliter
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Infigratinib (BGJ) and Its Metabolites: Part II	Infigratinib, C2 D1: Pre-dose	NA Nanogram per milliliter
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Infigratinib (BGJ) and Its Metabolites: Part II	Infigratinib, C2 D15: Pre-dose	4.65 Nanogram per milliliter
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Infigratinib (BGJ) and Its Metabolites: Part II	Infigratinib, C3 D1: Pre-dose	NA Nanogram per milliliter
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Infigratinib (BGJ) and Its Metabolites: Part II	Infigratinib, EOT	2.42 Nanogram per milliliter
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Infigratinib (BGJ) and Its Metabolites: Part II	BHS697, C1 D1: 1.5 hrs	4.83 Nanogram per milliliter
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Infigratinib (BGJ) and Its Metabolites: Part II	BHS697, C1 D8: Pre-dose	2.17 Nanogram per milliliter
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Infigratinib (BGJ) and Its Metabolites: Part II	BHS697, C1 D15: Pre-dose	1.64 Nanogram per milliliter
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Infigratinib (BGJ) and Its Metabolites: Part II	BHS697, C1 D15: 0.5 hr	2.14 Nanogram per milliliter
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Infigratinib (BGJ) and Its Metabolites: Part II	BHS697, C1 D15: 1.5 hrs	6.83 Nanogram per milliliter
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Infigratinib (BGJ) and Its Metabolites: Part II	BHS697, C1 D15: 2.5 hrs	8.53 Nanogram per milliliter
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Infigratinib (BGJ) and Its Metabolites: Part II	BHS697, C1 D15: 4 hrs	6.89 Nanogram per milliliter
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Infigratinib (BGJ) and Its Metabolites: Part II	BHS697, C1 D15: 6 hrs	5.57 Nanogram per milliliter
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Infigratinib (BGJ) and Its Metabolites: Part II	BHS697, C1 D21: Pre-dose	1.37 Nanogram per milliliter
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Infigratinib (BGJ) and Its Metabolites: Part II	BHS697, C2 D1: Pre-dose	NA Nanogram per milliliter
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Infigratinib (BGJ) and Its Metabolites: Part II	BHS697, C2 D15: Pre-dose	2.83 Nanogram per milliliter
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Infigratinib (BGJ) and Its Metabolites: Part II	BHS697, C3 D1: Pre-dose	NA Nanogram per milliliter
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Infigratinib (BGJ) and Its Metabolites: Part II	BHS697, EOT	1.69 Nanogram per milliliter
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Infigratinib (BGJ) and Its Metabolites: Part II	CQM157, C1 D1: 1.5 hrs	13.0 Nanogram per milliliter
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Infigratinib (BGJ) and Its Metabolites: Part II	CQM157, C1 D8: Pre-dose	14.1 Nanogram per milliliter
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Infigratinib (BGJ) and Its Metabolites: Part II	CQM157, C1 D15: Pre-dose	11.1 Nanogram per milliliter
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Infigratinib (BGJ) and Its Metabolites: Part II	CQM157, C1 D15: 0.5 hr	12.0 Nanogram per milliliter
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Infigratinib (BGJ) and Its Metabolites: Part II	CQM157, C1 D15: 1.5 hrs	21.3 Nanogram per milliliter
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Infigratinib (BGJ) and Its Metabolites: Part II	CQM157, C1 D15: 2.5 hrs	28.3 Nanogram per milliliter
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Infigratinib (BGJ) and Its Metabolites: Part II	CQM157, C1 D15: 4 hrs	25.0 Nanogram per milliliter
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Infigratinib (BGJ) and Its Metabolites: Part II	CQM157, C1 D15: 6 hrs	32.2 Nanogram per milliliter
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Infigratinib (BGJ) and Its Metabolites: Part II	CQM157, C1 D21: Pre-dose	9.65 Nanogram per milliliter
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Infigratinib (BGJ) and Its Metabolites: Part II	CQM157, C2 D1: Pre-dose	NA Nanogram per milliliter
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Infigratinib (BGJ) and Its Metabolites: Part II	CQM157, C2 D15: Pre-dose	15.5 Nanogram per milliliter
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Infigratinib (BGJ) and Its Metabolites: Part II	CQM157, C3 D1: Pre-dose	NA Nanogram per milliliter
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Infigratinib (BGJ) and Its Metabolites: Part II	CQM157, EOT	11.9 Nanogram per milliliter

Secondary

Plasma Concentration for Ribociclib (LEE) and Its Metabolite: Part II

LEQ803 is metabolite of ribociclib. Maximum treatment exposure for Part II was of 97.0 weeks.

Arm	Measure	Group	Value (GEOMETRIC_MEAN)	Dispersion
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Ribociclib (LEE) and Its Metabolite: Part II	LEQ803, C3 D1: Pre-dose	7.88 Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Ribociclib (LEE) and Its Metabolite: Part II	Ribociclib, C1 D15: 4 hrs	368 Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Ribociclib (LEE) and Its Metabolite: Part II	Ribociclib, C3 D1: Pre-dose	1.16 Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Ribociclib (LEE) and Its Metabolite: Part II	Ribociclib, C1 D1: 1.5 hrs	220 Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Ribociclib (LEE) and Its Metabolite: Part II	Ribociclib, C1 D15: 6 hrs	434 Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Ribociclib (LEE) and Its Metabolite: Part II	LEQ803, C1 D1: 4 hrs	65.2 Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Ribociclib (LEE) and Its Metabolite: Part II	Ribociclib, C2 D15: Pre-dose	103 Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Ribociclib (LEE) and Its Metabolite: Part II	LEQ803, C1 D15: 2.5 hrs	130 Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Ribociclib (LEE) and Its Metabolite: Part II	Ribociclib, C1 D15: 8 hrs	311 Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Ribociclib (LEE) and Its Metabolite: Part II	Ribociclib, C1 D15: 0.5 hr	86.1 Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Ribociclib (LEE) and Its Metabolite: Part II	LEQ803, C2 D15: Pre-dose	90.0 Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Ribociclib (LEE) and Its Metabolite: Part II	LEQ803, C2 D1: Pre-dose	6.68 Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Ribociclib (LEE) and Its Metabolite: Part II	Ribociclib, C1 D16: 24 hrs	94.0 Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Ribociclib (LEE) and Its Metabolite: Part II	LEQ803, C1 D15: Pre-dose	76.0 Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Ribociclib (LEE) and Its Metabolite: Part II	Ribociclib, C2 D1: Pre-dose	NA Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Ribociclib (LEE) and Its Metabolite: Part II	Ribociclib, C1 D8: Pre-dose	77.4 Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Ribociclib (LEE) and Its Metabolite: Part II	Ribociclib, C1 D21: Pre-dose	105 Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Ribociclib (LEE) and Its Metabolite: Part II	LEQ803, C1 D16: 24 hrs	84.5 Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Ribociclib (LEE) and Its Metabolite: Part II	LEQ803, C1 D15: 4 hrs	138 Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Ribociclib (LEE) and Its Metabolite: Part II	LEQ803, C1 D1: 1.5 hrs	57.1 Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Ribociclib (LEE) and Its Metabolite: Part II	Ribociclib, C1 D15: 1.5 hrs	204 Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Ribociclib (LEE) and Its Metabolite: Part II	LEQ803, C1 D15: 6 hrs	175 Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Ribociclib (LEE) and Its Metabolite: Part II	LEQ803, C1 D8: Pre-dose	64.3 Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Ribociclib (LEE) and Its Metabolite: Part II	Ribociclib, EOT	1.94 Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Ribociclib (LEE) and Its Metabolite: Part II	LEQ803, C1 D21: Pre-dose	73.8 Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Ribociclib (LEE) and Its Metabolite: Part II	LEQ803, C1 D15: 8 hrs	135 Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Ribociclib (LEE) and Its Metabolite: Part II	LEQ803, C1 D15: 1.5 hrs	92.3 Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Ribociclib (LEE) and Its Metabolite: Part II	Ribociclib, C1 D15: Pre-dose	98.4 Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Ribociclib (LEE) and Its Metabolite: Part II	LEQ803, C4 D1: Pre-dose	7.19 Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Ribociclib (LEE) and Its Metabolite: Part II	Ribociclib, C4 D1: Pre-dose	1.22 Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Ribociclib (LEE) and Its Metabolite: Part II	Ribociclib, C1 D15: 2.5 hrs	321 Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Ribociclib (LEE) and Its Metabolite: Part II	LEQ803, C1 D15: 0.5 hr	75.5 Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Ribociclib (LEE) and Its Metabolite: Part II	LEQ803, EOT	10.4 Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Ribociclib	Plasma Concentration for Ribociclib (LEE) and Its Metabolite: Part II	Ribociclib, C1 D1: 4 hrs	213 Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Infigratinib	Plasma Concentration for Ribociclib (LEE) and Its Metabolite: Part II	LEQ803, C2 D1: Pre-dose	14.5 Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Infigratinib	Plasma Concentration for Ribociclib (LEE) and Its Metabolite: Part II	LEQ803, C1 D15: Pre-dose	37.1 Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Infigratinib	Plasma Concentration for Ribociclib (LEE) and Its Metabolite: Part II	LEQ803, C1 D16: 24 hrs	46.8 Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Infigratinib	Plasma Concentration for Ribociclib (LEE) and Its Metabolite: Part II	LEQ803, C1 D15: 0.5 hr	39.5 Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Infigratinib	Plasma Concentration for Ribociclib (LEE) and Its Metabolite: Part II	Ribociclib, C1 D15: 0.5 hr	59.7 Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Infigratinib	Plasma Concentration for Ribociclib (LEE) and Its Metabolite: Part II	LEQ803, C1 D15: 1.5 hrs	72.6 Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Infigratinib	Plasma Concentration for Ribociclib (LEE) and Its Metabolite: Part II	LEQ803, C1 D15: 2.5 hrs	92.5 Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Infigratinib	Plasma Concentration for Ribociclib (LEE) and Its Metabolite: Part II	LEQ803, C1 D15: 6 hrs	90.2 Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Infigratinib	Plasma Concentration for Ribociclib (LEE) and Its Metabolite: Part II	Ribociclib, C1 D15: 1.5 hrs	95.9 Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Infigratinib	Plasma Concentration for Ribociclib (LEE) and Its Metabolite: Part II	LEQ803, C1 D15: 8 hrs	79.8 Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Infigratinib	Plasma Concentration for Ribociclib (LEE) and Its Metabolite: Part II	Ribociclib, C1 D15: 2.5 hrs	126 Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Infigratinib	Plasma Concentration for Ribociclib (LEE) and Its Metabolite: Part II	Ribociclib, C1 D1: 4 hrs	84.5 Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Infigratinib	Plasma Concentration for Ribociclib (LEE) and Its Metabolite: Part II	Ribociclib, C1 D15: 6 hrs	109 Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Infigratinib	Plasma Concentration for Ribociclib (LEE) and Its Metabolite: Part II	Ribociclib, C1 D1: 1.5 hrs	117 Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Infigratinib	Plasma Concentration for Ribociclib (LEE) and Its Metabolite: Part II	Ribociclib, C1 D15: 8 hrs	83.6 Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Infigratinib	Plasma Concentration for Ribociclib (LEE) and Its Metabolite: Part II	LEQ803, EOT	69.3 Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Infigratinib	Plasma Concentration for Ribociclib (LEE) and Its Metabolite: Part II	Ribociclib, C1 D16: 24 hrs	25.6 Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Infigratinib	Plasma Concentration for Ribociclib (LEE) and Its Metabolite: Part II	Ribociclib, C1 D8: Pre-dose	32.3 Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Infigratinib	Plasma Concentration for Ribociclib (LEE) and Its Metabolite: Part II	LEQ803, C2 D15: Pre-dose	45.6 Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Infigratinib	Plasma Concentration for Ribociclib (LEE) and Its Metabolite: Part II	Ribociclib, C2 D1: Pre-dose	19.5 Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Infigratinib	Plasma Concentration for Ribociclib (LEE) and Its Metabolite: Part II	Ribociclib, C2 D15: Pre-dose	41.5 Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Infigratinib	Plasma Concentration for Ribociclib (LEE) and Its Metabolite: Part II	Ribociclib, C3 D1: Pre-dose	NA Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Infigratinib	Plasma Concentration for Ribociclib (LEE) and Its Metabolite: Part II	Ribociclib, EOT	60.3 Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Infigratinib	Plasma Concentration for Ribociclib (LEE) and Its Metabolite: Part II	Ribociclib, C1 D15: Pre-dose	28.2 Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Infigratinib	Plasma Concentration for Ribociclib (LEE) and Its Metabolite: Part II	LEQ803, C1 D1: 1.5 hrs	70.2 Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Infigratinib	Plasma Concentration for Ribociclib (LEE) and Its Metabolite: Part II	LEQ803, C1 D1: 4 hrs	50.8 Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Infigratinib	Plasma Concentration for Ribociclib (LEE) and Its Metabolite: Part II	LEQ803, C1 D8: Pre-dose	49.3 Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Infigratinib	Plasma Concentration for Ribociclib (LEE) and Its Metabolite: Part II	LEQ803, C3 D1: Pre-dose	2.75 Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Capmatinib	Plasma Concentration for Ribociclib (LEE) and Its Metabolite: Part II	Ribociclib, C1 D15: 8 hrs	182 Nanogram per milliliter	Geometric Coefficient of Variation 27.1
Part II: Encorafenib + Binimetinib + Capmatinib	Plasma Concentration for Ribociclib (LEE) and Its Metabolite: Part II	LEQ803, C1 D15: 1.5 hrs	82.7 Nanogram per milliliter	Geometric Coefficient of Variation 0.7
Part II: Encorafenib + Binimetinib + Capmatinib	Plasma Concentration for Ribociclib (LEE) and Its Metabolite: Part II	Ribociclib, C2 D15: Pre-dose	53.7 Nanogram per milliliter	Geometric Coefficient of Variation 51.2
Part II: Encorafenib + Binimetinib + Capmatinib	Plasma Concentration for Ribociclib (LEE) and Its Metabolite: Part II	LEQ803, C1 D16: 24 hrs	42.5 Nanogram per milliliter	Geometric Coefficient of Variation 13.8
Part II: Encorafenib + Binimetinib + Capmatinib	Plasma Concentration for Ribociclib (LEE) and Its Metabolite: Part II	Ribociclib, C1 D16: 24 hrs	52.7 Nanogram per milliliter	Geometric Coefficient of Variation 90.4
Part II: Encorafenib + Binimetinib + Capmatinib	Plasma Concentration for Ribociclib (LEE) and Its Metabolite: Part II	LEQ803, C1 D1: 4 hrs	73.5 Nanogram per milliliter	Geometric Coefficient of Variation 20.4
Part II: Encorafenib + Binimetinib + Capmatinib	Plasma Concentration for Ribociclib (LEE) and Its Metabolite: Part II	Ribociclib, C2 D1: Pre-dose	1.59 Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Capmatinib	Plasma Concentration for Ribociclib (LEE) and Its Metabolite: Part II	Ribociclib, C1 D8: Pre-dose	30.7 Nanogram per milliliter	Geometric Coefficient of Variation 33.5
Part II: Encorafenib + Binimetinib + Capmatinib	Plasma Concentration for Ribociclib (LEE) and Its Metabolite: Part II	Ribociclib, C1 D15: 6 hrs	239 Nanogram per milliliter	Geometric Coefficient of Variation 37.2
Part II: Encorafenib + Binimetinib + Capmatinib	Plasma Concentration for Ribociclib (LEE) and Its Metabolite: Part II	Ribociclib, C1 D1: 1.5 hrs	107 Nanogram per milliliter	Geometric Coefficient of Variation 40.6
Part II: Encorafenib + Binimetinib + Capmatinib	Plasma Concentration for Ribociclib (LEE) and Its Metabolite: Part II	Ribociclib, C1 D1: 4 hrs	205 Nanogram per milliliter	Geometric Coefficient of Variation 96
Part II: Encorafenib + Binimetinib + Capmatinib	Plasma Concentration for Ribociclib (LEE) and Its Metabolite: Part II	Ribociclib, C1 D15: 4 hrs	341 Nanogram per milliliter	Geometric Coefficient of Variation 42.9
Part II: Encorafenib + Binimetinib + Capmatinib	Plasma Concentration for Ribociclib (LEE) and Its Metabolite: Part II	LEQ803, C1 D21: Pre-dose	43.7 Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Capmatinib	Plasma Concentration for Ribociclib (LEE) and Its Metabolite: Part II	Ribociclib, C1 D15: 2.5 hrs	718 Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Capmatinib	Plasma Concentration for Ribociclib (LEE) and Its Metabolite: Part II	LEQ803, EOT	5.06 Nanogram per milliliter	Geometric Coefficient of Variation 4.6
Part II: Encorafenib + Binimetinib + Capmatinib	Plasma Concentration for Ribociclib (LEE) and Its Metabolite: Part II	Ribociclib, C1 D15: 1.5 hrs	200 Nanogram per milliliter	Geometric Coefficient of Variation 240.3
Part II: Encorafenib + Binimetinib + Capmatinib	Plasma Concentration for Ribociclib (LEE) and Its Metabolite: Part II	LEQ803, C1 D15: 8 hrs	95.2 Nanogram per milliliter	Geometric Coefficient of Variation 50.1
Part II: Encorafenib + Binimetinib + Capmatinib	Plasma Concentration for Ribociclib (LEE) and Its Metabolite: Part II	LEQ803, C1 D15: 6 hrs	111 Nanogram per milliliter	Geometric Coefficient of Variation 27.6
Part II: Encorafenib + Binimetinib + Capmatinib	Plasma Concentration for Ribociclib (LEE) and Its Metabolite: Part II	LEQ803, C1 D15: 0.5 hr	32.1 Nanogram per milliliter	Geometric Coefficient of Variation 0.7
Part II: Encorafenib + Binimetinib + Capmatinib	Plasma Concentration for Ribociclib (LEE) and Its Metabolite: Part II	Ribociclib, EOT	1.49 Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Capmatinib	Plasma Concentration for Ribociclib (LEE) and Its Metabolite: Part II	LEQ803, C1 D15: Pre-dose	32.9 Nanogram per milliliter	Geometric Coefficient of Variation 25.7
Part II: Encorafenib + Binimetinib + Capmatinib	Plasma Concentration for Ribociclib (LEE) and Its Metabolite: Part II	LEQ803, C2 D1: Pre-dose	4.10 Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Capmatinib	Plasma Concentration for Ribociclib (LEE) and Its Metabolite: Part II	LEQ803, C1 D15: 4 hrs	140 Nanogram per milliliter	Geometric Coefficient of Variation 23.4
Part II: Encorafenib + Binimetinib + Capmatinib	Plasma Concentration for Ribociclib (LEE) and Its Metabolite: Part II	LEQ803, C1 D8: Pre-dose	38.1 Nanogram per milliliter	Geometric Coefficient of Variation 9.1
Part II: Encorafenib + Binimetinib + Capmatinib	Plasma Concentration for Ribociclib (LEE) and Its Metabolite: Part II	LEQ803, C1 D1: 1.5 hrs	68.2 Nanogram per milliliter	Geometric Coefficient of Variation 2.4
Part II: Encorafenib + Binimetinib + Capmatinib	Plasma Concentration for Ribociclib (LEE) and Its Metabolite: Part II	Ribociclib, C1 D15: Pre-dose	30.7 Nanogram per milliliter	Geometric Coefficient of Variation 24.9
Part II: Encorafenib + Binimetinib + Capmatinib	Plasma Concentration for Ribociclib (LEE) and Its Metabolite: Part II	LEQ803, C1 D15: 2.5 hrs	126 Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Capmatinib	Plasma Concentration for Ribociclib (LEE) and Its Metabolite: Part II	Ribociclib, C1 D21: Pre-dose	102 Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Capmatinib	Plasma Concentration for Ribociclib (LEE) and Its Metabolite: Part II	Ribociclib, C1 D15: 0.5 hr	35.4 Nanogram per milliliter	Geometric Coefficient of Variation 66.6
Part II: Encorafenib + Binimetinib + Capmatinib	Plasma Concentration for Ribociclib (LEE) and Its Metabolite: Part II	LEQ803, C2 D15: Pre-dose	45.7 Nanogram per milliliter	Geometric Coefficient of Variation 6.8
Part II: Encorafenib + Binimetinib + Buparlisib	Plasma Concentration for Ribociclib (LEE) and Its Metabolite: Part II	Ribociclib, C2 D15: Pre-dose	36.0 Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Buparlisib	Plasma Concentration for Ribociclib (LEE) and Its Metabolite: Part II	LEQ803, EOT	23.5 Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Buparlisib	Plasma Concentration for Ribociclib (LEE) and Its Metabolite: Part II	Ribociclib, C2 D1: Pre-dose	1.07 Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Buparlisib	Plasma Concentration for Ribociclib (LEE) and Its Metabolite: Part II	LEQ803, C2 D1: Pre-dose	2.70 Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Buparlisib	Plasma Concentration for Ribociclib (LEE) and Its Metabolite: Part II	LEQ803, C2 D15: Pre-dose	28.0 Nanogram per milliliter	—
Part II: Encorafenib + Binimetinib + Buparlisib	Plasma Concentration for Ribociclib (LEE) and Its Metabolite: Part II	Ribociclib, EOT	45.8 Nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 300 mg	Plasma Concentration for Ribociclib (LEE) and Its Metabolite: Part II	LEQ803, C2 D1: Pre-dose	8.48 Nanogram per milliliter	Geometric Coefficient of Variation 154.5
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 300 mg	Plasma Concentration for Ribociclib (LEE) and Its Metabolite: Part II	Ribociclib, C1 D1: 1.5 hrs	230 Nanogram per milliliter	Geometric Coefficient of Variation 119.7
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 300 mg	Plasma Concentration for Ribociclib (LEE) and Its Metabolite: Part II	Ribociclib, C1 D1: 4 hrs	354 Nanogram per milliliter	Geometric Coefficient of Variation 58.5
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 300 mg	Plasma Concentration for Ribociclib (LEE) and Its Metabolite: Part II	Ribociclib, C1 D8: Pre-dose	100 Nanogram per milliliter	Geometric Coefficient of Variation 49.9
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 300 mg	Plasma Concentration for Ribociclib (LEE) and Its Metabolite: Part II	Ribociclib, C1 D15: Pre-dose	104 Nanogram per milliliter	Geometric Coefficient of Variation 54.2
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 300 mg	Plasma Concentration for Ribociclib (LEE) and Its Metabolite: Part II	Ribociclib, C1 D15: 0.5 hr	179 Nanogram per milliliter	Geometric Coefficient of Variation 65
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 300 mg	Plasma Concentration for Ribociclib (LEE) and Its Metabolite: Part II	Ribociclib, C1 D15: 1.5 hrs	508 Nanogram per milliliter	Geometric Coefficient of Variation 95.2
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 300 mg	Plasma Concentration for Ribociclib (LEE) and Its Metabolite: Part II	Ribociclib, C1 D15: 2.5 hrs	627 Nanogram per milliliter	Geometric Coefficient of Variation 68.3
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 300 mg	Plasma Concentration for Ribociclib (LEE) and Its Metabolite: Part II	Ribociclib, C1 D15: 4 hrs	707 Nanogram per milliliter	Geometric Coefficient of Variation 62.2
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 300 mg	Plasma Concentration for Ribociclib (LEE) and Its Metabolite: Part II	Ribociclib, C1 D15: 6 hrs	578 Nanogram per milliliter	Geometric Coefficient of Variation 55.9
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 300 mg	Plasma Concentration for Ribociclib (LEE) and Its Metabolite: Part II	Ribociclib, C1 D15: 8 hrs	477 Nanogram per milliliter	Geometric Coefficient of Variation 55.2
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 300 mg	Plasma Concentration for Ribociclib (LEE) and Its Metabolite: Part II	Ribociclib, C1 D16: 24 hrs	120 Nanogram per milliliter	Geometric Coefficient of Variation 64.9
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 300 mg	Plasma Concentration for Ribociclib (LEE) and Its Metabolite: Part II	Ribociclib, C1 D21: Pre-dose	112 Nanogram per milliliter	Geometric Coefficient of Variation 75.8
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 300 mg	Plasma Concentration for Ribociclib (LEE) and Its Metabolite: Part II	Ribociclib, C2 D1: Pre-dose	7.00 Nanogram per milliliter	Geometric Coefficient of Variation 377.8
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 300 mg	Plasma Concentration for Ribociclib (LEE) and Its Metabolite: Part II	Ribociclib, C2 D15: Pre-dose	107 Nanogram per milliliter	Geometric Coefficient of Variation 59.4
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 300 mg	Plasma Concentration for Ribociclib (LEE) and Its Metabolite: Part II	Ribociclib, C3 D1: Pre-dose	4.06 Nanogram per milliliter	Geometric Coefficient of Variation 172.4
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 300 mg	Plasma Concentration for Ribociclib (LEE) and Its Metabolite: Part II	Ribociclib, C4 D1: Pre-dose	1.59 Nanogram per milliliter	Geometric Coefficient of Variation 31.6
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 300 mg	Plasma Concentration for Ribociclib (LEE) and Its Metabolite: Part II	Ribociclib, C5 D1: Pre-dose	2.16 Nanogram per milliliter	Geometric Coefficient of Variation 35.5
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 300 mg	Plasma Concentration for Ribociclib (LEE) and Its Metabolite: Part II	Ribociclib, EOT	29.0 Nanogram per milliliter	Geometric Coefficient of Variation 292.1
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 300 mg	Plasma Concentration for Ribociclib (LEE) and Its Metabolite: Part II	LEQ803, C1 D1: 1.5 hrs	47.5 Nanogram per milliliter	Geometric Coefficient of Variation 97.4
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 300 mg	Plasma Concentration for Ribociclib (LEE) and Its Metabolite: Part II	LEQ803, C1 D1: 4 hrs	81.1 Nanogram per milliliter	Geometric Coefficient of Variation 55.6
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 300 mg	Plasma Concentration for Ribociclib (LEE) and Its Metabolite: Part II	LEQ803, C1 D8: Pre-dose	53.7 Nanogram per milliliter	Geometric Coefficient of Variation 36.5
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 300 mg	Plasma Concentration for Ribociclib (LEE) and Its Metabolite: Part II	LEQ803, C1 D15: Pre-dose	55.1 Nanogram per milliliter	Geometric Coefficient of Variation 33.9
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 300 mg	Plasma Concentration for Ribociclib (LEE) and Its Metabolite: Part II	LEQ803, C1 D15: 0.5 hr	60.8 Nanogram per milliliter	Geometric Coefficient of Variation 36.9
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 300 mg	Plasma Concentration for Ribociclib (LEE) and Its Metabolite: Part II	LEQ803, C1 D15: 1.5 hrs	112 Nanogram per milliliter	Geometric Coefficient of Variation 46.9
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 300 mg	Plasma Concentration for Ribociclib (LEE) and Its Metabolite: Part II	LEQ803, C1 D15: 2.5 hrs	133 Nanogram per milliliter	Geometric Coefficient of Variation 45.4
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 300 mg	Plasma Concentration for Ribociclib (LEE) and Its Metabolite: Part II	LEQ803, C1 D15: 4 hrs	152 Nanogram per milliliter	Geometric Coefficient of Variation 31.2
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 300 mg	Plasma Concentration for Ribociclib (LEE) and Its Metabolite: Part II	LEQ803, C1 D15: 6 hrs	145 Nanogram per milliliter	Geometric Coefficient of Variation 27.2
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 300 mg	Plasma Concentration for Ribociclib (LEE) and Its Metabolite: Part II	LEQ803, C1 D15: 8 hrs	128 Nanogram per milliliter	Geometric Coefficient of Variation 27.6
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 300 mg	Plasma Concentration for Ribociclib (LEE) and Its Metabolite: Part II	LEQ803, C1 D16: 24 hrs	63.1 Nanogram per milliliter	Geometric Coefficient of Variation 36.1
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 300 mg	Plasma Concentration for Ribociclib (LEE) and Its Metabolite: Part II	LEQ803, C1 D21: Pre-dose	58.1 Nanogram per milliliter	Geometric Coefficient of Variation 39.1
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 300 mg	Plasma Concentration for Ribociclib (LEE) and Its Metabolite: Part II	LEQ803, C2 D15: Pre-dose	58.3 Nanogram per milliliter	Geometric Coefficient of Variation 42.7
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 300 mg	Plasma Concentration for Ribociclib (LEE) and Its Metabolite: Part II	LEQ803, C3 D1: Pre-dose	7.57 Nanogram per milliliter	Geometric Coefficient of Variation 61.4
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 300 mg	Plasma Concentration for Ribociclib (LEE) and Its Metabolite: Part II	LEQ803, C4 D1: Pre-dose	5.72 Nanogram per milliliter	Geometric Coefficient of Variation 6.9
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 300 mg	Plasma Concentration for Ribociclib (LEE) and Its Metabolite: Part II	LEQ803, C5 D1: Pre-dose	6.07 Nanogram per milliliter	Geometric Coefficient of Variation 28.9
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 300 mg	Plasma Concentration for Ribociclib (LEE) and Its Metabolite: Part II	LEQ803, EOT	20.6 Nanogram per milliliter	Geometric Coefficient of Variation 152.2
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 400 mg	Plasma Concentration for Ribociclib (LEE) and Its Metabolite: Part II	LEQ803, C1 D1: 4 hrs	63.2 Nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 400 mg	Plasma Concentration for Ribociclib (LEE) and Its Metabolite: Part II	LEQ803, C1 D21: Pre-dose	52.9 Nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 400 mg	Plasma Concentration for Ribociclib (LEE) and Its Metabolite: Part II	Ribociclib, C1 D21: Pre-dose	69.9 Nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 400 mg	Plasma Concentration for Ribociclib (LEE) and Its Metabolite: Part II	Ribociclib, C1 D16: 24 hrs	91.8 Nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 400 mg	Plasma Concentration for Ribociclib (LEE) and Its Metabolite: Part II	Ribociclib, C1 D1: 4 hrs	268 Nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 400 mg	Plasma Concentration for Ribociclib (LEE) and Its Metabolite: Part II	LEQ803, C2 D15: Pre-dose	66.8 Nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 400 mg	Plasma Concentration for Ribociclib (LEE) and Its Metabolite: Part II	Ribociclib, C1 D15: 2.5 hrs	393 Nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 400 mg	Plasma Concentration for Ribociclib (LEE) and Its Metabolite: Part II	Ribociclib, C1 D15: Pre-dose	64.7 Nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 400 mg	Plasma Concentration for Ribociclib (LEE) and Its Metabolite: Part II	Ribociclib, C1 D1: 1.5 hrs	185 Nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 400 mg	Plasma Concentration for Ribociclib (LEE) and Its Metabolite: Part II	LEQ803, C1 D15: 2.5 hrs	137 Nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 400 mg	Plasma Concentration for Ribociclib (LEE) and Its Metabolite: Part II	LEQ803, C1 D15: Pre-dose	49.2 Nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 400 mg	Plasma Concentration for Ribociclib (LEE) and Its Metabolite: Part II	LEQ803, C1 D16: 24 hrs	59.6 Nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 400 mg	Plasma Concentration for Ribociclib (LEE) and Its Metabolite: Part II	LEQ803, C1 D8: Pre-dose	47.2 Nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 400 mg	Plasma Concentration for Ribociclib (LEE) and Its Metabolite: Part II	Ribociclib, C1 D8: Pre-dose	80.5 Nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 400 mg	Plasma Concentration for Ribociclib (LEE) and Its Metabolite: Part II	LEQ803, C1 D1: 1.5 hrs	59.0 Nanogram per milliliter	—
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 400 mg	Plasma Concentration for Ribociclib (LEE) and Its Metabolite: Part II	Ribociclib, C2 D15: Pre-dose	113 Nanogram per milliliter	—
Part II: Encorafenib 100 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Plasma Concentration for Ribociclib (LEE) and Its Metabolite: Part II	LEQ803, C1 D21: Pre-dose	80.2 Nanogram per milliliter	—
Part II: Encorafenib 100 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Plasma Concentration for Ribociclib (LEE) and Its Metabolite: Part II	LEQ803, C1 D1: 1.5 hrs	63.6 Nanogram per milliliter	—
Part II: Encorafenib 100 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Plasma Concentration for Ribociclib (LEE) and Its Metabolite: Part II	Ribociclib, C1 D8: Pre-dose	127 Nanogram per milliliter	—
Part II: Encorafenib 100 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Plasma Concentration for Ribociclib (LEE) and Its Metabolite: Part II	Ribociclib, EOT	22.8 Nanogram per milliliter	—
Part II: Encorafenib 100 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Plasma Concentration for Ribociclib (LEE) and Its Metabolite: Part II	Ribociclib, C2 D15: Pre-dose	102 Nanogram per milliliter	—
Part II: Encorafenib 100 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Plasma Concentration for Ribociclib (LEE) and Its Metabolite: Part II	LEQ803, C2 D15: Pre-dose	61.1 Nanogram per milliliter	—
Part II: Encorafenib 100 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Plasma Concentration for Ribociclib (LEE) and Its Metabolite: Part II	LEQ803, C2 D1: Pre-dose	80.8 Nanogram per milliliter	—
Part II: Encorafenib 100 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Plasma Concentration for Ribociclib (LEE) and Its Metabolite: Part II	Ribociclib, C2 D1: Pre-dose	132 Nanogram per milliliter	—
Part II: Encorafenib 100 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Plasma Concentration for Ribociclib (LEE) and Its Metabolite: Part II	Ribociclib, C1 D21: Pre-dose	115 Nanogram per milliliter	—
Part II: Encorafenib 100 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Plasma Concentration for Ribociclib (LEE) and Its Metabolite: Part II	LEQ803, EOT	31.2 Nanogram per milliliter	—
Part II: Encorafenib 100 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Plasma Concentration for Ribociclib (LEE) and Its Metabolite: Part II	LEQ803, C1 D8: Pre-dose	71.2 Nanogram per milliliter	—
Part II: Encorafenib 100 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Plasma Concentration for Ribociclib (LEE) and Its Metabolite: Part II	Ribociclib, C1 D1: 1.5 hrs	784 Nanogram per milliliter	—

Secondary

Progression-Free Survival (PFS): Part I

PFS was defined as the time from the start date of study drug in Part I until documented PD or death due to any cause. All participants who had not progressed or died at the time of the data cut-off were censored at the date of last tumor assessment (other than those who were unknown or missing) prior to cut-off date or start date of new anti-neoplastic therapy, whichever is earlier. Per RECIST 1.1, PD= At least a 20% increase in the sum of diameter of all measured target lesions, taking as reference the smallest sum of diameter of all target lesions recorded at or after baseline. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. Kaplan Meier method used for estimation.

Time frame: From start of study drug until documented PD or death due to any cause or censoring date (maximum treatment exposure for Part I was 403.7 weeks)

Population: For Part I, FAS consisted of all participants who received at least 1 dose (partial or full) of encorafenib or binimetinib.

Arm	Measure	Value (MEDIAN)
Part II: Encorafenib + Binimetinib + Ribociclib	Progression-Free Survival (PFS): Part I	11.1 Months
Part II: Encorafenib + Binimetinib + Infigratinib	Progression-Free Survival (PFS): Part I	3.3 Months

Secondary

Summary of Genomic Biomarkers From Tumor Samples: Part I

Number of participants with multiple alterations in genomic biomarkers like biomarker BRAF, CCND1, CDK4, EGFR, FGFR1, FGFR4, KRAS, MET, NRAS, PIK3CA, and PTEN were reported and alterations included copy number variant/copy number ratio (CNV/CNR), rearrangement, short variant. It was not necessary that all biomarkers had all alterations. Baseline = last non-missing value prior to the first dose of study treatment.

Time frame: Baseline up to end of treatment (EOT) (maximum treatment exposure for Part I was 403.7 weeks)

Population: For Part I, FAS consisted of all participants who received at least 1 dose (partial or full) of encorafenib or binimetinib.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Part II: Encorafenib + Binimetinib + Ribociclib	Summary of Genomic Biomarkers From Tumor Samples: Part I	BRAF: CNV/CNR at Baseline	4 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Summary of Genomic Biomarkers From Tumor Samples: Part I	BRAF: CNV/CNR at EOT	2 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Summary of Genomic Biomarkers From Tumor Samples: Part I	BRAF: Rearrangement/Genomic Position at Baseline chr7:140482508-140482692	0 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Summary of Genomic Biomarkers From Tumor Samples: Part I	BRAF: Rearrangement/Genomic Position at Baseline chr7:140487121-140487285	0 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Summary of Genomic Biomarkers From Tumor Samples: Part I	BRAF: Rearrangement/Genomic Position at Baseline chr7:140487916-140488167	0 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Summary of Genomic Biomarkers From Tumor Samples: Part I	BRAF: Rearrangement/Genomic Position at Baseline chr7:140488878-140489055	0 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Summary of Genomic Biomarkers From Tumor Samples: Part I	BRAF: Rearrangement/Genomic Position at Baseline cchr7:140489413-140489576	0 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Summary of Genomic Biomarkers From Tumor Samples: Part I	BRAF: Rearrangement/Genomic Position at Baseline chr7:140490446-140490656	0 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Summary of Genomic Biomarkers From Tumor Samples: Part I	BRAF: Rearrangement/Genomic Position at Baseline chr7:140491528-140491878	0 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Summary of Genomic Biomarkers From Tumor Samples: Part I	BRAF: Rearrangement/Genomic Position at Baseline chr7:140491580-140491878	0 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Summary of Genomic Biomarkers From Tumor Samples: Part I	BRAF: Rearrangement/Genomic Position at Baseline chr7:140492969-140493301	0 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Summary of Genomic Biomarkers From Tumor Samples: Part I	BRAF: Rearrangement/Genomic Position at EOT chr7:140481691-140482150	1 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Summary of Genomic Biomarkers From Tumor Samples: Part I	BRAF: Rearrangement/Genomic Position at EOT chr7:140482057-140482467	0 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Summary of Genomic Biomarkers From Tumor Samples: Part I	BRAF: Rearrangement/Genomic Position at EOT chr7:140482081-140482482	1 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Summary of Genomic Biomarkers From Tumor Samples: Part I	BRAF: Rearrangement/Genomic Position at EOT chr7:140482088-140482296	0 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Summary of Genomic Biomarkers From Tumor Samples: Part I	BRAF: Rearrangement/Genomic Position at EOT chr7:140482167-140482382	1 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Summary of Genomic Biomarkers From Tumor Samples: Part I	BRAF: Rearrangement/Genomic Position at EOT chr7:140482495-140482731	0 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Summary of Genomic Biomarkers From Tumor Samples: Part I	BRAF: Rearrangement/Genomic Position at EOT chr7:140482644-140482867	0 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Summary of Genomic Biomarkers From Tumor Samples: Part I	BRAF: Rearrangement/Genomic Position at EOT chr7:140483058-140483257	1 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Summary of Genomic Biomarkers From Tumor Samples: Part I	BRAF: Rearrangement/Genomic Position at EOT chr7:140486136-140486408	1 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Summary of Genomic Biomarkers From Tumor Samples: Part I	BRAF: Rearrangement/Genomic Position at EOT chr7:140486274-140486561	0 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Summary of Genomic Biomarkers From Tumor Samples: Part I	BRAF: Rearrangement/Genomic Position at EOT chr7:140489019-140489575	0 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Summary of Genomic Biomarkers From Tumor Samples: Part I	BRAF: Rearrangement/Genomic Position at EOT chr7:140489219-140489431	1 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Summary of Genomic Biomarkers From Tumor Samples: Part I	BRAF: Rearrangement/Genomic Position at EOT chr7:140489830-140490002	0 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Summary of Genomic Biomarkers From Tumor Samples: Part I	BRAF: Rearrangement/Genomic Position at EOT chr7:140491411-140491879	0 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Summary of Genomic Biomarkers From Tumor Samples: Part I	BRAF: Rearrangement/Genomic Position at EOT chr7:140492091-140492240	1 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Summary of Genomic Biomarkers From Tumor Samples: Part I	BRAF: Rearrangement/Genomic Position at EOT chr7:140492379-140492708	0 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Summary of Genomic Biomarkers From Tumor Samples: Part I	BRAF: Rearrangement/Genomic Position at EOT chr7:140492714-140492997	0 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Summary of Genomic Biomarkers From Tumor Samples: Part I	BRAF: Rearrangement/Genomic Position at EOT chr7:140493601-140493951	0 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Summary of Genomic Biomarkers From Tumor Samples: Part I	BRAF: Rearrangement/Genomic Position at EOT chr7:140493858-140494232	1 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Summary of Genomic Biomarkers From Tumor Samples: Part I	BRAF: Short variant/amino acid change at Baseline V600E	46 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Summary of Genomic Biomarkers From Tumor Samples: Part I	BRAF: Short variant/amino acid change at Baseline V600G	1 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Summary of Genomic Biomarkers From Tumor Samples: Part I	BRAF: Short variant/amino acid change at Baseline V600K	4 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Summary of Genomic Biomarkers From Tumor Samples: Part I	BRAF: Short variant/amino acid change at Baseline V600R	1 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Summary of Genomic Biomarkers From Tumor Samples: Part I	BRAF: Short variant/amino acid change at EOT V600E	18 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Summary of Genomic Biomarkers From Tumor Samples: Part I	BRAF: Short variant/amino acid change at EOT V600K	0 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Summary of Genomic Biomarkers From Tumor Samples: Part I	BRAF: Short variant/amino acid change at EOT V600R	1 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Summary of Genomic Biomarkers From Tumor Samples: Part I	CCND1: CNV/CNR at Baseline	1 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Summary of Genomic Biomarkers From Tumor Samples: Part I	CDK4: CNV/CNR at Baseline	3 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Summary of Genomic Biomarkers From Tumor Samples: Part I	EGFR: CNV/CNR at Baseline	1 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Summary of Genomic Biomarkers From Tumor Samples: Part I	EGFR: CNV/CNR at EOT	1 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Summary of Genomic Biomarkers From Tumor Samples: Part I	FGFR1: CNV/CNR at Baseline	1 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Summary of Genomic Biomarkers From Tumor Samples: Part I	FGFR1: CNV/CNR at EOT	1 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Summary of Genomic Biomarkers From Tumor Samples: Part I	FGFR4: CNV/CNR at Baseline	1 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Summary of Genomic Biomarkers From Tumor Samples: Part I	KRAS: CNV/CNR at Baseline	2 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Summary of Genomic Biomarkers From Tumor Samples: Part I	MET: CNV/CNR at Baseline	4 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Summary of Genomic Biomarkers From Tumor Samples: Part I	MET: CNV/CNR at EOT	3 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Summary of Genomic Biomarkers From Tumor Samples: Part I	MET: Rearrangement/Genomic Position at EOT chr7:116321020-116321260	1 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Summary of Genomic Biomarkers From Tumor Samples: Part I	NRAS: CNV/CNR at Baseline	0 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Summary of Genomic Biomarkers From Tumor Samples: Part I	PIK3CA: CNV/CNR at Baseline	1 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Summary of Genomic Biomarkers From Tumor Samples: Part I	PTEN: CNV/CNR at Baseline	4 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Summary of Genomic Biomarkers From Tumor Samples: Part I	PTEN: CNV/CNR at EOT	5 Participants
Part II: Encorafenib + Binimetinib + Ribociclib	Summary of Genomic Biomarkers From Tumor Samples: Part I	PTEN: Rearrangement/Genomic Position at EOT chr10:89720538-89720776	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Summary of Genomic Biomarkers From Tumor Samples: Part I	BRAF: Rearrangement/Genomic Position at EOT chr7:140492379-140492708	1 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Summary of Genomic Biomarkers From Tumor Samples: Part I	BRAF: CNV/CNR at Baseline	9 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Summary of Genomic Biomarkers From Tumor Samples: Part I	MET: CNV/CNR at EOT	5 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Summary of Genomic Biomarkers From Tumor Samples: Part I	BRAF: CNV/CNR at EOT	3 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Summary of Genomic Biomarkers From Tumor Samples: Part I	BRAF: Rearrangement/Genomic Position at EOT chr7:140492714-140492997	1 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Summary of Genomic Biomarkers From Tumor Samples: Part I	BRAF: Rearrangement/Genomic Position at Baseline chr7:140482508-140482692	1 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Summary of Genomic Biomarkers From Tumor Samples: Part I	EGFR: CNV/CNR at EOT	1 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Summary of Genomic Biomarkers From Tumor Samples: Part I	BRAF: Rearrangement/Genomic Position at Baseline chr7:140487121-140487285	1 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Summary of Genomic Biomarkers From Tumor Samples: Part I	BRAF: Rearrangement/Genomic Position at EOT chr7:140493601-140493951	1 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Summary of Genomic Biomarkers From Tumor Samples: Part I	BRAF: Rearrangement/Genomic Position at Baseline chr7:140487916-140488167	1 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Summary of Genomic Biomarkers From Tumor Samples: Part I	PTEN: CNV/CNR at EOT	10 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Summary of Genomic Biomarkers From Tumor Samples: Part I	BRAF: Rearrangement/Genomic Position at Baseline chr7:140488878-140489055	1 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Summary of Genomic Biomarkers From Tumor Samples: Part I	BRAF: Rearrangement/Genomic Position at EOT chr7:140493858-140494232	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Summary of Genomic Biomarkers From Tumor Samples: Part I	BRAF: Rearrangement/Genomic Position at Baseline cchr7:140489413-140489576	1 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Summary of Genomic Biomarkers From Tumor Samples: Part I	FGFR1: CNV/CNR at Baseline	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Summary of Genomic Biomarkers From Tumor Samples: Part I	BRAF: Rearrangement/Genomic Position at Baseline chr7:140490446-140490656	1 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Summary of Genomic Biomarkers From Tumor Samples: Part I	BRAF: Short variant/amino acid change at Baseline V600E	53 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Summary of Genomic Biomarkers From Tumor Samples: Part I	BRAF: Rearrangement/Genomic Position at Baseline chr7:140491528-140491878	1 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Summary of Genomic Biomarkers From Tumor Samples: Part I	MET: Rearrangement/Genomic Position at EOT chr7:116321020-116321260	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Summary of Genomic Biomarkers From Tumor Samples: Part I	BRAF: Rearrangement/Genomic Position at Baseline chr7:140491580-140491878	1 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Summary of Genomic Biomarkers From Tumor Samples: Part I	BRAF: Short variant/amino acid change at Baseline V600G	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Summary of Genomic Biomarkers From Tumor Samples: Part I	BRAF: Rearrangement/Genomic Position at Baseline chr7:140492969-140493301	1 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Summary of Genomic Biomarkers From Tumor Samples: Part I	FGFR1: CNV/CNR at EOT	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Summary of Genomic Biomarkers From Tumor Samples: Part I	BRAF: Rearrangement/Genomic Position at EOT chr7:140481691-140482150	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Summary of Genomic Biomarkers From Tumor Samples: Part I	BRAF: Short variant/amino acid change at Baseline V600K	7 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Summary of Genomic Biomarkers From Tumor Samples: Part I	BRAF: Rearrangement/Genomic Position at EOT chr7:140482057-140482467	1 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Summary of Genomic Biomarkers From Tumor Samples: Part I	PTEN: CNV/CNR at Baseline	13 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Summary of Genomic Biomarkers From Tumor Samples: Part I	BRAF: Rearrangement/Genomic Position at EOT chr7:140482081-140482482	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Summary of Genomic Biomarkers From Tumor Samples: Part I	BRAF: Short variant/amino acid change at Baseline V600R	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Summary of Genomic Biomarkers From Tumor Samples: Part I	BRAF: Rearrangement/Genomic Position at EOT chr7:140482088-140482296	1 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Summary of Genomic Biomarkers From Tumor Samples: Part I	FGFR4: CNV/CNR at Baseline	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Summary of Genomic Biomarkers From Tumor Samples: Part I	BRAF: Rearrangement/Genomic Position at EOT chr7:140482167-140482382	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Summary of Genomic Biomarkers From Tumor Samples: Part I	BRAF: Short variant/amino acid change at EOT V600E	19 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Summary of Genomic Biomarkers From Tumor Samples: Part I	BRAF: Rearrangement/Genomic Position at EOT chr7:140482495-140482731	1 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Summary of Genomic Biomarkers From Tumor Samples: Part I	NRAS: CNV/CNR at Baseline	1 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Summary of Genomic Biomarkers From Tumor Samples: Part I	BRAF: Rearrangement/Genomic Position at EOT chr7:140482644-140482867	1 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Summary of Genomic Biomarkers From Tumor Samples: Part I	BRAF: Short variant/amino acid change at EOT V600K	4 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Summary of Genomic Biomarkers From Tumor Samples: Part I	BRAF: Rearrangement/Genomic Position at EOT chr7:140483058-140483257	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Summary of Genomic Biomarkers From Tumor Samples: Part I	KRAS: CNV/CNR at Baseline	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Summary of Genomic Biomarkers From Tumor Samples: Part I	BRAF: Rearrangement/Genomic Position at EOT chr7:140486136-140486408	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Summary of Genomic Biomarkers From Tumor Samples: Part I	BRAF: Short variant/amino acid change at EOT V600R	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Summary of Genomic Biomarkers From Tumor Samples: Part I	BRAF: Rearrangement/Genomic Position at EOT chr7:140486274-140486561	1 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Summary of Genomic Biomarkers From Tumor Samples: Part I	PTEN: Rearrangement/Genomic Position at EOT chr10:89720538-89720776	1 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Summary of Genomic Biomarkers From Tumor Samples: Part I	BRAF: Rearrangement/Genomic Position at EOT chr7:140489019-140489575	1 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Summary of Genomic Biomarkers From Tumor Samples: Part I	CCND1: CNV/CNR at Baseline	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Summary of Genomic Biomarkers From Tumor Samples: Part I	BRAF: Rearrangement/Genomic Position at EOT chr7:140489219-140489431	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Summary of Genomic Biomarkers From Tumor Samples: Part I	MET: CNV/CNR at Baseline	6 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Summary of Genomic Biomarkers From Tumor Samples: Part I	BRAF: Rearrangement/Genomic Position at EOT chr7:140489830-140490002	1 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Summary of Genomic Biomarkers From Tumor Samples: Part I	CDK4: CNV/CNR at Baseline	2 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Summary of Genomic Biomarkers From Tumor Samples: Part I	BRAF: Rearrangement/Genomic Position at EOT chr7:140491411-140491879	1 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Summary of Genomic Biomarkers From Tumor Samples: Part I	PIK3CA: CNV/CNR at Baseline	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Summary of Genomic Biomarkers From Tumor Samples: Part I	BRAF: Rearrangement/Genomic Position at EOT chr7:140492091-140492240	0 Participants
Part II: Encorafenib + Binimetinib + Infigratinib	Summary of Genomic Biomarkers From Tumor Samples: Part I	EGFR: CNV/CNR at Baseline	3 Participants

Secondary

Time to Reach Cmax at Steady State (Tmax, ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II

Time frame: C1 D15: 0.5 hour ± 10 min; 1 hour ± 10 min; 1.5 hour ± 15 min; 2 hour ± 15 min; 2.5 hour ± 15 min; 4 hour ± 30 min; 6 hour ± 30 min; 8 hour ± 60 min; 24 hour ± 2 hour

Arm	Measure	Group	Value (MEDIAN)
Part II: Encorafenib + Binimetinib + Ribociclib	Time to Reach Cmax at Steady State (Tmax, ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Binimetinib metabolite, AR00426032	1.50 Hour
Part II: Encorafenib + Binimetinib + Ribociclib	Time to Reach Cmax at Steady State (Tmax, ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Binimetinib	1.50 Hour
Part II: Encorafenib + Binimetinib + Ribociclib	Time to Reach Cmax at Steady State (Tmax, ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Buparlisib	1.50 Hour
Part II: Encorafenib + Binimetinib + Ribociclib	Time to Reach Cmax at Steady State (Tmax, ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Encorafenib	1.33 Hour
Part II: Encorafenib + Binimetinib + Infigratinib	Time to Reach Cmax at Steady State (Tmax, ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Binimetinib metabolite, AR00426032	2.75 Hour
Part II: Encorafenib + Binimetinib + Infigratinib	Time to Reach Cmax at Steady State (Tmax, ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Binimetinib	2.75 Hour
Part II: Encorafenib + Binimetinib + Infigratinib	Time to Reach Cmax at Steady State (Tmax, ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Encorafenib	1.54 Hour
Part II: Encorafenib + Binimetinib + Infigratinib	Time to Reach Cmax at Steady State (Tmax, ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Buparlisib	1.50 Hour
Part II: Encorafenib + Binimetinib + Capmatinib	Time to Reach Cmax at Steady State (Tmax, ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Infigratinib metabolite, BHS697	2.50 Hour
Part II: Encorafenib + Binimetinib + Capmatinib	Time to Reach Cmax at Steady State (Tmax, ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Encorafenib	1.50 Hour
Part II: Encorafenib + Binimetinib + Capmatinib	Time to Reach Cmax at Steady State (Tmax, ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Binimetinib	1.50 Hour
Part II: Encorafenib + Binimetinib + Capmatinib	Time to Reach Cmax at Steady State (Tmax, ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Binimetinib metabolite, AR00426032	1.50 Hour
Part II: Encorafenib + Binimetinib + Capmatinib	Time to Reach Cmax at Steady State (Tmax, ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Infigratinib	2.50 Hour
Part II: Encorafenib + Binimetinib + Capmatinib	Time to Reach Cmax at Steady State (Tmax, ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Infigratinib metabolite, CQM157	5.75 Hour
Part II: Encorafenib + Binimetinib + Buparlisib	Time to Reach Cmax at Steady State (Tmax, ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Binimetinib metabolite, AR00426032	1.50 Hour
Part II: Encorafenib + Binimetinib + Buparlisib	Time to Reach Cmax at Steady State (Tmax, ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Capmatinib	1.53 Hour
Part II: Encorafenib + Binimetinib + Buparlisib	Time to Reach Cmax at Steady State (Tmax, ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Encorafenib	1.50 Hour
Part II: Encorafenib + Binimetinib + Buparlisib	Time to Reach Cmax at Steady State (Tmax, ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Binimetinib	1.50 Hour
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 300 mg	Time to Reach Cmax at Steady State (Tmax, ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Binimetinib	1.50 Hour
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 300 mg	Time to Reach Cmax at Steady State (Tmax, ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Encorafenib	1.50 Hour
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 300 mg	Time to Reach Cmax at Steady State (Tmax, ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Binimetinib metabolite, AR00426032	4.00 Hour
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 300 mg	Time to Reach Cmax at Steady State (Tmax, ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Capmatinib	1.50 Hour
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 400 mg	Time to Reach Cmax at Steady State (Tmax, ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Binimetinib	1.50 Hour
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 400 mg	Time to Reach Cmax at Steady State (Tmax, ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Binimetinib metabolite, AR00426032	1.92 Hour
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 400 mg	Time to Reach Cmax at Steady State (Tmax, ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Capmatinib	1.50 Hour
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Capmatinib 400 mg	Time to Reach Cmax at Steady State (Tmax, ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Encorafenib	1.50 Hour
Part II: Encorafenib 100 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Time to Reach Cmax at Steady State (Tmax, ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Encorafenib	2.37 Hour
Part II: Encorafenib 100 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Time to Reach Cmax at Steady State (Tmax, ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Binimetinib	1.38 Hour
Part II: Encorafenib 100 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Time to Reach Cmax at Steady State (Tmax, ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Binimetinib metabolite, AR00426032	1.38 Hour
Part II: Encorafenib 100 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Time to Reach Cmax at Steady State (Tmax, ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Ribociclib	5.92 Hour
Part II: Encorafenib 100 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Time to Reach Cmax at Steady State (Tmax, ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Ribociclib metabolite, LEQ803	5.92 Hour
Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 400 mg	Time to Reach Cmax at Steady State (Tmax, ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Ribociclib	2.45 Hour
Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 400 mg	Time to Reach Cmax at Steady State (Tmax, ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Encorafenib	1.47 Hour
Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 400 mg	Time to Reach Cmax at Steady State (Tmax, ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Binimetinib	1.47 Hour
Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 400 mg	Time to Reach Cmax at Steady State (Tmax, ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Ribociclib metabolite, LEQ803	4.98 Hour
Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 400 mg	Time to Reach Cmax at Steady State (Tmax, ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Binimetinib metabolite, AR00426032	1.47 Hour
Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Time to Reach Cmax at Steady State (Tmax, ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Ribociclib metabolite, LEQ803	3.18 Hour
Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Time to Reach Cmax at Steady State (Tmax, ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Encorafenib	1.00 Hour
Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Time to Reach Cmax at Steady State (Tmax, ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Ribociclib	3.18 Hour
Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Time to Reach Cmax at Steady State (Tmax, ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Binimetinib metabolite, AR00426032	1.50 Hour
Part II: Encorafenib 200 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Time to Reach Cmax at Steady State (Tmax, ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Binimetinib	1.50 Hour
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 400 mg	Time to Reach Cmax at Steady State (Tmax, ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Binimetinib	1.50 Hour
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 400 mg	Time to Reach Cmax at Steady State (Tmax, ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Ribociclib	1.50 Hour
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 400 mg	Time to Reach Cmax at Steady State (Tmax, ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Encorafenib	1.50 Hour
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 400 mg	Time to Reach Cmax at Steady State (Tmax, ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Ribociclib metabolite, LEQ803	1.50 Hour
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 400 mg	Time to Reach Cmax at Steady State (Tmax, ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Binimetinib metabolite, AR00426032	1.50 Hour
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 600 mg	Time to Reach Cmax at Steady State (Tmax, ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Binimetinib	1.58 Hour
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 600 mg	Time to Reach Cmax at Steady State (Tmax, ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Ribociclib metabolite, LEQ803	4.12 Hour
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 600 mg	Time to Reach Cmax at Steady State (Tmax, ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Encorafenib	1.58 Hour
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 600 mg	Time to Reach Cmax at Steady State (Tmax, ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Binimetinib metabolite, AR00426032	1.65 Hour
Part II: Encorafenib 200 mg/ Binimetinib 45 mg + Ribociclib 600 mg	Time to Reach Cmax at Steady State (Tmax, ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Ribociclib	3.65 Hour
Part II: Encorafenib 300 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Time to Reach Cmax at Steady State (Tmax, ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Ribociclib	0.50 Hour
Part II: Encorafenib 300 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Time to Reach Cmax at Steady State (Tmax, ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Binimetinib	1.08 Hour
Part II: Encorafenib 300 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Time to Reach Cmax at Steady State (Tmax, ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Ribociclib metabolite, LEQ803	1.08 Hour
Part II: Encorafenib 300 mg/ Binimetinib 30 mg + Ribociclib 600 mg	Time to Reach Cmax at Steady State (Tmax, ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II	Binimetinib metabolite, AR00426032	1.08 Hour

Secondary

Time to Response (TTR): Part I

TTR was defined as the time between the start date of study drug in Part I and first documented response (CR or PR). RECIST v1.1: a) CR = disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must had a reduction in short axis to \<10 mm. Disappearance of all non-target lesions. In addition, all lymph nodes assigned a non-target lesion must be non-pathological in size (\<10 mm short axis) and b) PR = at least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters. Kaplan Meier method used for estimation.

Time frame: From start date of study drug till first documented response (CR or PR) (maximum treatment exposure for Part I was 403.7 weeks)

Arm	Measure	Value (MEDIAN)
Part II: Encorafenib + Binimetinib + Ribociclib	Time to Response (TTR): Part I	1.4 Months
Part II: Encorafenib + Binimetinib + Infigratinib	Time to Response (TTR): Part I	0.72 Months

Secondary

TTR: Part II

TTR was defined as the time between the start date of study drug in Part II and first documented response (CR or PR). RECIST v1.1: a) CR = disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must had a reduction in short axis to \<10 mm. Disappearance of all non-target lesions. In addition, all lymph nodes assigned a non-target lesion must be non-pathological in size (\<10 mm short axis) and b) PR = at least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters. Kaplan Meier method used for estimation.

Time frame: From start date of study drug till first documented response (CR or PR) (maximum treatment exposure for Part II was 97.0 weeks)

Arm	Measure	Value (MEDIAN)
Part II: Encorafenib + Binimetinib + Ribociclib	TTR: Part II	4.1 Months

Source: ClinicalTrials.gov · Data processed: Feb 18, 2026

LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma

Conditions

Keywords

Brief summary

Detailed description

Related papers

Interventions

Sponsors

Study design

Eligibility

Inclusion criteria

Exclusion criteria

Design outcomes

Primary

Secondary

Countries

Participant flow

Recruitment details

Participants by arm

Withdrawals & dropouts

Baseline characteristics

Adverse events

Outcome results

Overall Response Rate (ORR): Part II

Actual Dose Intensity: Part I

Actual Dose Intensity: Part II

Apparent Total Plasma Clearance at Steady State (Cl, ss/F) of Encorafenib, Binimetinib, Ribociclib, Capmatinib, and Buparlisib: Part II

Apparent Volume of Distribution at Steady State (Vz, ss/F) of Encorafenib, Binimetinib, Ribociclib, Capmatinib, and Buparlisib: Part II

Area Under the Concentration-time Curve From Time Zero to Time Tau at Steady-State (AUCtau,ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Capmatinib, and Buparlisib: Part II

DCR: Part II

Disease Control Rate (DCR): Part I

DOR: Part II

Duration of Response (DOR): Part I

Elimination Half-life at Steady State (t1/2, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Capmatinib, and Buparlisib: Part II

Last Measurable Plasma Concentration at Steady State (Clast, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II

Maximum Observed Plasma Concentration at Steady State (Cmax,ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II

Measured Concentration at the End of a Dosing Interval at Steady State (Ctrough, ss) of Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II

Number of Participants With Adverse Events (AEs) and Serious AEs (SAEs): Part I

Number of Participants With AEs and SAEs: Part II

Number of Participants With At Least One Dose Interruption: Part I

Number of Participants With At Least One Dose Interruption: Part II

Number of Participants With At Least One Dose Reduction: Part I

Number of Participants With At Least One Dose Reduction: Part II

Number of Participants With Dose Limiting Toxicities (DLTs) in Cycle 1: Part II

Number of Participants With Newly Occurring Notably Abnormal Vital Signs: Part I

Number of Participants With Newly Occurring Notably Abnormal Vital Signs: Part II

Number of Participants With Notable ECG Values: Part II

Number of Participants With Notable Electrocardiograms (ECG) Values: Part I

Number of Participants With Worst Post-baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) v4.03 Grade: Part I

Number of Participants With Worst Post-baseline Hematology Results Based on CTCAE v4.03 Grade: Part II

Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part I

Number of Participants With Worst Post-baseline Serum Chemistry Results Based on CTCAE v4.03 Grade: Part II

Overall Survival (OS): Part II

PFS: Part II

Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part I

Plasma Concentration for Binimetinib (MEK) and Its Metabolite: Part II

Plasma Concentration for Buparlisib (BKM): Part II

Plasma Concentration for Capmatinib (INC): Part II

Plasma Concentration for Encorafenib (LGX): Part I

Plasma Concentration for Encorafenib (LGX): Part II

Plasma Concentration for Infigratinib (BGJ) and Its Metabolites: Part II

Plasma Concentration for Ribociclib (LEE) and Its Metabolite: Part II

Progression-Free Survival (PFS): Part I

Summary of Genomic Biomarkers From Tumor Samples: Part I

Time to Reach Cmax at Steady State (Tmax, ss) for Encorafenib, Binimetinib, Binimetinib Metabolite, Ribociclib, Ribociclib Metabolite, Infigratinib, Infigratinib Metabolites, Capmatinib, and Buparlisib: Part II

Time to Response (TTR): Part I

TTR: Part II